Mammalian m-AAA Proteases as Key Regulators of Mitochondrial Function - Analysis of Dominant Negative Mutant Variants by Raschke, Ines
  
 
 
Mammalian m-AAA Proteases as  
Key Regulators of Mitochondrial Function – 
Analysis of Dominant Negative Mutant Variants  
 
 
 
 
 
I n a u g u r a l - D i s s e r t a t i o n 
zur 
Erlangung des Doktorgrades 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Universität zu Köln 
 
 
 
 
vorgelegt von 
Ines Raschke 
aus Hildesheim 
Köln, 2009 
  
 
 
Mammalian m-AAA Proteases as  
Key Regulators of Mitochondrial Function – 
Analysis of Dominant Negative Mutant Variants  
 
 
 
 
 
I n a u g u r a l - D i s s e r t a t i o n 
zur 
Erlangung des Doktorgrades 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Universität zu Köln 
 
 
 
 
vorgelegt von 
Ines Raschke 
aus Hildesheim 
Köln, 2009 
  
 
 
 
 
 
 
 
 
 
 
ये ǓनभÛथ Üयरे ͪवÛस को समͪप ॔है 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Berichterstatter: 
Professor Dr. Thomas Langer 
Professor Dr. Mats Paulsson 
Tag der mündlichen Prüfung: 15. Mai 2009
 5 
Abstract 
To ensure the removal of excess and non-assembled proteins, mitochondria require a 
protein quality control system which is constituted by several proteases located in different 
compartments of mitochondria. m-AAA proteases, oligomeric ATP-dependent 
metallopeptidases, are key components of this system active at the matrix side of the inner 
membrane. Human m-AAA proteases build up homo- and hetero-oligomeric complexes 
composed of AFG3L2 and SPG7. Mice express a third subunit, Afg3l1, resulting in a 
variety of possible isoenzymes. Interestingly, mutations or deletions of one subunit of 
mammalian m-AAA proteases cause neurodegeneration in distinct regions of the central 
and peripheral nervous system in mouse and human, indicating that different tissues, in 
particular neurons, require a specific subset of isoenzymes. The yeast m-AAA protease can 
also act as a processing enzyme regulating mitochondrial biogenesis, raising the question 
which activity is linked to the pathogenesis of the associated diseases. Which molecular 
functions of mammalian m-AAA proteases contribute to different disease states are poorly 
understood. Mammalian m-AAA proteases have been linked to the processing of the 
dynamin-like GTPase OPA1 implying a role of mammalian m-AAA proteases in 
mitochondrial fusion. Therefore, to further elucidate the function of mammalian 
m-AAA proteases it was necessary to identify more substrates of the proteases. 
In this study, a mutation in the Walker B motif of the ATPase domain of 
Afg3l2/AFG3L2 was identified as dominant negative substrate trap. Using this novel 
approach, expression of dominant negative mutant variants in human cells, interacting 
partners and putative substrates have been identified providing further insights into the 
molecular functions of mammalian m-AAA proteases in mitochondria. These proteases 
were demonstrated to be present in a supercomplex with prohibitins together regulating 
cell proliferation and mitochondrial fusion by stabilizing l-OPA1. In parallel, m-AAA 
proteases interact with SLP2 and control stress induced mitochondrial hyperfusion pointing 
to the formation of another supercomplex containing the proteases and SLP2. The 
precursor of AFG3L2 itself and MICS1, an inner membrane protein crucial for cristae 
organization and apoptosis, were identified as possible substrates.  
Linking m-AAA protease functions to mitochondrial fusion, cristae organization and 
apoptosis may help to unravel the molecular mechanisms underlying neurodegeneration 
associated with mutations in human m-AAA proteases. 
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1. Introduction 
1.1. Mitochondria in life and pathogenesis  
It is widely believed that the mitochondrion was originally derived from a free-living α-
prokaryotic organism which explains the presence of a compact mitochondrial DNA 
(mtDNA). The genome encodes for key subunits of the electron transport chain and RNA 
components needed for mitochondrial translation (Falkenberg et al., 2007). Mitochondria 
are double-membrane bound organelles that are indispensable for the viability of a 
eukaryotic cell. It is therefore not surprising that numerous proteins involved in the 
biogenesis of these organelles are encoded by essential genes (Neupert and Herrmann, 
2007). Mitochondria perform a variety of functions in anabolism and catabolism, energy 
conversion, apoptosis, calcium signaling and reactive oxygen production (Pinton et al., 
2008; Scheffler, 1999). In the yeast Saccharomyces cerevisiae, none of these functions 
determine the essential character of the organelles. For instance, the citric acid cycle or 
oxidative phosphorylation can be inactivated by targeted gene deletions or by the loss of 
mitochondrial DNA without affecting the viability of yeast cells in the presence of 
fermentable carbon sources. However, the essential function of mitochondria is the Iron-
sulfur (Fe/S) protein biogenesis (Lill et al., 2005). Fe/S proteins are involved in a wide 
variety of cellular processes such as respiration, cofactor biosynthesis, ribosome 
biogenesis, regulation of gene expression, and DNA-RNA metabolism (Lill and 
Muhlenhoff, 2008). Therefore, it is not surprising that a loss-of-function mutation in one of 
the genes involved in iron-sulfur cluster biogenesis FXN (frataxin) leads to the clinical 
syndrome Friedreich ataxia (FRDA) which is characterized by impaired mitochondrial iron 
storage and metabolism (Campuzano et al., 1997; Campuzano et al., 1996). 
Mitochondria are complex organelles whose dysfunction are responsible for a broad 
spectrum of human diseases (DiMauro and Schon, 2008). Mitochondrial dysfunctions 
cause over 50 diseases ranging from neonatal fatalities to adult onset neurodegeneration 
and are probably contributing to cancer and type II diabetes (DiMauro, 2004; DiMauro 
and Schon, 2003; Lowell and Shulman, 2005; Wallace, 2005).  
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1.2. Oxidative phosphorylation system (OXPHOS) 
The mitochondrial oxidative phosphorylation system (OXPHOS) is the final 
biochemical pathway for the vast majority of eukaryotes to produce the principal fuel of 
the cell − ATP (Saraste, 1999). The essential constituents are commonly shared and 
localized in the inner mitochondrial membrane, i.e., the four major protein complexes of 
the standard respiratory chain and the FOF1-ATP synthase (complex V), together designated 
as OXPHOS complexes (Figure 1).  
The complexes I (NADH: ubiqinone oxidoreducatese), III (ubiqinol:cytochrome c 
oxidoreductase), and IV (cytochrome c oxidase, also referred to as COX) transduce the 
energy of nutritional compounds by vectorial proton translocation across the inner 
membrane. This energy is used by the FOF1-ATP synthase to produce ATP from ADP and 
inorganic phosphate as well as a driving force for other processes like import of nuclear-
encoded proteins into mitochondria. The two mobile redox components ubiquinone 
(Coenzyme Q) and cytochrome c act as cosubstrates in the respiratory chain. The smallest 
and most hydrophilic respiratory chain complex, succininate:ubiquinone oxidoreductase 
(complex II), incorporates the heterodimeric succinate dehydrogenase of the matrix-located 
citric acid cycle and feeds electrons from succinate oxidation into the respiratory chain 
without proton pumping [for review (Krause, 2007)].  
 
However, there is substantial evidence that complexes I, III and IV in mitochondria of 
mammalians and other organisms are organized as supramolecular networks in the inner 
membrane (Schägger and Pfeiffer, 2000). This view is strengthened by the fact that the 
mitochondrial inner membrane is structurally subdivided into two main areas, the inner 
boundary membrane and the cristae, which are separated from each other by cristae 
junctions (Frey et al., 2002; Mannella, 2006; Reichert and Neupert, 2002; Zick et al., 
2009). In fact, the OXPHOS complexes are predominantly located in the protein-rich 
cristae and represent the most abundant protein components, thermodynamically 
favouring the aggregation into large supramolecular structures (Gilkerson et al., 2003; 
Helms, 2002; Vereb et al., 2003; Vogel et al., 2006; Wurm and Jakobs, 2006). It is 
speculated that these supramolecular arrangements facilitate the channelling of the 
substrates ubiquinone and cytochrome c or similar enzymatic advantages. Metabolites can 
be directly delivered from one enzyme to the next. Experimental evidence is given by the 
fact that supercomplexes display an increased activity of complex I (Schägger and Pfeiffer, 
2000). Therefore, supercomplexes are called respirasomes or metabolons  
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Figure 1: The mitochondrial respiratory chain. 
The OXPHOS complexes generate an electrochemical gradient over the mitochondrial inner membrane 
(IM). NADH is oxidized to NAD+.The electrons (e-) are transferred from NADH via complex I (CI) and 
ubiquinone (Q) to CIII. Afterwards they pass through the peripheral e--carrier cytochrome (cyt) c and 
CIV to the terminal acceptor oxygen, which is reduced to water. The electrochemical proton gradient is 
used by CV. Modified from (Vonck and Schäfer, 2009). IMS, intermembrane space; M, matrix; H+, 
proton. 
 
 
(Krause, 2007; Krause et al., 2004; Marques et al., 2007; Schägger, 2001; Schägger and 
Pfeiffer, 2000; Wittig et al., 2006; Wittig and Schägger, 2009). Another crucial function of 
respiratory chain supercomplexes appears to be the assembly or stabilization of complex I, 
the largest and most intricate respiratory complex. It is suggested that complex III and IV 
are involved to various extends in the assembly or stabilisation of complex I in mammals 
(Diaz et al., 2006; McKenzie et al., 2006; Schägger et al., 2004). The mitochondrial ATP 
synthase dimerizes and forms higher oligomeric structures. These dimer ribbons enforce a 
strong local curvature on the membrane which is hypothesized to increase the local proton 
concentration and to thereby optimize its own performance (Strauss et al., 2008). Notably, 
supercomplexes are necessary to keep cells and organisms in healthy condition (Wittig and 
Schägger, 2009).  
1.2.1. Defects of the oxidative phosphorylation system  
It is not surprising that a pathological change of the OXPHOS activity has definite 
consequences for the cell and the body. The OXPHOS can be directly or indirectly 
affected. A direct influence is characterized by mutations in genes which interfere either 
with the structure or the assembly of the various subunits and their prosthetic groups of the 
respiratory chain complexes and supercomplexes. Human OXPHOS diseases or 
mitochondrial encephalomyopathies are often characterized by multiple deficiencies of 
two or more respiratory complexes (Wittig and Schägger, 2009). They are especially 
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interesting from the genetic point of view because the respiratory chain is the only 
metabolic pathway in the cell that is under dual control of the mtDNA and the nuclear 
DNA (nDNA) (DiMauro, 2004). There remains a considerable lack of understanding of the 
pathogenic mechanism involved in the development of clinical symptoms and the 
deterioration seen in many patients. The central role of OXPHOS in metabolism suggests 
that many of these features are related to abnormal metabolic consequences of the defects 
(Munnich et al., 1992; Smeitink et al., 2006).  
 
Of the approximately 90 proteins that build up the respiratory chain, 13 are encoded 
by mtDNA (Falkenberg et al., 2007). Human mitochondrial DNA is a 16.569-kb circular, 
double stranded molecule, which contains 37 genes: besides the 13 structural genes, 2 
rRNA and 22 tRNA genes (DiMauro and Schon, 2008; Falkenberg et al., 2007). Disease 
related mutations are therefore not only found in protein coding genes, but also in genes 
which affect mitochondrial protein synthesis due to mutations in tRNA or rRNA genes. 
Most common diseases associated with protein-coding genes are NARP (neuropathy, 
ataxia, retinitis pigmentosa), MILS (maternally inherited Leigh syndrome, see below) and 
LHON (Leber’s hereditary optic neuropathy). NARP and MILS are associated with 
mutations in the ATPase6 gene (DiMauro, 2004; DiMauro and Davidzon, 2005). However, 
the mtDNA has lost more than 99 % of its original genes and most of its autonomy 
(DiMauro and Schon, 2008). Mitochondria now depend on nuclear factors for all basic 
functions. Disorders due to mutations in nDNA are very numerous since most respiratory 
chain subunits are nucleus-encoded – and, more importantly – because correct structure 
and functioning of the respiratory chain requires many steps, all of which are under the 
control of nDNA (DiMauro, 2004). Most mutations in nDNA encoded complex I or 
complex II subunits, cause Leigh syndrome (LS) which is characterized by 
neuropathological lesions already during early childhood caused by defective oxidative 
metabolism on the developing nervous system (DiMauro and Schon, 2008). Most 
mutations in complex I subunits cause LHON which is linked to mutations in both, 
mtDNA and nDNA. It leads to blindness in young adults. The pathology is linked to 
degeneration of retinal ganglion cells (Carelli et al., 2007).  
 
OXPHOS function and activity does not only depend on protein components but on 
the lipid environment as well. Complexes of the respiratory chain are embedded in the 
lipid milieu of the inner mitochondrial membrane (Wittig and Schägger, 2009). Cardiolipin 
(bisphosphatidyl glycerol) belongs to a subclass of phospholipids, in which backbones and 
head groups are formed from repeating units of phosphoryl and glycerol moieties 
(polyglycerophospholipids) (Schlame, 2008). It has a dimeric structure, i.e. it contains four 
Introduction 
 
14 
fatty acid chains. It is ubiquitous in eukaryotes and predominantly found in the 
mitochondrial inner membrane where it constitutes about 20% of the total lipids (Kent, 
1995; Schlame et al., 2000). It seems that the physical properties of cardiolipin allow a 
number of interactions that may have implications for the structural organization of 
biological membranes (Schlame, 2008). Loss of cardiolipin in yeast correlates with 
structural lability of the respiratory supercomplexes and with functional deficiency of the 
complex IV moiety that was found to be in an almost inactive but reversible resting state 
(Pfeiffer et al., 2003). Milder defects in the cardiolipin (CL) biosynthesis pathway had 
similar effects. Deletion of Taz1 (tafazzin), the cardiolipin transacylase or cardiolipin 
remodeler, reduces the stability of yeast respirasomes. This mutant contained a modified 
cardiolipin with altered fatty acid chain length and changed degree of unsaturation on 
position C2 (Brandner et al., 2005). Yeast Taz1 physically assembles in complexes with the 
ATP synthase and ADP/ATP carrier. In the absence of CL, the interaction is reduced 
compared to when CL is present (Claypool et al., 2008). 
Similarly, studies of Barth syndrome patients with deficient cardiolipin-remodeling due 
to mutations in the tafazzin gene, showed reduced stability of human respiratory 
supercomplexes (McKenzie et al., 2006). McKenzie observed an enhanced release of 
complex IV from I1III2IVn supercomplexes. This means that the altered cardiolipin affected 
specifically the stability of the complex III–IV interaction in yeast and human respirasomes. 
Thus, the devastating effects of Barth syndrome, clinically characterized by cardioskeletal 
myopathy, neutropenia and abnormal growth (Barth et al., 1983), can be explained by a 
reduced amount of respiratory complexes which is due to the decreased respirasome 
stability (Schlame and Ren, 2006; Wittig and Schägger, 2009). 
1.3. Mitochondrial dynamics 
The view of mitochondria constituting a bean-like structure is still found in textbooks 
for students in school and university. However, this structure is restricted to certain 
mammalian tissues, e.g. skeletal muscle. Meanwhile, experimental evidences favor the 
existence of dynamic interconnected networks that acquire specialized shapes, undergo 
changes in number and intracellular distribution and reorganize their morphology, often in 
response to the metabolic needs of the cell (Cerveny et al., 2007; Detmer and Chan, 2007; 
Hoppins et al., 2007; Suen et al., 2008; Westermann, 2008). The change of mitochondrial 
morphology rapidly adapting to cellular demands is critical for a number of important 
processes including calcium signaling, ROS protection, mtDNA maintenance  
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Figure 2: Human dynamin-related proteins (DRPs) involved in mitochondrial dynamics. 
(A) All DRPs contain a GTPase domain that binds and hydrolyses GTP, a middle domain and a GTPase 
effector domain (GED) that are involved in oligomerization and stimulation of GTPase activity. All 
contain a lipid interacting domain, either a pleckstrin-homology (PH) domain or transmembrane 
domains (TM, black). The mRNA of OPA1 is alternatively spliced. Involved exons are indicated in grey. 
(B) The core fusion machinery. The heptad regions (HR) of mitofusins (MFNs) are important for tethering 
of mitochondrial outer membrane. Bax/Bak control assembly of MFN2. OPA1 and MFN1 mediate inner 
membrane fusion. OPA1 is regulated by proteolytic processing and is also important for the cristae 
structure. 
(C) Model of mitochondrial fission mediated by DRP1. DRP1 undergoes GTP-driven assembly into a 
helical structure which drives the constriction of the mitochondrial tubule. 
MTS, mitochondrial targeting signal; CC, coiled coil region; IMS, intermembrane space; OM, outer 
membrane; IM, inner membrane; CM, cristae membrane. 
Modified from (Delettre et al., 2001; Hoppins and Nunnari, 2009; Lackner and Nunnari, 2009; Praefcke 
and McMahon, 2004; Zhang and Chan, 2007). 
 
 
 
and aging, developmental processes and apoptosis (Balaban et al., 2005; Chen et al., 
2003; Szabadkai et al., 2006; Tang et al., 2009; Youle and Karbowski, 2005). But, the 
fundamental functions of mitochondrial fusion are thought to be content mixing and to 
distribute mtDNA within the mitochondrial population and maintain respiratory competent 
and energized organelles, on the one hand. On the other hand, fission is required to 
efficiently distribute organelles to distal parts of the cell and is crucial for quality control by 
mitophagy and apoptosis (Hoppins et al., 2007; Lackner and Nunnari, 2009; Twig et al., 
2008). 
Mitochondrial morphology is maintained by two opposing events: fusion on the one 
hand, and division on the other hand. Much progress has been made in analyzing the 
components of fission and fusion machineries, but understanding the complex 
physiological functions of mitochondrial dynamics is just at its beginning. Intriguingly, 
major key players in fission and fusion belong to the same protein family, the dynamin 
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superfamily or dynamin-related protein family (DRPs) that mediate a variety of cellular 
processes [reviewed in (Praefcke and McMahon, 2004)]. The dynamins are structurally 
similar but functionally diverse GTP-binding proteins with sizes ranging from 70 to 
100 kD. More precisely, fission and fusion proteins belong to a subgroup called dynamin-
like GTPases [reviewed in (Hoppins et al., 2007; Hoppins and Nunnari, 2009; Lackner and 
Nunnari, 2009; Praefcke and McMahon, 2004; Suen et al., 2008)]. All DRPs possess a 
highly conserved GTPase domain that adopts the core fold common to all regulatory 
GTPases and certain additional regions predicted to adopt coiled-coil structures, referred to 
as middle domain and GTPase effector domain (GED) (Lackner and Nunnari, 2009; 
Praefcke and McMahon, 2004). Figure 2 A shows the domain architecture of the dynamin-
like GTPases involved in fusion and fission of mammalian mitochondria. Middle domain 
and GED domain participate in intra- and inter-molecular interactions that are required for 
self assembly and assembly stimulated hydrolysis (Sever et al., 1999; Smirnova et al., 
1999).  
1.3.1. Mitochondrial division 
Yeast Dnm1 and its human homologue Drp1 drive mitochondrial fission (Otsuga et al., 
1998; Smirnova et al., 1998) (see Figure 2). Yellow fluorescent protein targeted Drp1 was 
shown to cycle between mitochondria and the cytosol. Only a small fraction associated 
with mitochondrial outer membranes indicating continuous exchange of subunits between 
cytosolic and assembled Dnm/Drp1 (Legesse-Miller et al., 2003; Wasiak et al., 2007). In 
analogy to yeast, it is assumed that Drp1 assembles into spirals at constriction sites of 
mitochondrial division which is needed for its function (Ingerman et al., 2005; Jensen et 
al., 2000). GTP-driven Dnm1 self-assembly drives mitochondrial membrane constriction 
and is therefore necessary for mitochondrial fission (Hinshaw and Schmid, 1995; Naylor et 
al., 2006) (Figure 2 C). Dnm1/Drp1-dependent mitochondrial division requires additional 
players to target the mitochondrial division dynamin to the mitochondrial surface, most 
notably Fis1, which is anchored to the outer mitochondrial membrane via a C-terminal 
transmembrane domain (Mozdy et al., 2000). However, Drp1 recruitment is not altered in 
mammalian cells lacking Fis1 suggesting additional mechanisms to target Drp1 (Lee et al., 
2004). Upon stimulation of apoptosis Drp1 gets massively recruited to mitochondria 
indicating that those additional factors also increase following the induction of apoptosis 
(Breckenridge et al., 2003; Frank et al., 2001; Germain et al., 2005). Drp1 participates not 
only in the fission of mitochondria, but also in the regulation of the shape of other 
organells, such as peroxisomes (Schrader, 2006). 
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1.3.2. Mitochondrial fusion 
Mitochondrial fission is balanced by fusion. In vitro fusion assays provided evidence 
that inner and outer membrane fusion events are separable and have distinct energy 
requirements (Malka et al., 2005; Meeusen et al., 2004). However, both processes are 
certainly linked and the idea of communication between these machineries resulting in 
coupled outer and inner membrane fusion is favoured (Hoppins et al., 2007). The first 
protein identified to be involved in mitochondrial outer membrane fusion was the fuzzy 
onions gene (Fzo1) (Hales and Fuller, 1997). Subsequently, homologues in other species 
including mammals and yeast could be defined. Interestingly, mammals express two Fzo1 
homologues which were termed the mitofusins, mitofusin 1 and mitofusin 2, Mfn1 and 
Mfn2, respectively (Hermann et al., 1998; Rojo et al., 2002; Santel and Fuller, 2001) (see 
Figure 2 A). Mitofusins are essential for embryonic development: lacking either Mfn1 or 
Mfn2 in mice is embryonic lethal (Chen et al., 2003). In cell culture models, it has been 
shown that mitofusins are essential for mitochondrial fusion: knockout mouse embryonic 
fibroblasts of Mfn1 or Mfn2 show predominantly fragmented mitochondria and have 
greatly reduced mitochondrial fusion in vivo (Chen et al., 2005; Chen et al., 2003). They 
share an N-terminal GTPase domain and a bipartite transmembrane domain at the C-
terminus which spans the outer membrane of mitochondria, resulting in an orientation to 
the cytosol of both amino- and carboxy-termini (Fritz et al., 2001; Rojo et al., 2002). Two 
hydrophobic heptad repeats flank the transmembrane domains which are thought to form 
helical coiled-coil structures (Brown et al., 1996; Hoppins et al., 2007). Intermolecular as 
well as intramolecular assemblies exist within mitofusins and are crucial for fusion activity 
(Griffin and Chan, 2006) (see Figure 2 B). Additionally, in vitro experiments showed that 
Mfn1, and to a lesser extent Mfn2, can form homo-oligomeric complexes in trans, 
indicating that mitofusins and Fzo1 enable the GTP dependent tethering of outer 
membranes through complexes formed by molecules derived from opposing membranes 
(Hoppins et al., 2007; Ishihara et al., 2004). Human MFN2 is linked to Charcot-Marie-
Tooth (CMT2A – see chapter  1.3.4) disease (Züchner et al., 2004). Interestingly, homo-
oligomeric complexes formed by many Mfn2 disease mutants are non-functional for 
mitochondrial fusion. Notably, wild-type Mfn1, but not Mfn2, complements mutant Mfn2 
through the formation of hetero-oligomeric complexes, including complexes that form in 
trans between mitochondria (Detmer and Chan, 2007). This might explain the 
susceptibility of tissues with low expression of Mfn1 in CMT2A pathogenesis. A 
conditional knockout of mitofusins in the cerebellum of mice revealed a requirement of 
Mfn2, but not of Mfn1, for Purkinje cells (Chen et al., 2007). This underlines a close 
interplay of both mitofusins (Amiott et al., 2008; Detmer and Chan, 2007). In summary, 
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analysis of the functions of Mfn1 and Mfn2 and their kinetic properties reveal differences, 
indicating that their exact roles in fusion may not be completeIy redundant (Ishihara et al., 
2004). Intriguingly, de Brito and Scorrano showed recently that Mfn2 is enriched at contact 
sites between the endoplasmic reticulum (ER) and mitochondria, thereby regulating both, 
the morphology of the ER and mitochondria and tethering both organelles to each other. 
This function of Mfn2 is important for mitochondrial calcium uptake (de Brito and 
Scorrano, 2008).  
 
Interestingly, the proapoptotic Bcl-2 family members Bax and Bak also effect 
mitochondrial dynamics (Karbowski et al., 2002; Karbowski et al., 2006) (Figure 2 B). Bax 
colocalizes with Drp1 and Mfn2 proteins during programmed cell death (Karbowski et al., 
2002). Additionally, in non-apoptotic cells Bax and Bak regulate the assembly of Mfn2 into 
high molecular weight complexes allowing fusion (Karbowski et al., 2006).  
 
Outer and inner membrane fusion are separable events, but nevertheless, are 
interconnected (Malka et al., 2005; Meeusen et al., 2004). In yeast, one of the essential 
components of mitochondrial fusion is Ugo1 (Sesaki and Jensen, 2001; Sesaki et al., 2003; 
Wong et al., 2003). Ugo1 is an outer membrane protein with its N-terminus in the cytosol 
and the C-terminus inside of mitochondria (Sesaki and Jensen, 2001). Since it physically 
interacts independently with both, the inner and outer membrane fusion machineries, it is 
proposed to function as an adaptor, creating a two membrane spanning fusion complex 
(Sesaki and Jensen, 2001; Sesaki and Jensen, 2004; Wong et al., 2003). Ugo1, a modified 
member of the mitochondrial transporter family, has three transmembrane domains acting 
as a dimer in outer and inner membrane fusion. Hoppins et al. suggested that it acts after 
membrane tethering, indicating its operation at the lipid-mixing step of fusion (Coonrod et 
al., 2007; Hoppins et al., 2009).  
 
However, neither a mammalian homologue of Ugo1 exists nor an analogue of Ugo1 
has been identified so far. Hoppins hypothesized that one of the approximately 50 
members of the transport/carrier protein family in humans might be one Ugo1 analogue 
(Hoppins et al., 2009). However, direct interaction of Mfn1, Mfn2 and OPA1 has been 
demonstrated by co-immunoprecipitation experiments (Guillery et al., 2008). Whether this 
interaction is sufficient to mediate correlated inner and outer membrane fusion is not 
understood. However, OPA1 is involved in the inner membrane fusion, and interestingly, 
this depends on Mfn1, but not on Mfn2 (Cipolat et al., 2004). OPA1 (as its yeast 
homologue Mgm1) is a large GTPase of the DRP family which is attached to the inner 
membrane facing the GTPase domain to the intermembrane space (Olichon et al., 2003; 
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Olichon et al., 2002; Wong et al., 2000; Wong et al., 2003) (Figure 2 B). Lacking either 
Mgm1 or OPA1 in cells results in fragmented mitochondria (Sesaki et al., 2003; Wong et 
al., 2000). Both proteins harbor an N-terminal mitochondrial targeting sequence (MTS), 
two consecutive hydrophobic segments, a coiled coil domain, a GTPase domain, and a 
GED (GTPase effector domain: middle and a C-terminal coiled-coil domain) (Hoppins et 
al., 2007; Hoppins and Nunnari, 2009; Zhang and Chan, 2007) (see Figure 2 A).  
It has been shown that yeast Mgm1 mediates fusion through oligomerization, GTP 
hydrolysis and binding to negatively charged phospholipids (like cardiolipin, phosphatic 
acid, phosphatidylserine, and phosphatidylinositol 3,4-bisphosphate) (Meglei and 
McQuibban, 2009). Yeast Mgm1 gives rise for an alternative topogenesis. At steady state 
two isoforms exist. A long isoform is attached to the inner membrane (l-Mgm1), whereas a 
short isoform, generated by ATP-dependent processing of l-Mgm1 by the inner membrane 
rhomboid protease Pcp1, is soluble in the intermembrane space (s-Mgm1) (Herlan et al., 
2004; Herlan et al., 2003; McQuibban et al., 2003). Both isoforms are important for fusion 
activity and mtDNA maintenance, although l-Mgm1 can support reduced levels of fusion 
in cells (Herlan et al., 2003; Sesaki et al., 2003). Interestingly, in vitro fusion assays by 
Meeusen et al. with temperature sensitive mutants of Mgm1 revealed functional outer 
membrane fusion whereas inner membrane fusion was abolished, although membranes 
stayed in close contact. More precisely, authors demonstrated that a functional GTPase 
domain and GED in trans enable tethering on opposing membranes. Thus, in addition to 
fusion of inner membranes to single lipid bilayers, Mgm1 promotes the tethering of 
membranes which is needed prior to fusion (Meeusen et al., 2006).  
OPA1 is also present as l-OPA1 and s-OPA1 isoforms, but the human OPA1 gene 
encodes 31 exons of which exon 4, 4b and 5b are involved in tissue and cell type specific 
alternative splicing resulting in the generation of eight different mRNA variants (Delettre et 
al., 2001; Olichon et al., 2002; Satoh et al., 2003) (Figure 2 A). Alternative splicing and 
subsequent processing results in the accumulation of five apparent isoforms of the OPA1 
protein, two long and three short isoforms, of which both are needed for full fusion activity 
indicating that the balance between both isoforms regulates mitochondrial fusion (Delettre 
et al., 2001; Duvezin-Caubet et al., 2007; Ishihara et al., 2006; Olichon et al., 2003; 
Olichon et al., 2007; Song et al., 2007). In addition to the mitochondrial processing 
peptidase (MPP) processing site, the polypeptides encoded by each mRNA splice form 
contain an S1 cleavage site, and some also contain a more C-terminal S2 cleavage site 
(Ishihara et al., 2006) (Figure 2 A). S2 cleavage is carried out by the i-AAA protease facing 
the inter membrane space (Yme1), whereas the protease cleaving at site S1 is not known 
(Griparic et al., 2007; Song et al., 2007). The mammalian homologue of yeast Pcp1, 
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presenilin-associated rhomboid-like (PARL), and Paraplegin (see chapter  0), a subunit of 
the m-AAA protease, have been implicated in this processing (Cipolat et al., 2006; Frezza 
et al., 2006; Ishihara et al., 2006). Interestingly, reconstituted OPA1 in yeast can be 
processed by the m-AAA protease but not by PARL (Duvezin-Caubet et al., 2007). OPA1 
and Mgm1 were linked to apoptosis via its role of cristae maintenance besides 
mitochondrial fusion (Frezza et al., 2006; Meeusen et al., 2006), which is discussed in the 
next paragraph. 
1.3.3. Inner membrane dynamics  
The inner membrane of mitochondria is organized in two morphologically distinct 
domains, the inner boundary membrane (IBM) and the cristae membrane (CM) which are 
connected by narrow tubular cristae junctions (CJ) (Frey et al., 2002; Mannella, 2006; 
Mannella et al., 2001; Reichert and Neupert, 2002; Vogel et al., 2006). Electron 
tomography revealed that cristae are not simply random folds in the inner membrane but 
rather internal compartments formed by invaginations of the membrane (Mannella, 2006). 
Furthermore, the ultrastructure of mitochondria varies considerably between tissues, 
organisms and the physiological state of the cell (Zick et al., 2009). For instance, 
dependent on the energy status of the cell two conformations have been observed: a 
“condensed” conformation (condensed matrix) characterized by a large swollen intra-
cristal space volume (respiratory state III − high ADP), and an “orthodox” state, where the 
volume was considerably smaller (respiratory state IV − low ADP) (Zick et al., 2009). Due 
to different functions the IBM and the CM are distinct from each other, e.g. the CM is 
enriched in proteins involved in oxidative phosphorylation, iron/sulphur cluster 
biogenesis, protein synthesis and transport of mtDNA-encoded proteins, whereas the IBM 
is enriched in proteins involved in fusion and protein transport of nuclear-encoded 
proteins. Interestingly, the observed distribution of proteins has been shown to change 
upon variations of the physiological state, further underlining a dynamic organization of 
the inner membrane (Vogel et al., 2006). 
1.3.3.1. The ATP synthase and cardiolipin as cristae organizers? 
Several proteins or protein complexes have been implicated in cristae structure or 
organization. Influencing the oligomeric state or the proton channel ATP6 of the F1FO-ATP 
synthase revealed disarranged cristae [reviewed in (Zick et al., 2009)]. It is discussed that 
dimerization and oligomerization of this complex generates a certain membrane curvature 
to the CM, increasing locally the proton concentration and thereby optimizing the 
performance of the ATP synthase (Dudkina et al., 2006; Minauro-Sanmiguel et al., 2005; 
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Strauss et al., 2008). Additionally, stability of the F1FO-ATP synthase affects the membrane 
potential pointing to a role for organization of specific microdomains of OXPHOS 
complexes in the CM resulting in optimized respiration (Bornhovd et al., 2006). 
Interestingly, lymphoblast mitochondria from Barth syndrome patients having mutations in 
the cardiolipin remodeler tafazzin have abnormalities involving adhesions of inner 
mitochondrial membranes with subsequent collapse of the intracristae space (Acehan et 
al., 2007). Cristae density is reduced and the structure is altered suggesting that tafazzin 
affects cristae morphogenesis caused by reduced cardiolipin (or cardiolipin derivative) 
levels. However, it is not clear whether the observed effects are caused by a yet unknown 
structural role of tafazzin on CMs or by an indirect effect due to reduced stability of the 
supercomplexes of the respiratory chain (Acehan et al., 2007). Nevertheless, this study 
links alterations in levels of specific phospholipids to inner membrane dynamics. 
1.3.3.2. Cristae remodelling during apoptosis 
Alterations and remodelling of inner membrane structures are evident in numerous 
human disorders and during apoptosis (Zick et al., 2009). A central step in the 
mitochondrial apoptotic pathway is the release of soluble proteins upon selective 
permeabilization of the outer membrane including cytochrome c (cyt c) or apoptosis 
inducing factor (AIF) (Green and Kroemer, 2004). Cristae remodelling upon apoptosis is 
widely believed but the answer to the question “what comes first? – cyt c release or the 
changes of the cristae structure?” is highly controversial. Sun et al. proposes that cristae 
remodelling and, in particular, the widening of the cristae junctions are necessary to 
release cyt c. Additionally, it was shown that caspases seemed to remodel cristae and to 
widen the CJ independent of the release of cyt c and the loss of the mitochondrial 
membrane potential (Sun et al., 2007). Interestingly, Frezza stated that the tightness of CJ 
correlated with oligomerization of the long (membrane anchored) and short (soluble) 
OPA1 isoforms. Widening of CJ induced by the truncated BH3-only protein Bid (tBid) 
facilitated cyt c release (Frezza et al., 2006; Scorrano et al., 2002).  
Conversely, Yamaguchi observed a narrowing of CJ which goes along with the 
disassembly of OPA1 complexes and increased availability of cyt c at the outer membrane 
(Yamaguchi et al., 2008). It is hypothesized that in the Bcl-2 inhibitable Bax/Bak-
dependent intrinsic pathway of apoptosis the release of cyt c from mitochondria is a 
consequence of two carefully coordinated events: formation of outer membrane pores and 
opening of cristae junctions triggered by OPA1 oligomer disassembly. Both steps are 
necessary for the complete release of cyt c (Yamaguchi and Perkins, 2009). Interestingly, 
both, mitochondrial outer membrane permeabilization and CJ opening were caspase 
independent events speaking against caspase induced late and gross changes of cristae 
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morphology like it was suggested by Sun (Sun et al., 2007; Yamaguchi et al., 2008). 
Notably, a disassembly mutant of OPA1 blocked cyt c release and apoptosis, but not Bax 
activation (Yamaguchi et al., 2008).  
Three candidate proteins have been implicated in CJ formation: OPA1, mitofilin and 
the prohibitins (Zick et al., 2009). OPA1 is discussed above. Deletion of the inner 
membrane protein Mitofilin demonstrated disorganized cristae. Closely packed stacks of 
concentric sheets without visible CJs have been observed, with no effect on mitochondrial 
morphology but an increased sensitivity towards apoptotic stress (John et al., 2005). 
Prohibitins have been reported to form large ring-like complexes with a diameter fitting 
well to those reported for CJs (Tatsuta et al., 2005) (see  1.4.2). Mammalian prohibitins are 
linked to OPA1 processing and will be discussed in the next chapter. 
1.3.3.3. Interfering with OPA1 processing – a trigger for apoptosis? 
Distinct triggers of apoptosis induce the processing of OPA1 (Guillery et al., 2008; 
Ishihara et al., 2006) (see chapter  1.3.5.3) which causes an altered cristae morphogenesis. 
Prohibitins exert essential function for cristae morphogenesis by controlling the stability of 
long OPA1 isoforms (Merkwirth et al., 2008). Loss of function of prohibitins leads to 
fragmentation of mitochondria, disorganized mainly vesicular cristae and an increased 
sensitivity towards apoptotic stimuli (see chapter  1.4.2). LETM1 (yeast Mdm38), whose 
downregulation and overexpression has been linked to mitochondrial morphology and 
cristae aberrations which has been implicated in regulating OPA1 processing and to 
sensitize cells to apoptosis triggered by certain inducers (Dimmer et al., 2008; Piao et al., 
2009; Tamai et al., 2008). LETM1 is an inner-membrane protein with a large domain 
extruding into the matrix. It interacts with the mitochondrial AAA-ATPase BCS1L which is 
important for respiratory complex III assembly. Indeed, siRNA of both BCS1L and LETM1 
interfered with assembly of certain respiratory complexes and supercomplexes. 
Downregulation leads to a swollen matrix, overexpression to an opposite phenotype – 
swollen cristae (Tamai et al., 2008). The morphological changes upon siRNA were fully 
reversible upon treatment with the K+/H+ ionophore nigericin, suggesting a role for 
Mdm38/LETM1 as a K+/H+ antiporter. Whether the effect on cristae is due to its proposed 
transporter activity or to the stabilizing function of LETM1 on respiratory chain complexes 
remains open. Another protein interfering with mitochondrial cristae morphogenesis and 
resistance to apoptosis is MICS1, a protein residing in the inner membrane (Oka et al., 
2008). SiRNA mediated downregulation of this seven transmembrane domains spanning 
protein causes fragmentation, disorganized cristae and stimulates release of proapoptotic 
proteins. Cristae appeared less and became curved visualized by ring-like structures. 
Overexpression induced mitochondrial aggregation and partially inhibited cyt c release 
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during apoptosis, regardless of Bax activation. OPA1 processing is not impaired in general 
but was enhanced upon induction of apoptosis.  
However, whether LETM1 or MICS1 directly control cristae via OPA1 is not clear. 
Moreover, whether LETM1, MICS1 or the prohibitins affect the OPA1 complex or CJ 
opening remains elusive. In addition, the mechanism of how cristae and CJs are formed is 
also completely unknown. In conclusion, studying inner membrane dynamics is a 
complicated field, since observed phenotypes can probably not be explained by simply 
one specific or direct function of one protein or lipid. Future analyses will have to reveal 
the exact roles of the involved proteins OPA1, prohibitins, LETM1, MICS1, or mitofilin in 
determining cristae morphology, CJ opening and its link to apoptosis. 
1.3.4. Pathogenic alterations of mitochondrial dynamics 
Mitochondria constantly fuse and divide and must be distributed to reach areas of high 
energy demands, e.g. synaptic endings in neurons (Cerveny et al., 2007; Detmer and 
Chan, 2007; Knott et al., 2008). Interfering with these balanced mechanisms has severe 
consequences on cellular and organism level. Therefore, it is obvious that several human 
diseases are associated with mutations in genes that are essential for mitochondrial 
dynamics. Notably, the majority of these diseases involve the degeneration of specific 
nerves, indicating that neurons are particular prone to defects in mitochondrial dynamics 
(Bossy-Wetzel et al., 2003; Chen and Chan, 2006; Knott and Bossy-Wetzel, 2008; Knott et 
al., 2008). 
 
Heterozygous mutations in the fusion protein OPA1 cause autosomal dominant optic 
atrophy (ADOA), the Mendelian counterpart of LHON. It is the most common heritable 
form of optic neuropathy and is characterized by the degeneration of retinal ganglion cells, 
the axons of which form the optic nerve (Alexander et al., 2000; Delettre et al., 2000; 
DiMauro and Schon, 2008). The large majority of mutations in the OPA1 gene described 
to date is predicted to lead to a truncated OPA1 protein and to haploinsufficiency (Ferre et 
al., 2005). Classic DOA usually begins before 10 years of age, with a large variability in 
the severity of clinical expression, which may range from non-penetrant unaffected cases 
up to very severe, early onset cases, even within the same family carrying the same 
molecular defect (Amati-Bonneau et al., 2008; Carelli et al., 2007; Delettre et al., 2002). 
Recently, OPA1 has been linked to autophagy, the selective elimination of organelles. 
Before autophagy, mitochondria lose membrane potential (ΔΨm) and OPA1. 
Overexpression of OPA1 decreases mitochondrial autophagy (Twig et al., 2008).  
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Table 1: The genetic diseases of mitochondrial shaping proteins. 
Disease Major phenotype Gene affected Mitochondrial 
morpholgy 
Involvement of 
other organelles 
ADOA loss of retinal ganglion 
cells 
OPA1 probably fragmented not known 
CMT2A loss of sensorimotor 
axons 
MFN2 probably fragmented yes, ER 
CMT4A loss of sensorimotor 
axons 
GDAP probably fragmented not known 
WHS seizures LETM1 probably fragmented not known 
 
Lethal 
metabolic 
syndrome 
metabolic and CNS 
problems 
DRP1 elongated yes, peroxisomes 
Major pathological, genetic and mitochondrial features of genetic diseases associated with mutations in 
genes coding for mitochondria-shaping proteins are shown. See text for more detail. DOA, dominant 
optic atrophy; CMT, Charcot-Marie-Tooth type; WHS, Wolf-Hirschhorn syndrome; CNS, central 
nervous system. 
 
 
Additionally, OPA1+/- heterozygous mice have increased numbers of autophagosomes in 
the retinal ganglion cell layer indicating that ADOA is caused by an increase in abnormal 
mitochondria which are subjected to degradation by autophagy (White et al., 2009).  
Another fusion gene, MFN2 or mitofusin 2 is linked to Charcot-Marie-Tooth (CMT) 
disease (Züchner et al., 2004). CMT is one of the most common hereditary neuropathies. It 
is caused by mutations in at least 30 different genes. Patients suffer from progressive distal 
motor and sensory impairments that start in feet and the hands as a result of the 
degeneration of the long peripheral nerves. Depending on the type of CMT, these diseases 
are caused by either a primary defect in the Schwann cells that myelinate the peripheral 
nerves or by a defect in the neurons themselves (Detmer and Chan, 2007; Züchner and 
Vance, 2005). 40 mutations have been associated with MFN2 or CMT2A, leading to an 
axonopathy affecting neurons (Züchner et al., 2004). Although most patients with MFN2 
mutation don’t have optic atrophy and most patients with OPA1 mutation do not have 
CMT, some families harboring mutations in MFN2 show up phenotypes characterized by 
the coexistence of peripheral neuropathy and optic atrophy, like in ADOA (Züchner et al., 
2006). This CMT type 6 phenotype is presumably caused by deficient mitochondrial 
movement (DiMauro and Schon, 2008). Another form of CMT is accociated with defects in 
mitochondrial dynamics. Ganglioside-induced differentiation-associated protein-1 
(GDAP1) is mutated in CMT4A, one of the recessive forms (Niemann et al., 2005).  
The Wolf-Hirschhorn syndrome (WHS) is caused by a partial deletion of the short arm 
of one chromosome 4 resulting in severe pre-and post-natal growth retardation, 
impairment of muscle tone, severe mental retardation, developmental delay with 
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microcephaly, and in all cases, seizures (Zollino et al., 2003). The gene LETM1 (leucine 
zipper EF-hand-containing transmembrane protein 1 − homologue of yeast Mdm38) is 
deleted in all patients with seizures, suggesting a role for haploinsufficiency in the 
pathogenesis of seizures (Endele et al., 1999; Schlickum et al., 2004; Zollino et al., 2003).  
An infant patient with a dominant-negative fission gene DRP1 allele has been reported. 
This patient died at 1 month of age and had abnormalities, including reduced head growth, 
increased lactic acid and optic atrophy. Isolated fibroblasts from this patient showed 
elongated mitochondria and peroxisomes (Waterham et al., 2007).  
1.3.5. Regulation of mitochondrial dynamics 
Several steps of regulation have been already described above, e.g. the high molecular 
weight complex formation of mitofusin 2 which is dependent on Bax and Bak (Karbowski 
et al., 2006). However, recent studies have uncovered additional regulatory mechanisms 
that control the activity, assembly, distribution and stability of the key components for 
mitochondrial fusion and division. 
1.3.5.1. Regulation by post-translational modifications 
Post-translational modifications have been shown mainly for Drp1/Dnm1. Two 
phosphorylation events have been demonstrated in the GED of Drp1, which results 
dependent on the site in opposing effects for mitochondrial shape. Phosphorylation on site 
S616 promotes mitochondrial fission during mitosis. Conversely, dephosphorylation on 
S637 by the calcium-dependent phosphatase calcineurin promotes fission and is involved 
in the propagation of apoptosis (Chang and Blackstone, 2007; Cribbs and Strack, 2007; 
Jahani-Asl and Slack, 2007; Taguchi et al., 2007). Additionally, mitochondrial dysfunction, 
characterized by depolarization and increased cytosolic calcium levels, activates Drp1-
bound calcineurin. Calcineurin dephosphorylates Drp1 thereby recruiting Drp1 to 
mitochondria (Cereghetti et al., 2008).  
1.3.5.2. Regulation by the lipid milieu 
Downstream of the tethering of mitochondrial outer membranes in the fusion process 
acts mitochondrial phospholipase D (MitoPLD). This protein belongs to a superfamily of 
lipid-modifying enzymes. It targets to the mitochondrial surface and promotes trans-
mitochondrial membrane adherence in an Mfn-dependent manner by hydrolysing 
cardiolipin to generate the phosphatic acid (Choi et al., 2006). In addition to serving as a 
membrane anchoring site, phosphatic acid has been proposed to act as a fusogenic lipid in 
biophysical modeling studies by lowering the activation energy for membrane bending 
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during generation and expansion of fusion pores (Kooijman et al., 2003; Kozlovsky et al., 
2002).  
An interesting study by Osman et al. revealed a link between the lipid composition of 
mitochondrial membranes and the regulation of mitochondrial dynamics. Deletion of yeast 
Ups1, which has been previously shown to be involved in the alternative topogenesis of 
Mgm1, results in the loss of Cardiolipin and an accumulation of l-Mgm1. In contrast, 
knockout of Gep1 (homologue of Ups1) significantly impairs the formation of s-Mgm1, but 
results in decreased stability of phosphatidylethanolamine (Osman et al., 2009). Like 
Tafazzin, deletion of Gep1 leads to abberant cristae morphogenesis. The authors suggest a 
novel mechanism, namely that an altered phospholipid composition of the inner 
membrane impairs Mgm1 cleavage. In line, yeast Mgm1 mediates fusion by binding to 
negatively charged phospholipids like cardiolipin (Meglei and McQuibban, 2009). In 
conclusion, these findings imply a role of a certain lipid environment for divergent forms of 
membrane fusion (Cerveny et al., 2007; Choi et al., 2006; Osman et al., 2009; Zhang and 
Chan, 2007). Intriguingly, cardiolipin, previously shown to participate in mitochondria-
dependent apoptosis, provides an essential activating platform for caspase-8 on 
mitochondria (Gonzalvez et al., 2008). Thus, interfering with cardiolipin might directly 
affect programmed cell death pathways. 
1.3.5.3. Regulation by degradation and processing events 
Drp1 has been shown to get desumoylated by SENP5 (SUMO specific protease) 
dependent on Bax/Bak stimulation (Wasiak et al., 2007; Zunino et al., 2007). This 
modification correlates with the stable association of Drp1 with mitochondrial membranes 
(Wasiak et al., 2007). MARCH5, a mitochondrial E3 ubiquitin ligase, regulates the 
subcellular trafficking of Drp1, likely by impacting the correct assembly at scission sites or 
the disassembly step of fission complexes (Karbowski et al., 2007). However, whether 
sumoylation or ubiquitinylation targets Drp1 for degradation is unclear. 
The yeast mitofusin Fzo1 is an unstable protein and its steady state level is critical to 
maintain mitochondrial morphology. Either deletion or overexpression of Fzo1 alters 
mitochondrial fusion resulting in abnormal aggregated mitochondria (Escobar-Henriques et 
al., 2006; Fritz et al., 2003; Hermann et al., 1998; Rapaport et al., 1998). Two 
independent proteolytic pathways regulate Fzo1 steady state protein levels. During non-
vegetative growth, which is mimicked by adding the mating factor alpha to cells, Fzo1 is 
subjected to proteasome dependent degradation, and this subsequently leads to 
mitochondrial fragmentation (Escobar-Henriques et al., 2006; Neutzner and Youle, 2005). 
During vegetative growth, Fzo1 is degraded in a constitutive manner which depends on 
the F-box protein Mdm30 (Escobar-Henriques et al., 2006). F-box proteins are generally 
Introduction 
 
27 
thought to serve as substrate recognition elements of ubiquitin ligases of the Skp1-Cullin-F-
box (SCF) family (Petroski and Deshaies, 2005; Willems et al., 2004). However, in the 
absence of Mdm30, the steady state concentration of Fzo1 is increased and yeast cells 
accumulate aggregated and fragmented mitochondria (Fritz et al., 2003). Fzo1 gets 
ubiquitinylated by an SCF ubiquitin ligase that includes Mdm30 as a substrate recognition 
factor, thereby identifying a critical regulatory outer membrane protein being a target of the 
cytosolic ubiquitin-proteasome system (Cohen et al., 2008).  
Mgm1 and the mammalian OPA1 are cleaved to maintain mitochondrial fusion activity 
(Herlan et al., 2003; Ishihara et al., 2006; Olichon et al., 2003; Sesaki et al., 2003; Song et 
al., 2007). Long isoforms of Mgm1/OPA1 get processed upon import into mitochondria to 
create the short isoforms which, together with the long isoforms, assemble into fusion 
active OPA1 complexes (see chapter  1.3.2). This processing event is termed constitutive 
processing. However, it is distinct from an induced cleavage. In fact, processing of l-OPA1 
to s-OPA1 is stimulated to rapid completion by dissipation of the membrane potential with 
CCCP, subsequently followed by the fragmentation of the mitochondrial network 
(Duvezin-Caubet et al., 2006; Griparic et al., 2007; Guillery et al., 2008; Ishihara et al., 
2006; Song et al., 2007). Moreover, apoptosis induction and MOMP (mitochondrial outer 
membrane permeabilization) induce OPA1 cleavage as well (Guillery et al., 2008; Ishihara 
et al., 2006) (see  1.3.3.3). On a molecular level Baricault et al. hypothesized that 
decreased mitochondrial ATP levels, either generated by apoptosis induction, membrane 
potential dissipation or inhibition of ATP synthase, is the common and crucial stimulus that 
controls OPA1 processing. In addition, it as been reported that ectopic iron addition can 
activate OPA1 cleavage, whereas zinc inhibits this process (Baricault et al., 2007). In line, 
this processing event seems to be metalloprotease-mediated (Guillery et al., 2008). The 
induced processing is carried out at site S1 by a yet unknown protease (Song et al., 2007). 
Meanwhile, Loucks et al. identified a metal-independent fourth cleavage site in the N-
terminal region of cerebellar granule cell OPA1 which seem to be under the indirect 
control of certain caspases upon induction of apoptosis (Loucks et al., 2009). They claim 
that the truncated protein lacks a specific lysine residue within the GTPase domain which 
contributes to mitochondrial fragmentation. The protease cleaving at site S1 during 
constitutive processing of OPA1 to generate a balanced equilibrium of long and short 
OPA1 isoforms is unknown. Likewise, which protease/s cleave/s at site S1 upon induced 
processing and at the caspase-dependent processing site remains to be identified. Notably, 
as mitochondrial morphology depends on both long and short isoforms of OPA1, 
proteolytic processing is an important process regulating mitochondrial dynamics and 
apoptosis. 
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1.4. Protein quality control in mitochondria 
Most mitochondrial proteins are encoded by nuclear genes, whose unfolded protein 
products are imported into mitochondria by translocases in the inner and/or outer 
membrane (Neupert and Herrmann, 2007). Other mitochondrial proteins, which are 
encoded in the mitochondrial genome, are synthesized in the mitochondrial matrix which 
subsequently assemble into respiratory chain complexes in the inner membrane (Fontanesi 
et al., 2008; Rak et al., 2009). It is not surprising that the organization of the expression of 
two genomes and arrangement of all proteins and complexes in the four compartments of 
the highly dynamic mitochondria requires strict quality control surveillance. Indeed, this is 
maintained by a network of molecular pathways that include quality control machineries, 
such as chaperones and proteases (Broadley and Hartl, 2008). 
During protein import, the mitochondrial processing peptidase (MPP) (Brunner et al., 
1994), the intermediate peptidase (MIP) (Isaya et al., 1994; Kalousek et al., 1992) and the 
innermembrane peptidase (IMP) (Behrens et al., 1991; Esser et al., 1996; Schneider et al., 
1991) are responsible for the cleavage of targeting presequences of nuclearly encoded 
proteins. Molecular chaperone proteins of the Hsp70 and Hsp100 family stabilize 
misfolded proteins against aggregation or mediate the dissolution of protein aggregates and 
thereby ensure proteolysis (Bateman et al., 2002; Röttgers et al., 2002; Wagner et al., 
1994). Eukaryotic cells respond to the accumulation of unfolded proteins by sensing 
perturbations of protein homeostasis in a cellular compartment and, in turn, activate genes 
that enhance the protein-handling capacity of the compartment (Benedetti et al., 2006; Ron 
and Walter, 2007). This process is named unfolded protein response (UPR) which has been 
identified in the cytosol, in the ER (UPRER) and also within mitochondria (UPRmt) (Benedetti 
et al., 2006; Lindquist, 1986; Martinus et al., 1996; Ron and Walter, 2007; Ryan and 
Hoogenraad, 2007; Yoneda et al., 2004; Zhao et al., 2002). The UPRmt induces nuclear 
genes encoding the mitochondrial matrix chaperones Hsp60 and Hsp10 as well as MPP, 
the matrix serine protease ClpP and the inner membrane AAA protease Yme1 (Aldridge et 
al., 2007; Zhao et al., 2002). Proteases involved in the degradation of misfolded and non-
assembled proteins to peptides, which are subsequently either exported from the organelle 
or degraded further to amino acids, are derived from ATP-dependent bacterial proteases 
and highly conserved in eukaryotes (Koppen and Langer, 2007). ClpP, together with its 
AAA+ chaperone ClpX, and the Lon protease are active in the matrix of mitochondria 
(Koppen and Langer, 2007; Tatsuta and Langer, 2008). In E. coli, ClpXP can recognize its 
substrates which get unfolded by ClpX and then threaded into the ClpP proteolytic 
chamber through the narrow axial pores for degradation (Yu and Houry, 2007). Only the 
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unfolding and threading by the chaperone require ATP binding and hydrolysis, while 
proteolysis by ClpP is energy independent.  
The mitochondrial membrane is the protein-richest cellular membrane and contains the 
respiratory chain. Therefore, protein homeostasis is of major importance to maintain 
mitochondrial function. Membrane anchored ATP-dependent AAA proteases conduct the 
quality control surveillance in the inner membrane.  
1.4.1. AAA proteases as key regulators of protein quality control 
and mitochondrial biogenesis 
AAA (ATPases associated with various cellular activities) was first used to describe a 
class of ATP-hydrolyzing enzymes with a range of functional roles (Kunau et al., 1993). 
Subsequent work showed that AAA proteins are actually a subset of a much larger 
superfamily of ATPases, now referred to as AAA+ protein family (Neuwald et al., 1999). 
These P-loop NTPases are defined by the presence of the nominal P-loop, a conserved 
nucleotide phosphate-binding motif, also referred to as the Walker A motif, and a second, 
more variable region, called the Walker B motif. The Walker A motif is important for 
binding of nucleotides, which are typically ATP or GTP, and Mg2+ (Saraste et al., 1990; 
Snider and Houry, 2008; Walker et al., 1982). The glutamate side chain in the Walker B 
motif is thought to activate a water molecule for attack on the γ-phosphate of bound ATP, 
and therefore, is important for ATP hydrolysis (Baker and Sauer, 2006; Hersch et al., 2005) 
(Figure 3 B). It has been shown that specific residues in the pore of the ATPase are in 
contact with the substrate molecule (Martin et al., 2008). ATP binding and hydrolysis 
enable the moving of these residues thereby unfolding and pulling the substrate into the 
proteolytic chamber of the protease (Martin et al., 2008). 
In all organisms, many vital cellular processes, including membrane fusion, cell cycle 
regulation, organelle biogenesis, protein repair and degradation, are controlled by 
members of the AAA+ superfamily (Beyer, 1997; Mogk et al., 2008; Neuwald et al., 1999; 
Ogura and Wilkinson, 2001). The activity of AAA+ proteins relies on their ability to use the 
energy of ATP hydrolysis to generate a mechanical force, leading to the remodelling of 
bound substrates. ATP binding and hydrolysis is mediated by the conserved AAA domain, 
which additionally drives the oligomerization of AAA+ proteins, leading to the formation 
of barrel-shaped oligomers with a central channel (Mogk et al., 2004; Mogk et al., 2008; 
Sauer et al., 2004) (Figure 3). AAA proteases are a group of ATP-dependent 
metallopeptidases which are highly conserved membrane anchored protein complexes 
present from bacteria to human (Koppen et al., 2007; Langer et al., 2001). 
 
Introduction 
 
30 
 
 
Figure 3: Structural features of AAA proteases. 
(A) FtsH crystal structure from Thermus thermophilus. AAA proteases presumably form a hexameric 
structure, one subunit is highlighted in red. View from the cytosolic site to the membrane (view on the 
proteolytic domain of FtsH). 
(B) The Walker B motif with adjacent SRH region of the neighboring subunit. Both regions are 
highlighted in red. The arrow indicates the critical glutamate in the Walker B motif. The dashed line 
indicates the subunit border and the dashed circle the pore of the hexameric complex. 
 
 
The AAA domain at the aminoterminal end contains the Walker A and B motif and the 
conserved second region of homology (SRH). SRH residues function as intrasubunit 
(asparagin) and intersubunit (two arginines) sensors of the ATP γ-phosphate, the latter 
called an arginine finger. This arginine finger is only present in AAA proteins and not in 
other subgroups of AAA+ proteins (Ogura et al., 2004). It stimulates ATP hydrolysis needed 
for the activity of the enzyme (Hanson and Whiteheart, 2005; Ito and Akiyama, 2005; 
Karata et al., 1999; Korbel et al., 2004; Snider and Houry, 2008). AAA proteases belong to 
the M41 metallopeptidase family characterized by the canonical metal binding HExxH 
motif (Rawlings and Barrett, 1995) (see Figure 4). 
 
The bacterial protease FtsH is a cytoplasmic membrane protein that has N-terminally 
located transmembrane segments and a main cytosolic region consisting of AAA-ATPase 
and Zn2+-metalloprotease domains. It forms a homo-hexamer, which can be further 
complexed with an oligomer of the membrane-bound modulating factor HflKC, that is a 
homologue of the prohibitins (Browman et al., 2007; Ito and Akiyama, 2005) (see chapter 
 1.4.2). FtsH degrades a set of short-lived proteins, enabling cellular regulation at the level 
of protein stability [reviewed in (Ito and Akiyama, 2005)]. FtsH also degrades some miss-
assembled membrane proteins, contributing to their quality maintenance. It is an energy-
utilizing and processive endopeptidase with a special ability to dislocate membrane 
protein substrates out of the membrane, for which its own membrane-embedded nature is 
essential.  
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Targeted to the eukaryotic inner membrane of mitochondria by a sorting sequence at 
the N-terminus at least two AAA proteases exist, which face their active centers to 
opposing sites of the membrane. Yeast homo-oligomeric i-AAA protease built up by Yme1 
subunits is active in the intermembrane space, whereas the hetero-oligomeric m-AAA 
protease complex of Yta10 and Yta12 exposes its catalytic site to the matrix of yeast 
mitochondria (Koppen and Langer, 2007; Langer, 2000; Leonhard et al., 1996) (see Figure 
4). Several m-AAA protease isoenzymes are present in mammals (see below.) 
m- and i-AAA protease exert overlapping substrate specificity and conduct 
mitochondrial protein quality control surveillance (Lemaire et al., 2000; Leonhard et al., 
2000). They recognize the folding state of solvent-exposed domains and degrade non-
native and non-assembled membrane polypeptides (Arlt et al., 1996; Leonhard et al., 
1996; Leonhard et al., 1999). Some substrates of the m-AAA protease are known: subunits 
1 and 3 of cytochrome c oxidase (COX), cytochrome b (Cob) and the subunits 6, 8 and 9 
of the ATP-synthase (Arlt et al., 1996; Guélin et al., 1996). In addition to these integral 
membrane proteins, the m-AAA protease has also been demonstrated to degrade 
peripheral membrane proteins such as Atp7 (Korbel et al., 2004). In the absence of a 
functional i-AAA protease, yeast cells are characterized by a respiratory deficiency at high 
temperature, an inability to grow on glucose rich medium at low temperature, an increased 
rate of mtDNA escape to the nucleus, and a petite-negative phenotype, i.e. strongly 
impaired growth in the absence of mtDNA (Thorsness and Fox, 1993; Weber et al., 1995). 
Only a limited number of protein quality control substrates of the yeast i-AAA protease has 
been identified including non-assembled Cox2, unassembled prohibitin subunits PHB1 
and PHB2, as well as external NADH dehydrogenase (Nde1) (Augustin et al., 2005; 
Kambacheld et al., 2005; Nakai et al., 1995; Pearce and Sherman, 1995; Weber et al., 
1996). 
Intriguingly, the yeast m-AAA protease, in addition to its quality control function, has 
been shown to specifically process MrpL32, a subunit of the large mitochondrial 
ribosomal particle (Nolden et al., 2005). The phenotypes associated with deletions of 
either Yta10 or Yta12, namely the inability to grow on non-fermentable carbon sources and 
deficiencies in the synthesis of Cox1 and Cob, can be fully explained by an impaired 
MrpL32 processing: dysfunctional ribosomes fail to translate mitochondrial DNA and cause 
deficiency in the assembly of respiratory chain complexes (Arlt et al., 1998; Nolden et al., 
2005).  
However, AAA proteases exert also functions independently of their proteolytic 
activity. The yeast m-AAA protease dislocates the nuclear encoded cytochrome c 
peroxidase (Ccp1) thereby allowing its processing by the inner membrane rhomboid 
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protease Pcp1. This two-step processing of the ROS scavenger is important for the proper 
release of Ccp1 into the intermembrane space upon import into mitochondria (Esser et al., 
2002; Kwon et al., 2003; Tatsuta et al., 2007). Regarding this import function of the yeast 
m-AAA proteases, it is not surprising that Ccp1 processing takes place preferentially at the 
inner boundary membrane of mitochondria (Suppanz et al., 2009). A similar non-
proteolytic role has been suggested for the i-AAA protease during import of polynucleotide 
phosphorylase (PNPase) (Rainey et al., 2006). PNPase contains an N-terminal targeting 
signal that is cleaved off by MPP in the matrix followed by translocation of mature PNPase 
into the IMS. Import of mammalian PNPase into yeast mitochondria was shown to depend 
on the presence of the i-AAA protease subunit Yme1. However, PNPase is neither 
processed nor degraded by the i-AAA protease suggesting a non-proteolytic function of 
Yme1 in the translocation of PNPase across the inner membrane. 
 
Interestingly, AAA proteases have been linked to proteins important for the lipid 
environment. In fact, their deletions affect the integrity of cell and mitochondrial 
membranes. Bacterial FtsH is the sole, ATP-dependent and essential E. coli protease. It 
maintains the proper lipopolysaccharide/phospholipids ratio by degrading LpxC, a 
deacetylase for the biosynthesis of lipid A, the membrane embedded lipid moiety of 
lipopolysaccharides (Ogura et al., 1999). Impaired degradation results in lethal 
overaccumulation of lipopolysaccharides. In yeast, the majority of 
phosphatidylethanolamine (PE), an essential component of yeast mitochondria, is 
synthesized by phosphatidylserine decarboxylase 1 (Psd1), a component of the inner 
mitochondrial membrane (Voelker, 1997). Deletion of the i-AAA protease Yme1 enhanced 
Psd1 stability and increased slightly PE levels (Nebauer et al., 2007). Deletions of the 
subunits of the m-AAA protease either Yta10 or Yta12 diminish both, cardiolipin and PE 
levels (Osman et al., 2009). However, mechanisms causing these phenotypes are not 
understood. 
1.4.2. m-AAA proteases and prohibitins – highly conserved 
supercomplexes in the inner mitochondrial membrane 
The m-AAA protease exists in a large supercomplex together with prohibitins, PHB1 
and PHB2 (Steglich et al., 1999). The prohibitins are ubiquitously expressed in eukaryotes 
and highly conserved among species (Merkwirth and Langer, 2009; Mishra et al., 2006; 
Nijtmans et al., 2002; Steglich et al., 1999; Tatsuta et al., 2005). Prohibitin 1 and 2 face  
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Figure 4: Domain structure and topology of AAA proteases and prohibitins. 
(A) Domain structure of AAA proteases and prohibitins. m- and i-AAA proteases as well as prohibitins 
are targeted to mitochondria via their mitochondrial targeting signal (MTS). The aminoterminal domain 
(ND) is followed by the ATPase domain (AAA) and a carboxy-terminal proteolytic domain (PD). One 
(i-AAA) or two (m-AAA) hydrophobic regions anchore the protein in the inner membrane of 
mitochondria (IM) resulting in opposing topology. Aminoterminal helical (NH) region and C-terminal 
helical domain have been shown to be involved in substrate binding to yeast Yme1. Walker motifs A 
and B (WA, WB) are important for ATP binding and hydrolysis, respectively. The second region of 
homology (SRH) contains the arginine finger that stimulates ATP hydrolysis. The PD contains the 
canonical metal binding site of Zn2+-dependent metallopeptidases. Prohibitins contain one TM region 
and a domain which is characteriztic for members of the SPFH-family 
(stomatin/prohibitin/flotillin/HflKC). 
(B) The i-AAA protease exposes its active site to the intermembrane space (IMS) whereas the 
m-AAA protease is active at the matrix (M) site. The carboxy-terminal end of prohibitins is in the IMS. 
Prohibitins form ring-like structures which interact with m-AAA proteases to form a supercomplex. 
(C) Potential murine m-AAA protease isoenzymes. “?” indicates no experimental evidence. 
 
 
their carboxy-terminal end to the intermembrane space of mitochondria and form large 
ring-shaped complexes in the mitochondrial inner membrane (Tatsuta et al., 2005).  
Figure 4 shows the topology of the supercomplex in the inner membrane of mitochondria. 
Their putative structural role in cristae junction formation is discussed in chapter  1.3.3.3. 
Prohibitins have been proposed to exert chaperone activity (Nijtmans et al., 2000). 
Additionally, they are suggested to work as membrane scaffolds since they are homologous 
to members of the SPFH-family (for stomatin/prohibitin/flotillin/HflKC), which have been 
found in association with lipid rafts or directly interact with lipids (Browman et al., 2007; 
Merkwirth and Langer, 2009; Tavernarakis et al., 1999).  
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The high molecular weight complex of prohibitins and the m-AAA protease of 
approximately 2 MDa was first described for the bacterial homologues HflK and HflC 
(together HflKC) and FtsH (Kihara et al., 1996), however, later also in yeast and in the 
mammalian system (Metodiev, 2005; Steglich et al., 1999; Tatsuta et al., 2005). The role of 
this supercomplex is as unclear as the function of the prohibitins. The hflKC null mutation 
accelerates the degradation of SecY, a substrate of FtsH, in vivo (Kihara et al., 1996). In 
line, purified HflKC protein inhibits the SecY-degrading activity of purified FtsH protein in 
vitro (Kihara et al., 1996). In yeast, depletion of the prohibitins in strains which contain an 
increased amount of an unfolded/instable substrate of the m-AAA protease results in an 
accelerated processing of this substrate (Steglich et al., 1999). Therefore, Steglich and 
Kihara hypothesized that prohibitins or HflKC negatively regulate the proteolytic activity of 
the protease (Kihara et al., 1996; Steglich et al., 1999). Depletion of prohibitins in 
mammals has severe effects on cell proliferation, cristae morphogenesis  and mitochondrial 
morphology, all of which were linked to an induced processing of OPA1 (see  1.3.3.3) 
(Merkwirth et al., 2008). Thus, in line with results from Steglich and Kihara, Merkwirth 
proposed that the absence of prohibitins in mammalian cells may promote OPA1 
processing by m-AAA proteases (Merkwirth and Langer, 2009). 
1.4.3. Mammalian m-AAA proteases 
Homologues of the yeast m-AAA protease subunits exist in mammals which, when 
present as an active complex, can functionally substitute for the yeast m-AAA protease 
(Atorino et al., 2003; Koppen et al., 2007; Nolden et al., 2005). Human subunits 
paraglegin and AFG3L2 share 36-56 % sequence identity with their yeast counterparts and 
39 % with each other (Banfi et al., 1999; Casari et al., 1998). A phylogenetic tree is found 
in the appendix chapter  6.3.1. Interestingly, a third subunit Afg3l1 is expressed in mice but 
encoded by a pseudogene in humans (Kremmidiotis et al., 2001; Shah et al., 1998).  
The complex composition of mammalian m-AAA proteases differs from yeast. Active 
hetero- and homo-oligomeric assemblies can be formed by human and murine Afg3l2 and 
Afg3l1 subunits except for paraplegin which assembles only with the other subunits. As a 
consequence, a set of diverse m-AAA protease isoenzymes exist (Koppen et al., 2007) 
(Figure 4 C). Considerung the variety of m-AAA protease complexes, expression level and 
assembly of the subunits might alter enzymatic properties or substrate specificity of the 
protease (Koppen and Langer, 2007; Koppen et al., 2007; Martinelli et al., 2009). The 
situation may become even more complex considering different substrate compositions in 
certain cell types or tissues (Mootha et al., 2003). Therefore, it is not surprising that loss-of-
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function mutations in paraplegin or Afg3l2 lead to different phenotypes in mouse and 
human. Both human subunits are linked to different neurodegenerative diseases. Strikingly, 
like for diseases associated with mitochondrial dynamics, phenotypes observed are highly 
tissue-specific. 
1.4.3.1. Phenotypes associated with defects in mammalian m-AAA protease 
subunits 
Mutations in paraplegin or SPG7 are associated with an autosomal recessive form of 
hereditary spastic paraplegia (HSP) (Casari et al., 1998). HSP is a heterogeneous group of 
genetic disorders in which the main feature is progressive spasticity in the lower limbs due 
to pyramidal tract dysfunction. This also results in brisk reflexes, extensor plantar reflexes, 
muscle weakness and urinary urgency. These symptoms are the result of a ‘dying back’ 
degeneration of the cortico-spinal tracts. The longest fibers, innervating the lower 
extremities, are most affected (Depienne et al., 2007). The molecular mechanisms leading 
to axonal degeneration are probably as diverse and complex as the genetics of HSPs. It is 
believed, on the one hand, that cellular trafficking, and more particularly axonal 
transport –especially of mitochondria – is impaired. The first mitochondrial motility defect 
was identified in a family with autosomal dominant hereditary spastic paraplegia type 10 
(SPG10) and mutations in a gene encoding one of the kinesins, affecting regions involved 
in microtubule binding and subsequently mitochondrial transport (Fichera et al., 2004). On 
the other hand, mitochondrial dysfunction is the second process that leads to HSPs, and is 
exemplified by SPG13 and SPG7 (Depienne et al., 2007; Rugarli and Langer, 2006). HSP 
type 13 or SPG13 is caused by mutation in the chaperonin HSP60 (Hansen et al., 2002). 
However, HSP primary fibroblasts lacking SPG7 show reduced complex I activity and 
increased sensitivity to oxidant stress (Atorino et al., 2003).  
Mice lacking paraplegin (Spg7-/-) are affected by a distal axonopathy of spinal cord and 
peripheral axons characterized by axonal swelling and degeneration resembling the human 
disease (Ferreirinha et al., 2004). However, the phenotype is progressive and mice behave 
comparable to control littermates directly after birth. The earliest pathologic event in 
paraplegin-deficient mice at 4.5 month is the appearance of hypertrophic mitochondria 
with disrupted and swollen cristae in synaptic terminals. Later, axonal swellings occur 
through massive accumulation of organelles and neurofilaments, suggesting an impairment 
of anterograde axonal transport. Also retrograde axonal transport is delayed. 
Dominant mutations in the AFG3L2 gene cause spinocerebellar ataxia type 28 
(SCA28) (Cagnoli et al., 2008; DiBella et al., 2008). Autosomal dominant cerebellar ataxias 
are a clinically and genetically heterogenous group of neurodegenerative disorders 
primarily characterized by imbalance, progressive gait and limb ataxias, and dysarthria 
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(Harding, 1982). It is often associated with poor coordination of hands, speech, and eye 
movements (ophthalmoparesis). Pathogenesis mechanisms involve the degeneration of the 
cerebellum and the spinal cord (Cagnoli et al., 2006; Mariotti et al., 2008). Interestingly, 
mice having truncations in Afg3l2, leading to the loss of the protein (Afg3l2Emv66/Emv66), and 
mice having a critical mutation in the AAA domain (R389G) (Afg3l2par/par), show an 
extremely severe neuromuscular syndrome beginning at postnatal day 7 (P7) with 
hindlimbs paraparesis which progresses until complete tetraparesis and death, generally at 
P16 (Maltecca et al., 2008). Mouse models are characterized by delayed myelination and 
impairment of axonal radial growth in both the central nervous system (CNS) and 
peripheral nervous system (PNS). Mitochondrial morphology abnormalities are detected in 
motor and sensory neurons, more frequently in proximity of the nucleus. Mitochondria 
isolated from brains and spinal cord reveal reduced activity as well as reduced levels of 
complex I and complex III (Maltecca et al., 2008). However, non-neuronal tissues are not 
significantly affected in Afg3l2 mutant mice. These findings raise the possibilities that the 
phenotypes associated with Afg3l2 and paraplegin mutations reflect functional differences 
of m-AAA isoenzymes or might result from a tissue-specific expression of m-AAA protease 
subunits (Koppen et al., 2007).  
Further crossing of the Spg7-/- mice with the Afg3l2Emv66/Emv66 mice and further 
backcrossing with Spg7-/- mouse resulted in heterozygous Afg3l2 mice (Martinelli et al., 
2009). Spg7-/- Afg3l2Emv66/+ mice show an early-onset severe neurological phenotype, 
characterized by loss of balance, tremor, and ataxia. These mice display acceleration and 
worsening of the axonopathy observed in paraplegin-deficient mice. In addition, they 
exhibit a prominent cerebellar degeneration with loss of Purkinje cells and parallel fibers, 
and reactive astrogliosis. Mitochondria from affected tissues are prone to lose mtDNA, 
have unstable respiratory complexes, and display an impaired maturation of MrpL32. 
These data demonstrate genetic interaction between the m-AAA isoenzymes and suggest 
that different neuronal populations have variable thresholds of susceptibility to reduced 
levels of the m-AAA protease. Moreover, they implicate impaired mitochondrial proteolysis 
as a novel pathway in cerebellar degeneration (Martinelli et al., 2009). 
 
In conclusion, different mouse models exist which all aim to understand the molecular 
mechanisms causing the human diseases. However, HSP and SCA clearly demonstrate that 
mitochondrial dysfunction has emerged as a hallmark of neurodegenerative diseases (Lin 
and Beal, 2006). Mitochondria are regionally organized within some nerve cells, with 
higher accumulation in the nerve terminal. Synapses particularly need mitochondria to 
regulate calcium and ATP levels, thereby maintaining synaptic transmission and structure 
(Chen and Chan, 2006). But, what is the primary molecular effect within mitochondria in 
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the synaptic terminals lacking paraplegin? And why are in particular the neurons of the 
cortico-spinal tract affected? On the one hand, a reduced amount of m-AAA protease 
isoenzymes might fail to degrade non-assembled or misfolded polypeptides which 
accumulate and lead to certain stress stimuli, e.g. ROS. On the other hand, they could be 
incapable of processing a specific protein which interferes with the morphology of 
mitochondria. Giant mitochondria and swollen cristae have been observed. Is there any 
link to the mitochondrial dynamics machineries?  
Strikingly, m-AAA proteases have been linked to OPA1. Ishihara et al. showed that 
overexpression of Spg7 (paraplegin) in mouse embryonic fibroblasts leads to accelerated 
OPA1 processing and subsequently to fragmentation of mitochondria indicating that the m-
AAA protease might cleave OPA1 (Ishihara et al., 2006). However, mouse embryonic 
fibroblasts lacking paraplegin exhibit a wild type OPA1 pattern (Duvezin-Caubet et al., 
2007). Additionally, the different tissue-specificities of both disorders, ADOA (chapter 
 1.3.4) and HSP, suggest that tissue specific consequences of a paraplegin-deficiency cannot 
simply be reconciled with an impaired OPA1 function itself (Koppen and Langer, 2007).  
Certainly, to unravel HSP and SCA pathogenesis substrates of the mammalian 
m-AAA proteases must be identified. Tissue-specific, cellular and subcellular-specific 
organization of mitochondria as well as varying levels of different isoenzymes have to be 
considered. 
1.4.4. What determines a substrate? How is it recognized by AAA-
proteases? 
AAA proteases recognize the folding state of solvent-exposed domains (Leonhard et al., 
2000). Degradation initiation regions of a substrate polypeptide like a degradation tag may 
be first recognized by the outer surface of the helical subdomain of the ATPase domain 
(Niwa et al., 2002). This is the simplest way of recognizing a substrate which is thought to 
be independent of ATP hydrolysis. This first step is then followed by nucleotide-dependent 
conformational changes which drive translocation of the peptide tag through the central 
pore for successive events of endoproteolysis (Ito and Akiyama, 2005). The substrate has to 
be unfolded upon translocation. Different ATP-dependent proteases share distinct 
unfoldase activities, e.g. FtsH has been reported to be less powerful than other AAA+ 
proteases (Herman et al., 2003). Studies on the i-AAA protease subunit Yme1 of yeast 
allowed the identification of two helical binding regions, which form a lattice-like structure 
at the surface of the proteolytic cylinder and mediate the initial encounter of substrate 
proteins with the protease (Graef et al., 2007; Leonhard et al., 1999): helices C-terminal of 
the proteolytic domain (CH) and N-terminal helices of the AAA domain (NH), which are 
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located in close proximity to the membrane surfaces and highly negatively charged. Thus, 
substrate proteins initially interact with the i-AAA protease at the outer surface of the 
proteolytic cylinder, before they enter the proteolytic chamber (Graef et al., 2007). 
Evidence for substrate translocation into a proteolytic chamber through the central pore of 
mitochondrial AAA proteases has been obtained by mutational analysis of a conserved 
loop motif YVG (aromatic-hydrophobic-glycine) in Yme1 (Graef and Langer, 2006), which 
has been localized to the central pore of other hexameric AAA+ ring complexes (Wang et 
al., 2001).  
Furthermore, AAA protease-mediated degradation of inner membrane proteins involves 
the extraction of the substrate from the membrane bilayer (Leonhard et al., 2000). For FtsH, 
it is proposed that the first event in the recognition of a membrane protein substrate occurs 
within the membrane through interaction of a transmembrane segment of the substrate and 
the transmembrane regions of FtsH as well as with HflKC (Ito and Akiyama, 2005). 
However, it is completely unknown what kind of features of the transmembrane region are 
recognized by FtsH/HflKC. The ability of the m-AAA protease to mediate vectorial 
membrane dislocation of proteins in an ATP-dependent reaction has been directly 
demonstrated (Tatsuta et al., 2007). This membrane extraction of substrate proteins is likely 
to be facilitated by the membrane-embedded parts of AAA protease subunits which might 
form a pore-like structure or provide at least a more hydrophilic environment (Korbel et al., 
2004).  
An example for a signal of degradation is the membrane protein YccA, a substrate of 
the bacterial AAA protease. A mutant of the YccA protein with a shortened cytosolic tail at 
the N terminus is stable but it still remains associated with FtsH indicating the N-terminus 
of this protein is the signal for degradation (Karata et al., 2001; Kihara et al., 1998). 
Binding of YccA was not affected by this truncation, indicating that the binding to FtsH is 
mediated by another region of the protein. Therefore, it is most likely that also other 
substrates bind to the protease which cannot be degraded or processed due to mutations in 
the protease. In fact, that has been shown for the yeast m-AAA protease. Although neither 
the binding regions in Mrpl32, nor within the m-AAA protease are known, it traps Mrpl32 
when the enzyme is in an proteolytical inactive state (Nolden et al., 2005).  
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1.5. Aims of the thesis 
Yeast m-AAA proteases have been identified to be crucial regulators of mitochondrial 
quality control by degrading non-assembled and non-native polypeptides (Leonhard et al., 
2000). Additionally, they control mitochondrial biogenesis by processing of MrpL32, a 
subunit of the mitochondrial ribosome (Nolden et al., 2005). The processing explains the 
pleiotropic phenotypes associated with the loss of the m-AAA protease. Mammalian m-
AAA protease subunits are linked to neurodegenerative diseases whose pathogenesis’ 
underlying molecular mechanisms are poorly understood. To analyze the cellular and 
molecular role of mammalian m-AAA proteases, stable cell lines expressing dominant-
negative variants of mammalian m-AAA protease subunits were generated. 
One putative substrate has been identified, the dynamin-related protein OPA1, which 
has been shown being important for mitochondrial fusion and cristae morphogenesis 
(Cipolat et al., 2006; Duvezin-Caubet et al., 2007; Frezza et al., 2006; Ishihara et al., 
2006; Song et al., 2007). Therefore, initial experiments were aiming at analyzing the link 
between m-AAA proteases and OPA1 processing. However, impaired processing of OPA1 
is believed to not fully contribute to the phenotypes observed in the mammalian system 
(Koppen and Langer, 2007). Additionally, considering a tissue or cell type specific 
expression of m-AAA protease subunits and variations of the mitochondrial proteome even 
in single cells, most likely, also other substrate proteins in particular in different tissues or 
cell types may exist (Hollenbeck and Saxton, 2005; Mootha et al., 2003). In regard of this 
hypothesis, the dominant-negative mammalian m-AAA protease subunits were fused to an 
affinity purification tag. Considering the yeast data, these proteolytically inactive 
complexes should work as a substrate traps allowing the co-purification of substrates and 
interacting partners of m-AAA protease isoenzymes. Finding substrate proteins should 
provide further insights into the pathogenesis of the neurodegenerative diseases hereditary 
spastic paraplegia or spinocerebellar ataxia. 
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2. Material and Methods 
2.1. Material 
2.1.1. Chemicals 
Chemicals were purchased from Sigma, Merck or Roth unless stated otherwise. All 
buffers and solutions were prepared using ultrapure water (Milli-Q, Millipore).  
2.1.2. E. coli strains 
XL1-Blue (Stratagene) recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ 
proAB lacIqZ∆M15 Tn10 (Tetr)] 
XL10-Gold® (Stratagene) TetrΔ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 
thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZΔM15 
Tn10 (Tetr) Amy Camr] 
2.1.3. Mammalian cell lines 
FlpIn™ T-REx™-293 Invitrogen; expresses the Tet repressor from pcDNA6/TR; 
contains a single integrated Flp Recombination Target (FRT) 
site from pFRT/lacZeo; derived from 293 human embryonic 
kidney cells (Graham et al., 1977), for more information 
about the 293 parental cell line, see the ATCC Web site 
(www.atcc.org) and refer to ATCC number CRL-1573. 
T-REx™-HeLa Invitrogen; expresses the Tet repressor from pcDNA6/TR, 
derived from human cervical adenocarcinoma cells for more 
information about the HeLa parental cell line, see the ATCC 
Web site (www.atcc.org) and refer to ATCC number CCL-2. 
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2.1.4. Generation of expression plasmids 
For expression of human m-AAA protease subunits in FlpIn T-REx-293 cells (see  2.1.3), 
constructs consisting of the ORF of human SPG7 (paraplegin) (corresponding to amino 
acids 1-795) or human AFG3L2 (amino acids 1-797) fused to a C-terminal hexahistidine 
epitope tag were excised from the yeast multicopy plasmids YEplac118 ADH or YEplac112 
ADH (Gietz and Sugino, 1988), respectively (Mirko Koppen, unpublished). SPG7 was 
cloned using restriction enzymes XbaI and SalI and cloned into EcoRV and XhoI cut 
mammalian expression vector pcDNA5 FRT/TO (Invitrogen) enabling expression under the 
control of a tetracycline-inducible CMV promoter. The open reading frame of AFG3L2 was 
excised by KpnI and XhoI and ligated into KpnI and XhoI digested pcDNA5 FRT/TO. 
Murine Afg3l2 (amino acids 1-802) was amplified from murine cDNA and subcloned into 
pGEM®-T Easy (Promega). NotI restriction sites and a C-terminal Strep®II-tag (Schmidt et al., 
1996) fused to an octahistidine epitope tag were introduced by PCR using the 
oligonucleotides listed in Table 3. Mouse Afg3l2 was cloned by a NotI digest into pcDNA5 
FRT/TO. 
m-AAA protease subunits were mutated to substitute the catalytically active glutamate 
residues within the proteolytic centres (PC) and Walker B motifs (WB) in the ATPase 
domain by glutamine residues using the QuikChange® Site-Directed Mutagenesis Kit 
(Stratagene). Oligonucleotides used are listed in Table 3. The respective codons of the 
human and murine expression constructs were mutated from GAA to CAG or GAG to 
CAA, respectively. The mutated amino acids correspond to the following positions: human 
SPG7 (PC, SPG7E575Q; WB, SPG7E409Q), human AFG3L2 (PC, AFG3L2575Q; WB, 
AFG3L2E408Q), mouse Afg3l2 (WB, Afg3l2E407Q). All expression contructs were verified by 
DNA sequencing. 
 
Table 2: List of plasmids used in this study 
Plasmid  Reference  
YEplac181ADH1- SPG7 (1-795)-6His  Mirko Koppen, 
unpublished 
YEplac112ADH1- AFG3L2 (1-797)-6His  Mirko Koppen,  
unpublished 
pCMV14-rat Opa1 splice variant 1-3FLAG (Ishihara et al., 2006) 
pCMV14-rat Opa1 splice variant 1ΔS1-3FLAG (Ishihara et al., 2006) 
pcDNA5 FRT/TOCMVTetO2- SPG7 (1-795)-6His this study 
pcDNA5 FRT/TOCMVTetO2- SPG7E575Q (1-795)-6His this study 
pcDNA5 FRT/TOCMVTetO2- SPG7E409Q (1-795)-6His this study 
pcDNA5 FRT/TOCMVTetO2- AFG3L2 (1-797)-6His this study 
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Plasmid  Reference  
pcDNA5 FRT/TOCMVTetO2- AFG3L2E575Q (1-797)-6His this study 
pcDNA5 FRT/TOCMVTetO2- AFG3L2E408Q (1-797)-6His this study 
pcDNA5 FRT/TOCMVTetO2- Afg3l2 (1-802)-Strep®II-8His this study 
pcDNA5 FRT/TOCMVTetO2- Afg3l2E407Q (1-802)-Strep®II-8His this study 
pcDNA5 FRT/TOCMVTetO2- MICS1 (1-345)-4HA this study 
2.1.5. Oligonucleotides 
Table 3: List of oligonucleotides used in this study 
Oligo Description Sequence 
TL1048 3’-SPG7E575Q 5’-GGCGTGGCCCGACTGATGAAACGCAACCAC-3’ 
TL1049 5’-SPG7E575Q 5’-GTGGTTGCGTTTCATCAGTCGGGCCACGCC-3’ 
TL1050 3’-AFG3L2E575Q 5’-CCGCATGGCCTGCTTGGTGGTATGCCACAG-3’ 
TL1051 5’-AFG3L2E575Q 5’-CTGTGGCATACCACCAAGCAGGCCATGCGG-3’ 
TL3795 3’-AscI-8His-
Strep-tag® II-
Afg3l2 
5’-GGCGCGCCTTAGTGATGGTGATGGTGATGGTGGT 
GCTCGAGTTTTTCGAACTGCGGGTGGCTCCAGCTGAC
AACCTTCTCATT-3’ 
TL3796 5’-AscI-Afg3l2 5’-GGCGCGCCACATGGCCCACCGCTGCCTGC-3’ 
TL3895 5’-Afg3l2E407Q 5’-TCTCTTCATTGATCAGATTGATGCTGTGGG-3’ 
TL3896 3’-Afg3l2E407Q 5’-CCCACAGCATCAATCTGATCAATGAAGAGA-3’ 
TL4280 5’-SPG7E409Q 5’-TCGTCTACATCGATCAGATCGACGCGGTG-3’ 
TL4281 3’-SPG7E409Q 5’-CACCGCGTCGATCTGATCGATGTAGACGA-3’ 
TL4284 5’-AFG3L2E408Q 5’-TTGCATCCTCTTCATCGATCAAATCGATGCGGT-3’ 
TL4285 3’-AFG3L2E408Q 5’-ACCGCATCGATTTGATCGATGAAGAGGATGCAA-3’ 
TL4896 3’-NotI-
HindIII-4HA-
MICS1 
5’-AGCGGCCGCAAGCTTTAAGCGTAATCTGGAACA 
TCGTATGGGTAAGCGTAATCTGGAACATCGTATGG 
GTAAGCGTAATCTGGAACATCGTATGGGTAAGCGT 
AATCTGGAACATCGTATGGGTATTTCTTTCTGTTGC 
CTCCAGTTG-3’ 
TL4899 5’-KpnI-MICS1 5’-GGTACCGCCACCATGTTGGCTGCAAGGCTG-3’ 
 
2.1.6. Antibodies 
Table 4: List of immunoreagents used in this study. 
Antibody Antigen Dilution Reference; comments 
α-AFG3L2 Amino acids 413-828 of human 
AFG3L2 
1:8000 F. Taroni, unpublished 
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Antibody Antigen Dilution Reference; comments 
α-AFG3L2 Amino acids 413-828 of human 
AFG3L2 
1:500 this study; 
used for CO-IP 
α-Afg3l2 Amino acids 90-103 of Afg3l2 1:200 (Koppen et al., 2007) 
α-β-actin Actin N-terminal peptide 1:2000 Sigma 
α-CI Bovine complex I 30 kDa subunit 1:1000 Molecular Probes 
α-CII Bovine complex II 70 kDa subunit 1:1000 Molecular Probes 
α-CIII Bovine complex III core 2 subunit 1:1000 Molecular Probe 
α-CIV Bovine complex IV subunit II 1:1000 Molecular Probe 
α-DLP1 Amino acids 601-722 of rat DLP1 
(Drp1) 
1:500 BD Biosciences 
α-FLAG Synthetic FLAG peptide 
DYKDDDDK 
1:1000 Sigma 
α-HA Synthetic HA peptide YPYDVPDYA 1:3000 Roche 
α-MrpL32 Amino acids 83-98 of murine 
MrpL32 
1:500 (Nolden et al., 2005) 
α-OPA1 Amino acids 708-830 of human 
OPA1 
1:900 BD Biosciences 
α-PARP1 Synthetic peptide corresp. to the 
caspase cleavage site in PARP1. 
1:1000 Cell Signaling 
Technology 
α-PHB1 Recombinant C-terminus of human 
PHB1 
1:500 BioLegend 
α-PHB2 Recombinant C-terminus of human 
PHB2 
1:500 BioLegend 
α-SLP2 Amino acids 171-356 of human 
Stomatin-like 2 (SLP2) 
1:2000 GenWay Biotech 
2.2. Molecular biological methods 
Standard methods in molecular biology were performed according to protocols 
published in (Sambrook and Russell, 2001). Restriction enzymes were purchased from NEB 
(New England Biolabs). PCRs were carried out using the High Fidelity PCR Master (Roche). 
For isolation of plasmid DNA from E. coli the NucleoSpin Plasmid QuickPure® and 
NucleoBond® PC100 kits were used, for extraction of DNA from agarose gels the 
NucleoSpin® Extract II kit (all Machery Nagel) was used, all according to instructions of the 
manufacturer.  
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2.3. Cell biological methods 
2.3.1. Cell culture 
FlpIn T-REx-293 (FITR293) and T-REx-HeLa cells were cultured in high-glucose and stable 
glutamine containing Dulbeccos Modified Eagle´s Medium (DMEM+glutamax, PAA) 
supplemented with 7.5% [v/v] tetracycline-free fetal bovine serum (FBS, BIOCHROM), 
100 U/ml penicillin (PAA), 100 μg/ml streptomycin (PAA), 100 μM non-essential amino 
acids (PAA) and 1 mM sodium pyruvate (PAA). 15 µg/ml blasticidin (Invivogen) was added 
to maintain the Tet repressor. Cells were cultured at 37 °C, 5 % CO2 and 90 % humidity. 
Complete growth medium containing 10 % [v/v] DMSO was used for stepwise 
cryofreezing from -80 °C to -200 °C. After thawing FITR293 cells were cultivated without 
any selective reagent for 2 days. Detaching cells for splitting was performed by addition of 
1 x trypsin/EDTA (PAA) for 5 min at 37 °C.  
2.3.2. Transfections 
Transient transfections were performed using the GeneJuice® Transfection Reagent 
(Novagen) according to the manufacturer’s instructions. Unless otherwise noted cells were 
grown on 6-well plates and transfected with 1 µg of plasmid DNA followed by a second 
transfection 4 h later under identical conditions. Stable transformations were carried out 
using the FlpIn T-REx system (Invitrogen) (see  2.3.3). 
2.3.3. FlpIn T-REx system and selection of stable transformants 
The FlpIn T-REx system (Invitrogen) allows tetracycline-inducible and stable 
overexpression of a gene of interest in mammalian cell culture (see Figure 6). It is in detail 
explained in chapter  3.2.1. FITR293 cells expressing the Tet-repressor and harboring a 
genomically integrated FRT-site were grown on 6-well plate format with medium 
containing 100 µg/ml ZeocinTM (Invivogen). The FITR293 cell line was transfected twice 
with GeneJuice® Transfection Reagent (Novagen). In total, 3 µg DNA of pcDNA5 FRT/TO 
constructs containing the genes of interest (see  2.1.4) and Flp-recombinase expressing 
pOG44 plasmid with a ratio of 1:5 was used for transfection. Flp mediates site-directed 
recombination of the FRT-sites in the pcDNA5 FRT/TO vector and in the genome of the 
FITR293 cell line thereby allowing the stable integration of the gene of interest. During this 
process cells lose their resistance to Zeocin which was excluded from the growth medium 
by the time of transfection. By contrast, after recombination cells become resistant to 
Material and Methods 
 
45 
hygromycin B. After 48 h cells were transferred to a 10 cm plate to reach 25 % confluency, 
and selection with 150 µg/ml hygromycin B (Invivogen) was started. Growing clones were 
picked after 18-24 days and expanded to test for β-galactosidase activity and ZeocinTM 
sensitivity. Growth medium containing 100 µg/ml ZeocinTM was changed daily. Positive 
clones died after 7-14 days of this treatment. Expression was induced with 1 µg/ml 
tetracycline for 24 h (Fluka).  
2.3.4. β-galactosidase activity assay 
The β-galactosidase activity assay was performed to monitor the stable integration of 
the gene of interest into the genome of the FITR293 cells. Positive insertion results in the 
loss of β-galactosidase activity. The enzyme promotes lactose utilization. β-galactosidase 
hydrolyzes X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) (PEQLAB) into 
colorless galactose and 4-chloro-3-brom-indigo which forms an intense blue precipitate. 
Cells expressing β-galactosidase appear therefore blue under the light microscope. To 
visualize activity FITR293 cells were cultivated in 6 or 24 well plate format to a cell 
density of 60-80 %. Cells were washed twice with 1 x PBS (PAA) and fixed with 
0.2 % [v/v] glutaraldehyde and 2 % [v/v] formaldehyde in 1 x PBS for 5 min at 4 °C. After 
two washing steps with 1 x PBS, 1000 µl (6-well) and 200 µl (24 well) of the X-gal- solution 
was added to the cells and incubated 30 min at 37 °C.  
 
X-gal-solution:   1 mg/ml X-gal 
5 mM K3Fe(CN)6 
5 mM K4Fe(CN)6 
2 mM MgCl2 
0.02 % [v/v] NP-40 
0.01 % [w/v] SDS 
2.3.5. Cell proliferation assay 
The CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega) is an 
optimized MTT-derived colorimetric method for determining the number of viable cells in 
proliferation, cytotoxicity or chemosensitivity assays (Alley et al., 1988). The solution 
contains a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling 
reagent. The yellow MTS gets reduced by active dividing cells to produce the purple 
formazan product. 5 x 103 cells were seeded onto poly-L-lysine-coated 96-well plates and 
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expression was induced by 1 µg/ml tetracycline daily. Assays were performed by adding 
20 µl of the CellTiter 96® AQueous One Solution Reagent directly to culture wells containing 
100 µl of growth media, incubating for 1–4 hours and then recording absorbance at 
490 nm with a 96-well plate reader. The quantity of formazan product as measured by the 
absorbance at 490 nm is directly proportional to the number of living cells in culture. 
Assays were measured in quadruplicates and, unless otherwise stated, at least three 
independent experiments were performed. 
2.3.6. Measurement of respiratory activities 
2.3.6.1. Oxygen consumption in intact cells 
Respiration of intact cells was measured at 37°C with a Clark-type electrode oxygraph 
(Hansatech Inc.) in a heated water-jacketed chamber connected to a circulating water bath. 
The chamber volumes were set to 500 μl. The measurement with 2.5 x 106 cells started 
with recording the routine endogenous respiration. After observing steady state respiratory 
flux, ATP synthase was inhibited with 2 μM oligomycin for 5 min. This was followed by 
uncoupling of oxidative phosphorylation using stepwise titration of cyanide 
m-chlorophenylhydrazone (CCCP) with concentrations in the range of 250-750 nM. After 
5 min recording, cellular respiration was inhibited with 2 mM KCN and was corrected to 
KCN-insensitive respiration. The respiratory control ratio was obtained dividing the rates of 
oxygen consumption measured before and after the addition of CCCP. 
 
Respiration buffer:  250 mM sucrose 
20 mM HEPES pH7.4 
10 mM KH2PO4 
4 mM MgCl2 
1 mM EDTA 
5 mM glucose 
2 mM pyruvate 
4 mM glutamate 
2.3.6.2. Assessment of mitochondrial membrane potential 
Mitochondrial membrane potential is an important parameter of mitochondrial 
function and was measured by fluorescence-activated cell sorting (FACS, FACSCalibur 
equipped with CellQuest software (Becton Dickinson)) after staining of FITR293 cells with 
JC-1 (Molecular Probes) (Salvioli et al., 1997). JC-1, a lipophilic, cationic dye exhibits 
potential-dependent accumulation in mitochondria, indicated by a fluorescence emission 
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shift from green (~529 nm) to red (~590 nm). Consequently, mitochondrial membrane 
potential dissipation is indicated by a decrease in the red/green fluorescence intensity ratio. 
In healthy cells with high mitochondrial membrane potential, JC-1 spontaneously forms 
complexes known as J-aggregates with intense red fluorescence. On the other hand, in 
apoptotic or unhealthy cells with low membrane potential, JC-1 remains in the monomeric 
form, which shows only green fluorescence. Analysis of JC-1 fluorescence was examined 
with an excitation at 488 nm and emission was recorded at 535 nm and 590 nm. Staining 
was performed according to manufacturer’s instructions in growth medium ( 2.3.1) and 
membranes were depolarized by adding 100 µM CCCP as a positive control. 
2.3.6.3. Measurement of cellular ATP contents 
FITR293 cells were grown in glucose containing growth medium (see  2.3.1). 48 h 
before the induction of protein expression with tetracycline, growth medium was changed 
to medium containing 1 mM galactose. 1.5 x 106 FITR293 cells were harvested after 24 h 
induction with 1 µg/ml tetracycline and lysed immediately in 10% dichloric acid, 
neutralized in KOH and centrifuged at 15,000 x g for 15 min. ATP content was measured 
by a luminometric assay using luciferase. Based on an ATP standard curve and normalized 
on the total protein concentration the ATP basal level: nmol ATP/ µg protein was obtained. 
 
Luciferase buffer:  150 mM KCl 
    25 mM Tris pH 7.4 
10 mM KH2PO4 
2 mM MgCl2 
1 mM EDTA 
2.5 µg/ml luciferase 
15 µM luciferine 
2.3.7. Monitoring mitochondrial morphology using fluorescence 
microscopy 
To analyze mitochondrial morphology, cells were grown on poly-L-lysine coated 
coverslips and transfected with pDsRed2-Mito (Clontech). pDsRed2-Mito is a mammalian 
expression vector that encodes a fusion of Discosoma sp. red fluorescent protein (DsRed2) 
and the mitochondrial targeting sequence from subunit VIII of human cytochrome c 
oxidase (Mito). Sterile glass coverslips were incubated for 2 h with 0.01 % poly-L-lysine 
solution (Sigma) and rinsed twice with 1 x PBS (PAA). One day before transfection 1.2 x 
105 FITR293 cells were seeded on coated coverslips in 6-well plates. 24-48 h after 
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transfection expression was induced with 1 µg/ml tetracycline and 24 h later cells were 
fixed with 3 % [w/v] paraformaldehyde in 1 x PBS (PAA) for 15 min at 37°C. After 2 
washing steps with 1 x PBS cells were incubated for 5 min at 37°C in 1 µg/ml 4',6-
Diamidino-2-phenylindole (DAPI) (Roche) in 1 x PBS to visualize nuclear DNA. The DAPI 
staining solution was removed by rinsing twice with 1 x PBS and samples were mounted in 
ProLong® Gold Antifade Reagent (Molecular Probes). Fluorescently labeled mitochondria 
were examined using the DeltaVision microscope system and the Softworx software 
(Applied precision). Images were deconvolved and further edited using CORELDRAW™ 12 
Graphics Suite software (Corel Corporation). 
2.3.8. Analysis of cellular apoptosis  
To monitor apoptotic sensitivity FITR293 cell lines were treated with TNF-α which 
activates the death receptor pathway. 2-4 x 105 FITR293 cells were seeded one day before 
induction with 1 µg/ml tetracycline onto 6 well plates. After 24 h, medium was replaced 
with medium containing 0-20 ng/ml human TNF-α, 2 µg/ml cycloheximide and 1 µg/ml 
tetracycline. Cells were further incubated for 24 h, harvested in the medium, pelleted by 
centrifugation (1,200 x g, 5 min, RT) and washed twice with 1 x PBS (PAA). Total cell 
lysates were size fractionated by SDS-PAGE  2.4.3.1) and analyzed by immunoblotting 
( 2.5.1) using antibodies directed against PARP, one of the main cleavage targets of 
caspase-3 in vivo (Nicholson et al., 1995; Tewari et al., 1995).  
2.3.9. Isolation of mitochondria from tissue culture cells 
Mitochondria were isolated from FITR293 cells after inducing the expression of 
AFG3L2 variants with 1 µg/ml tetracycline. Cell cultured in 10 x 15 cm dishes were 
washed once with ice cold 1 x PBS (PAA) and removed from the tissue culture plate with 
cell scrapers (Sarstedt). After pelleting at 1,200 x g at 4 °C for 5 min and two washing steps 
with 5-10 ml ice cold 1 x PBS, cells were resuspended in 8 ml homogenization buffer and 
homogenized using the Potter S (Braun) moving the Teflon potter 10 times up and down. 
Homogenates were than differentially centrifuged: a first step of 1,200 x g at 4 °C for 5 min 
served to remove intact cells and nuclei and a second step at 10,000 x g (20 min, 4 °C) to 
obtain mitochondrial pellets. After washing mitochondrial enriched membranes with 
homogenization buffer and centrifuging step at 10,000 x g at 4 °C for 20 min mitochondria 
were resuspended in resuspension buffer. Protein concentration was assessed by the 
Bradford protein assay (BioRad) using IgG as standard. The mitochondrial fractions were 
diluted with resuspension buffer to a final protein concentration of 10 mg/ml. 
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Homogenization buffer: 220 mM mannitol 
70 mM sucrose 
10 mM HEPES pH 7.4 
1 x Complete Protease Inhibitor Cocktail (Roche) 
Resuspension buffer:  homogenization buffer with 1 mM EDTA 
2.3.10. Analysis of mitochondrial phospholipid composition 
2.3.10.1. Phospholipid extraction 
Phospholipids were extracted from mitochondria isolated from FITR293 cells induced 
with 1 µg/ml tetracycline for 24 h using protocols described for isolation of yeast 
phospholipids (Vaden et al., 2005). The mitochondrial membrane fraction (1 mg) was 
mixed with 2.5 ml chloroform/methanol [2:1, v/v] and vigorously shaken for 1 h in a 15 ml 
glasstube at RT. Samples were vortexed for 1 min after the addition of 300 µl water and 
centrifuged at 1,000 rpm for 5 min. The aqueous phase was removed and the organic 
phase was washed with 250 µl methanol/H2O [1:1, v/v]. Then, the samples were dried in 
1 ml glasstubes under a constant stream of air and lipids were dissolved in 100 µl 
chloroform. 
2.3.10.2. Phosphate determination 
To monitor the concentration of phospholipids a phosphate determination was 
performed (Rouser et al., 1970). 10 µl and 5 µl of the sample, and 2.5 nmol, 5 nmol, 
10 nmol, 20 nmol, 40 nmol of a 10 mg/ml phosphatidylcholine (PC) standard solution 
were transferred to separate 1 ml glasstubes. Phospholipids were dried under a continuous 
air stream. Then, 150 µl of a 70 % [v/v] perchloric acid were added, shortly vortexed and 
incubated for 40 min at 180 °C. At RT, 500 µl of H2O, 200 µl of 1.25% [w/v] ammonium 
molybdate-solution and 200 µl of 5% [w/v] ascorbic acid were combined with the sample 
with always shortly vortexing in between and incubated for 5 min at 80°C. Subsequently, 
the absorption at a wavelength of 797 nm was measured to produce a standard curve of PC 
in order to calculate the amount of mitochondrial phospholipids. 
2.3.10.3. Thin-layer chromatography (TLC) 
TLC analysis was preformed using 10 cm TLC plates (HPTLC Silica gel 60 F254, MERCK) 
which were activated in 1.8% [w/v] boric acid/ethanol by heating to 80 °C for at least 30 
min. Samples and standards (phosphatidylcholine, -ethanolamine, -serine, -glycerol, -
inositol and cardiolipin) were loaded using the robot Linomat 5 (LAMAG). The silica plates 
were dried after running and developed with chloroform/methanol/water [65:35:5, v/v/v] 
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and chloroform/ethanol/water/triethylamin [30:35:7:35, v/v/v/v] and stained with 470 mM 
CuSO4 in 8.5 % o-phosphoric acid. Finally, incubation at 180 °C visualized the 
phospholipids on the plate.  
2.4. Protein biochemistry methods 
2.4.1. Preparation of protein lysates from tissue culture cells 
For isolation of total cell lysates FITR293 cells were harvested by either trypsinization 
or by scraping (cell scraper, Sarstedt), pelleted at 1,200 x g at 4 °C and rinsed twice with 
1 x PBS (PAA). Afterwards, cells were lysed  in modified RIPA buffer by gentle shaking at 
750 rpm and 4°C for 2 h. Lysates were centrifuged for 20 min at 16,000 x g to remove 
unsolubilized material. Protein concentration was determined with a Bradford protein 
assay (BioRad) using IgG as standard and cell lysates were diluted with RIPA buffer to a 
final protein concentration of 10 mg/ml. 
 
RIPA buffer:   10 mM Tris/HCl pH 7.4 
150 mM NaCl 
1 mM EDTA 
1% [v/v] Triton X-100 
0.5% [w/v] sodiumdeoxycholate 
0.1% [w/v] sodium dodecyl sulphate (SDS) 
1 mM phenylmethylsulphonyl fluoride (PMSF) 
1 x Complete Protease Inhibitor Cocktail (Roche) 
2.4.2. Crosslinking of OPA1 
To test the ability of OPA1 to form a complex crosslinking with EDC (1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride) (Pierce) was performed (Frezza et al., 
2006; Yamaguchi et al., 2008). EDC is a zero-length crosslinking agent used to couple 
carboxyl groups to primary amines. It reacts with a carboxyl to form an amine-reactive 
O-acylisourea intermediate. For protein crosslinking, 150-200 µg isolated mitochondria 
were treated with EDC. Mitochondrial membranes were spun for 5 min at 12,000 x g and 
4 °C, and resupended in 10 mM EDC in 1 x PBS (PAA) and incubated at 37 °C for 30 min 
to enable crosslinking. Then, mitochondria were pelleted at 12,000 x g for 5 min and 
dissolved in SDS-PAGE sample loading buffer. Tris in the sample buffer quenched the 
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crosslinking reaction. Complexes were separated by 6-12 % [w/v] Tris-glycine SDS-PAGE, 
transferred onto nitrocellulose membranes, and probed using the OPA1 specific antibody 
(see Table 3). 
2.4.3. Polyacrylamide gel electrophoresis (PAGE) 
2.4.3.1. SDS-PAGE 
Besides standard Tris-glycine SDS-PAGEs (Laemmli, 1970) Tris-tricine SDS-PAGE was 
performed allowing better resolution of smaller proteins (Schägger, 2006; Schägger and 
von Jagow, 1987). The Protein Marker, Broad Range (2-212 kDa) (NEB) and the SeeBlue® 
Plus2 Pre-Stained Standard (Invitrogen) were used as molecular weight standards. 
2.4.3.2. BN/CN-PAGE and in-gel-activity stainings 
Blue native (BN)-PAGE was developed for the separation of mitochondrial membrane 
proteins and complexes in the mass range of 10 kDa to 10 MDa (Schägger and von Jagow, 
1991). Nonionic detergents are used for solubilization of biological membranes. The 
choice of a specific nonionic detergent depends on the detergent stability of the protein 
complexes of interest. One of the mildest detergents is digitonin. It has been used to isolate 
supramolecular associations of multiprotein complexes, thus identifying physiological 
protein–protein interactions without using chemical crosslinking (Schägger et al., 1994). 
CN- (clear- or colorless-) native PAGE offers general advantages for in-gel catalytic activity 
assays compared to blue native electrophoresis [reviewed in (Krause and Seelert, 2008)].  
Isolated mitochondria (150 µg) were solubilized using 10 g digitonin / g protein. 
Mitochondria were pelleted at 10,000 x g at 4 °C for 10 min and resuspended in 
resuspension (see chapter  2.3.9) or solubilization buffer. 15 µl of a 10 % [w/v] digitonin 
solution in solubilization buffer was added to the mitochondria. Samples were vigorously 
mixed at 1,400 rpm at 4° C and cleared by centrifugation for 30 min with 35,000 x g. 
Addition of 50 U benzonase (Novagen) diluted in solubilization buffer and addition of 
MgCl2 to a final concentration of 5 mM resulted in the degradation of interfering nucleic 
acids. To remove remaining unsoluble material which disturbs the running behaviour of 
the protein complexes an additional centrifugation step at 35,000 x g was performed 
before loading the gel. Next, complexes were separated according to their native 
molecular mass within a 3 %-13 % [w/v] native polyacrylamide gel with a 3 % [w/v] 
stacking gel using the Hoefer gel systems S400 or S600. Gel running was started with 
constant 100 V, followed by an increase to 500 V after samples entered the separation gel. 
A native molecular weight marker containing 10 µg catalase (Serva), alcohol 
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dehydrogenase, apoferritin, thyroglobulin, carbonic anhydrase and albumin (all Sigma) was 
used.  
 
Solubilization buffer:  50 mM NaCl 
50 mM imidazole pH 7.0 
5 mM 6-aminohexanoic acid 
10% (w/v) glycerol 
 
Activity of individual OXPHOS (oxidative phosphorylation) complexes was visualized 
directly in the CN-PAGE gels. CN-PAGE gels were rinsed with water and incubated in the 
respective solution for analyzing the activity of Complex I (NADH dehydrogenase 
complex) (Kuonen et al., 1986) and IV (cytochome c peroxidase complex) (Thomas et al., 
1976). After appropriate staining, gels were scanned and fixed in 50 % [v/v] methanol.  
 
NADH staining  100 mM Tris/HCl pH 7.4  
768 mM glycine 
0.08 % [w/v] nitro blue tetrazolium (NBT) 
0.014 % [w/v] NADH 
Cox staining   50 mM NaPi pH 7.4 (or KPi) 
0.05% [w/v] 3,3'-Diaminobenzidine(DAB)-Tetrahydrochlorid 
0.05 % [w/v] cytochrome c 
1 % [w/v] Katalase 
7.5 % [w/v] sucrose 
2.4.3.3. 2D-electrophoresis: BN-SDS-PAGE and dSDS-PAGE 
Mitochondrial complexes separated on a BN/CN-PAGE were analyzed further on a 
second dimensional denaturing polyacrylamide electrophoresis. The gel stripe was cut and 
incubated for 4 x 15 min in freshly prepared 2 % [w/v] SDS and 2 % [w/v] β-
mercaptoethanol in 66 mM NaHCO3. The stripe was then subjected to a 13 % [w/v] Tris-
tricine SDS-PAGE. Pouring and running of this gel was performed essentially as described 
previously (Krause and Seelert, 2008). BN/CN-SDS-PAGEs were either silver stained 
according to protocols that are optimized for staining sensitivity and compatibility with 
protein digestion and mass spectrometric analysis (Blum et al., 1987; Tebbe et al., 2005), 
or proteins were transferred on a PVDF membrane for immunoblotting (see chapter  2.5.1).  
In addition to BN/CN-SDS-PAGE a doubled SDS-PAGE (dSDS-PAGE) was performed:  a 
Tris-glycine SDS-PAGE containing 6 % [w/v] urea in the first dimension was combined 
with a Tris-tricine SDS-PAGE in the second dimension. These gel systems are reviewed in 
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(Rais et al., 2004; Schägger, 2006). To increase resolution of proteins in the high molecular 
weight range, Niederquell modified the published protocol: a 12 % [w/v] acrylamide 
concentration for the first dimension was used followed by a 10 % [w/v] acrylamide gel in 
the second dimension (Niederquell, 2008). Gel stripes were incubated in equilibration 
buffer for 30 min and 5 min in overlay buffe with gentle agitation at RT.  
 
Equilibration buffer:  0.12 M Tris/HCl pH 6.8 
    1% [w/v] SDS 
Overlay buffer:  0.15 M Tris/HCl pH 7.4 
    + a few grains bromphenol blue (Serva) 
2.4.4. Metal affinity chomatography of His-tagged AFG3L2 
To identify interaction partners or putative substrates of human AFG3L2 the protein 
was purified using a carboxy terminal hexahistidine epitope tag. All steps were performed 
at 4 °C. Mitochondria were isolated as described above ( 2.3.9) and centrifuged at 16,000 
x g for 10 min. 5-10 mg mitochondrial pellets were washed once with binding buffer 
without digitonin and solubilized in binding buffer containing 3 % [w/v] digitonin to 
generate a final protein concentration of 5 mg/ml by mixing at 1,400 rpm (6 g digitonin/ g 
protein). In parallel, Ni2+-beads (Ni Sepharose™ High Performance, GE) were pre-
equilibrated with binding buffer. The solubilized fraction of the mitochondrial solution was 
than separated from insoluble material by ultracentrifugation at 45,000 x g and incubated 
with 30 µl of the Ni2+-beads for 1-2 h by gently rotating. 20-fold bead volumes of binding 
buffer containing increasing concentration of imidazol were used during the following 
washing steps: 2 x 20 mM, 2 x 50 mM, 1 x 70 mM imidazol. Bound material was eluted 
by incubation with binding buffer including 300 mM imidazol. Samples were analyzed by 
gradient Tris-tricine gel electrophoresis or a dSDS-PAGE approach (see chapters  2.4.3.1 
and  2.4.3.3, respectively). Gels were stained with colloidal coomassie (Neuhoff et al., 
1990).  
 
Binding buffer: 50 mM Tris/HCl pH 8.0 
   150 mM NaCl 
20 mM imidazol 
   10 % [w/v] glycerol 
0.5 % [w/v] digitonin 
1 mM PMSF 
   1 x protease inhibitor cocktail without EDTA (Roche) 
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2.5. Immunological methods 
2.5.1. Immunoblotting 
Protein samples were size-fractionated by SDS-or BN/CN-PAGE and transferred to 
nitrocellulose (PROTRAN®, Whatman) or PVDF membranes (BioTrace™, PALL Life 
Sciences) according to an established protocol (Towbin et al., 1979). After transfer of 
proteins, membranes were incubated for 30-60 min at RT in blocking solution (5% [w/v] 
milk powder in 1 x TBS-Tween). Immunodecoration with a specific antiserum diluted in 
blocking solution was carried out for at least 60 min at RT or overnight at 4°C. 
Nitrocellulose membranes were washed three times for 5-10 min at RT with 
1 x-TBS-Tween. To detect bound primary antibodies, horseradish peroxidase-conjugated 
antibodies specific for immunoglobulin G of rabbit, mouse (BioRad) or chicken (Abcam) 
were applied in a dilution of 1:3,000-1:10,000 in blocking solution for 60 min. After 
washing the membranes three times with 1 x TBS-Tween, the chemiluminescence reagents 
ECL solution 1 and 2, were added in a mixture of 1:1. Chemiluminescence was detected 
by exposing the membranes to light-sensitive X-ray films (Super RX, Fuji). Stainings for 
OPA1 antibodies were carried out using 1 x TBS in all washing steps, and for the detection 
of the secondary antibody the Lumi-LightPLUS Western Blotting Substrate (Roche) was used 
according to manufacturer’s instructions. 
 
1 x TBS:   10 mM Tris/HCl pH 7.4  
150 mM NaCl 
1 x TBS-Tween  1 x TBS + 0.05 % [v/v] Tween 20 
ECL-solution 1:  100 mM Tris/HCl pH 8.5 
    250 μM luminol 
    400 μM p-coumaric acid 
ECL solution 2:  100 mM Tris/HCl pH 8.5 
    0.02% [v/v] H202 
2.5.2. Co-immunoprecipitation 
The protocol was modified from the published protocols for m-AAA protease subunit 
immunoprecipitation (IP) (Koppen et al., 2007; Metodiev, 2005). All steps were performed 
at 4 °C. Mitochondrial membranes isolated from FITR293 cells (500 µg) were lysed in Co-
IP buffer containing 2 % [w/v] digitonin and the total protein concentrations were adjusted 
to 1 mg/ml (20 g digitonin/ g protein) and mixed vigorously for 30 min. After centrifugation 
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with 35,000 x g for 15 min, 450 µl of the supernatant were applied onto 50 µl Protein A 
Sepharose™ CL-4B (GE) slurry (100 mg/ml) that were coupled with 12 µl antiserum directed 
against AFG3L2 (see  2.1.6) or preimmune antisera for 1 h and then further incubated with 
gentle rotation for 4 h. The beads were washed three times with binding buffer including 
0.5 % [w/v] digitonin followed by a washing step with 10 mM Tris/HCl pH 7.4. Antibody-
antigen complexes were eluted from the beads by incubation of the beads with 1 x 
Laemmli buffer (Laemmli, 1970) and boiling for 5 min.  
The monoclonal HA-antibody (20 µl) was coupled onto 30 µl Protein G Sepharose™ 4 
Fast Flow (GE). Co-IP of transiently transfected HA-tagged MICS1 and AFG3L2 from 
FITR293 cells expressing the distinct AFG3L2 variants was carried out using digitonin 
solubilized whole cells: 0.5-1.0 x 108 cells were washed twice with ice cold 1 x PBS (PAA) 
and resuspended in 2 ml Co-IP buffer containing 4 % [w/v] digitonin. Samples were lysed, 
bound to the HA-antibody-coupled protein G sepharose and treated as described above for 
the IPs using protein A beads. 
 
Co-IP buffer   50 mM NaCl 
50 mM potassium phosphate buffer (KPi) pH 7.0 
4 mM Mg-acetate 
10% [w/v] glycerol 
1 mM PMSF 
1 x protease inhibitor cocktail (Roche) 
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3. Results 
3.1. Mutational analysis of mammalian m-AAA proteases 
The yeast m-AAA protease has been demonstrated as an important regulator of 
mitochondrial function. It is involved in protein quality control and mitochondrial 
biogenesis by degrading non-assembled polypeptide and specific processing of MrpL32, 
respectively [reviewed in (Arnold and Langer, 2002; Koppen and Langer, 2007; Langer, 
2000; Nolden et al., 2006)]. MrpL32 is a nuclear encoded subunit of the large 
mitochondrial ribosomal particle and is processed upon import into mitochondria by the 
yeast m-AAA protease. This leads to the assembly of functional ribosomes and efficient 
mitochondrial translation (Nolden et al., 2005). 
The identification of MrpL32 as a substrate of the yeast m-AAA protease can explain 
the respiratory deficiency of m-AAA protease mutant yeast cells, preventing the growth on 
non-fermentable carbon sources (Nolden et al., 2005). However, MrpL32 processing in 
mammalian cells lacking subunits of the m-AAA protease is not as drastically impaired as it 
has been observed in yeast cells (Martinelli et al., 2009; Nolden et al., 2005). Therefore, it 
is hypothesized that mitochondrial dysfunction associated with the absence or mutation of 
mammalian m-AAA protease subunits is caused by an impaired processing of a yet 
unknown substrate or by an accumulation of misfolded polypeptides (Rugarli and Langer, 
2006). Consequently, the identification of new substrates of mammalian m-AAA proteases 
might help to elucidate the role of mammalian isoenzymes within mitochondria and the 
whole cell. 
Human m-AAA proteases constitute homo- and hetero-oligomeric complexes 
composed of AFG3L2 alone or together with paraplegin (SPG7) (Koppen et al., 2007). In 
contrast, the yeast m-AAA protease subunits Yta10 and Yta12 exclusively form hetero-
oligomeric complexes (Arlt et al., 1996). It has been shown that mutations in the canonical 
metal binding site (HExxH motif) in the proteolytic domain in both yeast subunits from 
glutamate to glutamine residues (PS-mutants) (see Figure 5) lead to respiratory deficiency 
resembling the Δyta10 and Δyta12 phenotype (Arlt et al., 1998). Interestingly, complex 
assembly and substrate binding properties were not affected (Arlt et al., 1998). 
Furthermore, substrate proteins which cannot be processed by the proteolytically inactive 
yeast m-AAA protease are trapped by the complex in vivo (Nolden et al., 2005), although 
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Figure 5: Domain structure and conservation of residues within Walker B and HExxH motifs of 
m-AAA proteases. 
The m-AAA proteases contain a mitochondrial targeting signal (MTS), an N-terminal domain (ND) 
containing two transmembrane regions (TM), the ATPase (AAA) and proteolytic domain (PD) at the C-
terminus resulting in a matrix-facing topology. Sequence alignments (generated by a ClustalW 
algorithm) are shown for FtsH from Thermus thermophilus, Yta10 and Yta12 from bakers yeast and 
human and murine m-AAA protease subunits. Arrows indicate the positions of mutations in the Walker 
B motif and the proteolytic site in the HExxH motif. WA, Walker A; WB, Walker B; HExxH, canonical 
metal binding site; PS, proteolytic site. (Accession numbers of the protein sequences are listed in  6.3.) 
 
 
an effective substrate trapping complex is achieved by mutating the proteolytic site (PS) in 
all subunits (Tatsuta et al., 2007). These findings immediately illustrate technical difficulties 
working with the mammalian proteins. Data from yeast suggest that substrates can only be 
trapped if the complex does not contain any catalytically active subunit. Therefore, a 
substrate trap approach with proteolytic mutants in a mammalian system would require a 
mutagenesis of all subunits. Interestingly, it has been shown that coexpression of Yta10 or 
Yta12 harboring point mutations in the Walker B motif of the AAA ATPase domain 
(Yta10E388Q, Yta12E448Q, WB see Figure 5) in combination with the wild type form of the 
respective other subunit did not or only weakly restore growth on non-fermentable carbon 
sources and the measured ATPase activity of the enzyme (Augustin, 2008, Hersch, 2005 
#2199). It was demonstrated that this mutation of the Walker B motif leads to trapping of 
ATP which inhibits ATP hydrolysis in the neighboring subunit. Additionally, expression of 
human paraplegin (SPG7) and AFG3L2 subunit variants (SPG7E409Q, AFG3L2E408Q) in yeast 
leads to similar effects on both hetero- and homo-oligomeric isoenzymes (Steffen Augustin, 
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manuscript in preparation). These findings indicate a conserved dominant negative effect of 
this mutation on the holo-enzymatic activity. Moreover, it was possible to co-purify yeast 
MrpL32 together with the yeast m-AAA protease complex that contained one subunit 
harboring a mutated Walker B motif (Steffen Augustin, personal communication). It is 
therefore conceivable that dominant negative variants can be used to study defective 
m-AAA proteases in the mammalian system. Therefore, the expression of the respective 
mutated mammalian m-AAA protease subunit in mammalian cells might be a suitable 
approach to identify putative interaction partners or substrates of mammalian 
m-AAA proteases.  
3.2. Generation of stable cell lines expressing mouse or 
human AFG3L2 variants 
3.2.1. The FlpIn T-REx system 
For expression of different m-AAA protease variants in mammalian cell culture 
FlpIn T-REx -293 (FITR293) cell lines stably and inducibly overexpressing human AFG3L2 
and murine Afg3l2 were generated. An inducible “tet-on”-system was used in order to 
monitor changes of putative phenotypes upon induction of expression in the respective 
cell line. The FITR293 cell line expresses the tetracycline repressor under the control of a 
CMV promoter and contains a blasticidin resistance gene. This human embryonic kidney 
derived cell line also expresses the lac Z gene encoding β-galactosidase which is fused to a 
Zeocin resistance protein (Figure 6 A) allowing a blue white screening of stable cell clones. 
Importantly, cells harbor an FRT (Flp-recombinase target) site in their genome enabling Flp 
(Flippase)-mediated recombination of a gene of interest into this site (Figure 6 A and B) 
(Andrews et al., 1985; Farley et al., 2000).  FITR293 cells can be transiently or stably 
transfected with pcDNA5 FRT/TO constructs containing the open reading frame of interest 
and FRT-sites under the control of a tetracycline-inducible promoter. Co-transfection with a 
Flp recombinase-expressing plasmid allows site-directed recombination and integration 
into the genome of the FITR293 cells. Cells with correctly inserted construct become 
hygromycin resistant, Zeocin sensitive and lose their β-galactosidase activity (Figure 6 B). 
Expression can be induced by addition of tetracycline or doxycycline which suppresses the 
binding of the tet repressor to the tet operator allowing the RNA-polymerase to bind to the 
promoter sequence (Figure 6 C). One possible drawback of this system is the low basal 
expression due to residual tetracycline in the tetracycline-reduced fetal bovine serum and 
to low binding affinity of the tet repressor, especially if the gene 
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Figure 6: FlpIn T-REx system. 
(A) FlpIn T-REx-293 (FITR293) cell line. Stable and inducible expression of target genes is achieved by 
transfection into the FITR293 cell line which expresses the tetracycline repressor under the control of a 
CMV promoter. Flp-mediated recombination results in uniform integration and stable expression target 
genes. 
(B) Stable integration by Flp-mediated recombination. pcDNA5 FRT/TO contains an FRT site and the 
ORF of m-AAA protease variants fused with a C-terminal epitope tag for affinity purification under the 
control of a tetracycline-inducible CMV promoter. Site-directed recombination by Flp causes a switch  
of the start codon (ATG) from the lacZ-Zeocin fusion to the Hygromycin resistance gene which results 
in Hygromycin resistance, Zeocin sensitivity and inactive β-galactosidase. 
(C) Tetracycline inducible expression. Expression is turned “on” by adding tetracycline (tet) or 
doxycyline (dox) to the growth medium. The tet operator is bound by tet repressor homodimers which 
are released upon tetracycline binding allowing gene expression. 
Modified from invitrogen.com. SU; subunit. 
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codes for a toxic protein. This effect was minimized by using tetracycline reduced serum in 
the growth medium and by titrating down the concentration of this serum. The benefit of 
the FlpIn T-REx system is the generation of stable cell lines allowing inducible and, more 
importantly, uniform expression of a gene of interest enabling direct comparative analysis 
of cell lines excluding effects of random integrations. 
3.2.2. Selection for AFG3L2 overexpressing cell lines 
FITR293 cells were transfected with pcDNA5 FRT/TO constructs containing the open 
reading frames of either murine Afg3l2 wild type (WT) or Walker B mutant (WB, 
Afg3l2E407Q), and human AFG3L2 variants: wild type (WT), the proteolytic site mutant (PS, 
AFG3L2E575Q) and constructs carrying a mutation in the Walker B motif (WB, AFG3L2E408Q). 
Murine cDNAs were fused to a C-terminal Strep®II-octahistidine epitope tag and human 
AFG3L2 to a C-terminal hexahistidine tag. Hygromycine resistance allowed positive 
selection for the insertion into the genome. Growing clones were tested for their β-
galactosidase activity (Figure 7 A) and Zeocin sensitivity as described in chapter  2.3.3. 
Clones lacking β-galactosidase activity and Zeocin resistance were tested for the transgene 
expression by the addition of tetracycline. A representative immunoblot analysis of total 
lysates of cells expressing AFG3L2 variants is shown in Figure 7 B. In several clones 
induction with tetracycline resulted in an increase of AFG3L2 protein levels. However, no 
size shift was visible of murine Afg3l2 expressing cell lines even in low percentage 
polyacrylamide gels suggesting a cleavage at the C- or at the N-terminus leading to a loss of 
the tag. The absence of the epitope tag was confirmed since the binding to either a Strep- 
or Ni2+- specific matrix or the detection using His- or StrepII-tag specific antibodies in 
Western Blots could not be established. However, human AFG3L2 could be purified via its 
C-terminal hexahistidine epitope tag (see chapter  3.5.1).  
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Figure 7: Selection of stable clones inducibly expressing AFG3L2. 
(A) β-galactosidase activity staining of FITR293 cells transfected with indicated plasmids. Expression of 
Flp recombinase from the pOG44 plasmid allows integration of AFG3L2 WT into the genome which 
was visualized due to the loss of blue staining. 
(B) Immunoblot analysis of total cell lysates of 8 clones selected with hygromycin for 3 weeks using 
antisera directed against human AFG3L2. Expression was induced by addition of tetracycline to the 
growth medium. Clones 6-8 behaved like untransfected FITR293 cells reflecting endogenous AFG3L2 
protein levels. Immunostaining with an antibody directed against β-actin served as a loading control. 
 
3.3. Mutation of the Walker B motif has a dominant-
negative effect on cell proliferation 
The m-AAA protease is part of a large supercomplex together with prohibitins, highly 
conserved and ubiquitously expressed inner membrane proteins, whose carboxy-terminal 
domains face the intermembrane space of mitochondria (Tatsuta et al., 2005). This high 
molecular weight complex of approximately 2 MDa was first described in yeast and later 
also detected in the mammalian system (Metodiev, 2005; Steglich et al., 1999). 
Knockdown experiments on a cellular level revealed an essential function of the prohibitin 
complex for cell proliferation pointing to a potential role of its assembly partner, the m-
AAA protease, in this process (Merkwirth et al., 2008; Schleicher et al., 2008). Thus, the 
cell proliferation of AFG3L2 overexpressing cells was assessed using a colorimetric assay 
(Figure 8). Treatment of tetracycline had no effect on the growth rate of the parental cell 
line (Figure 8 A). Furthermore, cells overexpressing AFG3L2/Afg3l2 WT showed no 
significant difference in proliferation (Figure 8 and B). In contrast, cells expressing the 
Walker B mutants (AFG3L2 WB or Afg3l2 WB) displayed a strongly reduced cell growth 
indicating a dominant-negative effect of this mutation on the endogenous protein (Figure 8 
A and B). To exclude that the mutation of the Walker B motif interferes with the complex 
assembly, two-dimensional BN/SDS-PAGE was performed. Immunoblot analysis identified 
 
Results 
 
62 
 
 
 
Figure 8: Impaired cell proliferation of Afg3l2/AFG3L2 overexpressing cells harboring a mutation in 
the Walker B motif. 
Colorimetric cell proliferation assay of stable FITR293 clones inducibly expressing murine (A) or human 
(B) AFG3L2 variants. Conversion of a tetrazolium compound to the formazan product was measured at 
490 nm which is directly proportional to the number of living cells in culture. Protein expression was 
induced with tetracycline and proliferation was assayed daily. Graphs represent means of 
quadruplicates ± standard deviation (SD) of one (B) or three independent (A) experiments. **, p<0.01; 
*** p<0.001. Filled symbols indicate with and open symbols without tetracycline.  
WT, wild type; PS, mutation in the proteolytic site (AFG3L2E575Q); WB, mutation in the Walker B motif 
(Afg3l2E407Q/AFG3L2E408Q). 
 
 
 
m-AAA proteases as part of complexes similar sized as in untransfected cells (see Figure 
17 A).  
In conclusion, cell proliferation needs the ATPase activity of the m-AAA protease. Cells 
expressing AFG3L2 PS did not show any markedly growth defect and behave like wild 
type expressing cell lines. However, data from yeast suggest that a putative effect of this 
mutation is suppressed by endogenous AFG3L2 protein, and, therefore, cannot be 
excluded (Arlt et al., 1998; Arlt et al., 1996). These findings confirm the results obtained 
with the yeast protease (Steffen Augustin, manuscript in preparation) suggesting that a 
mutation in the Walker B motif has a dominant negative effect over the wild type subunits. 
This indicates a conserved mechanism from yeast to man.  
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3.4. Mammalian m-AAA proteases are required for 
mitochondrial fusion 
Mitochondria are highly dynamic organelles which are actively transported throughout 
cells to defined subcellular locations. Furthermore, mitochondria vary in size and shape, 
and their internal structures can change in response to their physiological state (Detmer 
and Chan, 2007). This adaptation of mitochondria to cellular demands is critical for a 
number of important processes including calcium signaling, ROS protection, mtDNA 
maintenance, aging, developmental processes and apoptosis (Balaban et al., 2005; Chen et 
al., 2003; Szabadkai et al., 2006; Tang et al., 2009; Youle and Karbowski, 2005). To 
investigate a potential role of the mammalian m-AAA proteases in any of these pathways, 
the structure of the mitochondrial network was monitored, which is regulated by the 
balance between the antagonistic fusion and fission activities. For this purpose, 
mitochondrially targeted dsRed was transfected into m-AAA protease subunit 
overexpressing cell lines and mitochondrial morphology was assessed by fluorescence 
microscopy. Stable FITR293 cell lines inducibly overexpressing AFG3L2 WT and 
AFG3L2 PS mutant as well as control cells showed a tubular network whereas expression 
of the dominant negative AFG3L2 WB led to fragmentation in 75 % of the cells (Figure 9 A 
und B). Additionally, analysis of T-REx-HeLa cells transiently transfected with hexahistidine 
tagged human AFG3L2 and SPG7 WT, PS and WB confirmed the results observed in 
FITR293 cells: expression of the dominant-negative mutation of the Walker B motif variant 
of either SPG7 or AFG3L2 results in fragmentation of mitochondria or a disturbed 
mitochondrial network (Figure 9 C). These findings are in agreement with siRNA-mediated 
downregulation of m-AAA protease subunits. Loss of functional m-AAA protease 
complexes achieved by depletion of Afg3l2 and Afg3l1 in mouse embryonic fibroblasts 
caused fragmented mitochondria in more than 80 % of the cells, underscoring a role of 
mammalian m-AAA proteases in the regulation of mitochondrial dynamics (Ehses, 2008). 
As already described, either stable or transient overexpression of the respective 
m-AAA protease subunit mutated in the proteolytic site did not affect mitochondrial 
morphology (see chapter  3.3). In summary, a functional ATPase domain of the 
m-AAA protease is necessary to maintain a mitochondrial tubular network, whereas the 
proteolytic site does not seem to be involved because this mutation is not dominant 
negative. 
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Figure 9: Fragmentation of mitochondria upon expression of SPG7 or AFG3L2 Walker B mutant. 
Fluorescence microscopic analysis of mitochondrial morphology of stably transfected FITR293 
overexpressing human AFG3L2 variants (A and B) and transiently transfected T-REx-HeLa cells 
inducibly overexpressing human SPG7 or human AFG3L2 variants (C). 48 h after transfection with 
mitochondrial targeted DsRed expression was induced by tetracycline for 24 h and mitochondrial 
morphology was monitored by fluorescence microscopy. Images were deconvolved. >200 cells were 
scored and mitochondrial morphology was classified as tubular, intermediate or aggregated, and 
fragmented. Error bars indicate means ± standard deviation (SD) of at least three independent 
experiments. 
WT, wild type; PS, mutation in the proteolytic site (SPG7E575Q/AFG3L2E575Q); WB, mutation in the 
Walker B motif (SPG7E409Q/AFG3L2E408Q). 
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3.4.1. m-AAA proteases regulate the stability of long OPA1 isoforms 
In healthy cells, mitochondria form elongated tubules that continously divide and fuse 
to form a dynamic interconnected network, which is maintained by a balance between 
both opposing processes. Therefore, the fragmentation of mitochondria observed in cells 
expressing the dominant-negative mutation of the Walker B motif, can in principle be 
explained by two different possibilities: either by an impairment of the fusion machinery or 
by inducing the fission activity. To distinguish between these possibilities the steady state 
levels of mitochondrial fusion proteins were monitored. Many of the involved fusion and 
fission components have been identified and most of them are conserved among species 
(Hoppins et al., 2007). The antagonistic events – fusion and fission of mitochondrial 
membranes – are mainly regulated by dynamin-like GTPases (for review (Suen et al., 
2008)). Yeast Dnm1 or its human counterpart DRP1, the dynamin-related protein 1, a large 
GTPase, mediates fission in mammalian cells (Otsuga et al., 1998; Smirnova et al., 1998). 
DRP1 levels were not affected in AFG3L2 WB overexpressing FITR293 cells (Figure 10 B). 
In parallel, studies by Sarah Ehses confirmed that mitochondrial fission was not impaired. 
Transfection of mouse embryonic fibroblasts depleted of murine m-AAA protease subunits 
by siRNA with a dominant-negative variant of DRP1 (DRP1K38A) resulted in fragmentation 
of mitochondrial tubules due to impaired fusion (Sarah Ehses, personal communication). 
Wild type cells elongated due to ongoing fusion (James et al., 2003; Smirnova et al., 
1998). 
Mitochondrial fission is normally counter-balanced by fusion. The mammalian fusion 
machinery is mainly composed of three dynamin-like GTPases, the mitofusins, Mfn1 and 
Mfn2, in the outer and OPA1 in the inner mitochondrial membrane (Chen et al., 2003; 
Olichon et al., 2003; Santel and Fuller, 2001). OPA1 functions in mitochondrial fusion and 
cristae remodelling (Cipolat et al., 2004; Griparic et al., 2004; Olichon et al., 2003). 
Alternative splicing of the human OPA1 gene leads to the generation of eight distinct 
mRNA variants (Delettre et al., 2001; Olichon et al., 2002; Satoh et al., 2003) (see Figure 
2). Furthermore, OPA1 protein expression is regulated in a complex manner by post-
translational proteolytic cleavages resulting in the accumulation of five apparent isoforms 
of OPA1 protein (Delettre et al., 2001; Duvezin-Caubet et al., 2007; Ishihara et al., 2006; 
Olichon et al., 2003; Olichon et al., 2007; Song et al., 2007). Although OPA1 is 
ubiquitously expressed, mutations in the OPA1 gene lead to autosomal dominant optic 
atrophy (ADOA) affecting only the optic nerve and retinal ganglion cells (Alexander et al., 
2000; Delettre et al., 2000; Johnston et al., 1979). The yeast rhomboid protease Pcp1 has 
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Figure 10: Expression of the Walker B mutants induces processing of OPA1. 
(A) Immunoblot analysis of FITR293 cell lysates using antisera specifically recognizing OPA1. After 
induction with tetracycline stable cell lines inducibly overexpressing human AFG3L2 (upper panel) and 
murine Afg3l2 (lower panel) variants were harvested, lysed and analyzed by SDS-PAGE and subsequent 
immunoblotting using antibodies directed against murine Afg3l2 and human AFG3L2. Notably, murine 
Afg3l2 in FITR runs higher than the human homologue in SDS-PAGE. Immunostaining for β-actin and 
SLP2 with specific antisera served as loading controls.  
(B) Immunoblot analysis of FITR293 cell lysates using antisera specifically recognizing Drp1. Cells 
expressing murine Afg3l2 were treated as in (A). 
(a) and (b) indicate long OPA1 and (c-e) short OPA1 isoforms. WT, wild type; PS, mutation in the 
proteolytic site (AFG3L2E575Q); WB, mutation in the Walker B motif (Afg3l2E407Q/AFG3L2E408Q). 
 
 
 
been shown to cleave the OPA1 homologue Mgm1 (Herlan et al., 2004; Herlan et al., 
2003; McQuibban et al., 2003; Sesaki et al., 2003), and its mammalian counterpart PARL 
was also reported to be involved in OPA1 processing (Cipolat et al., 2006). Similarly, the 
m-AAA protease subunit SPG7 was proposed to cleave OPA1 (Ishihara et al., 2006). 
However, PARL or SPG7 knockout mouse embryonic fibroblasts produce a normal wild 
type OPA1 pattern (Duvezin-Caubet et al., 2007; Ehses, 2008; Guillery et al., 2008). 
Interestingly, reconstituted OPA1 in yeast can be processed by yeast, human or murine 
m-AAA protease isoenzymes identifying OPA1 as a putative substrate of mammalian 
m-AAA proteases (Duvezin-Caubet et al., 2007). Thus, the aim of the following 
experiments was to clarify the role of mammalian m-AAA proteases for the processing of 
OPA1. 
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3.4.1.1. Expression of a dominant-negative Walker B mutant leads to an 
accumulation of short OPA1 isoforms 
In order to verify an effect of the tetracycline-inducible overexpression of 
m-AAA protease mutant variants on the accumulation of OPA1 isoforms, FITR293 cell 
lysates were analyzed by immunoblotting using antibodies directed against OPA1 (Figure 
10 A). Five isoforms could be detected in control as well as in Afg3l2 and AFG3L2 WT and 
PS cell lines. Two long isoforms a and b give rise to three short isoforms c-e which are 
generated by processing of the long isoforms (Duvezin-Caubet et al., 2007). The observed 
pattern is similar to those observed in HeLa cells (Duvezin-Caubet et al., 2007; Song et al., 
2007). Considering a role for the m-AAA protease as processing peptidase, an impaired 
processing of OPA1 should result in the accumulation of long isoforms. However, 
interfering with the function of the protease by expressing the dominant-negative mutant 
variant did not cause an accumulation of long OPA1 isoforms as it was initially suggested 
(Duvezin-Caubet et al., 2007). In contrast, the long OPA1 isoforms were not detectable 
while short forms accumulated in cell lines expressing murine Afg3l2 (Figure 10 A, lower 
panel) or human AFG3L2 WB (Figure 10 A, upper panel). These findings are consistent 
with data obtained by siRNA mediated downregulation of m-AAA protease subunits, 
although the effect seems to be more prominent in mouse embryonic fibroblasts in which 
mainly shortest isoform e accumulated (Ehses, 2008).  
In summary, lack of functional m-AAA proteases obtained by expression of 
Afg3l2/AFG3L2 WB leads to accelerated processing and/or enhanced degradation of 
OPA1. The observed effect can be either explained by an induced processing or an 
increased turnover of l-OPA1 isoforms. These data suggest that OPA1 is not processed or 
degraded by m-AAA proteases. In contrast, m-AAA proteases seem to contribute to the 
stability of l-OPA1 isoforms thereby regulating mitochondrial dynamics. 
3.4.1.2. The energy metabolism is not impaired in cells expressing dominant-
negative Walker B mutants 
Defects in mitochondrial morphology reflect often primary impairments of 
mitochondrial function. Mitochondrial dysfunction and the dissipation of the membrane 
potential across the inner membrane can induce OPA1 processing and mitochondrial 
fragmentation (Duvezin-Caubet et al., 2006; Griparic et al., 2007; Ishihara et al., 2006; 
Ishihara et al., 2003; Song et al., 2007). It has also been shown that induction of apoptosis 
and MOMP (mitochondrial outer membrane permeabilization) induce OPA1 cleavage 
(Guillery et al., 2008; Ishihara et al., 2006). Baricault et al. hypothesized that decreased 
mitochondrial ATP levels, either generated by induction of apoptosis,  
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Figure 11: Energy status of FITR293 cells upon expression of dominant negative Afg3l2 variant. 
(A) Oxygraph measurements of intact FITR293 cells expressing murine Afg3l2 variants. Respiration was 
measured under routine conditions, after the addition of 2 μM oligomycin (OLG) and during titrations 
with CCCP. Respiratory control ratio (RCR) was determined from the ratio of CCCP-induced to 
oligomycin-inhibited respiration. Bars represent means ± standard deviation (SD) of at least three 
independent experiments. (***) p<0.001.  
(B) Determination of cellular ATP levels upon expression of Afg3l2. 48 h before induction of expression 
standard glucose containing growth medium was changed to medium containing 1 mM galactose. Cells 
were harvested after 24 h induction with tetracycline and lysed. ATP content was measured by a 
luciferase assay.  
(C) Maintenance of membrane potential upon expression of Afg3l2 WB. FITR293 cells were treated 
24 h with tetracycline, stained with JC-1 and analyzed by FACS. To dissipate the membrane potential 
the uncoupler CCCP was used.  
OLG, oligomycin; CCCP, carbonyl cyanide m-chlorophenylhydrazone; -, untransfected control cells; 
WT, wild type; WB, mutation in the Walker B motif (Afg3l2E407Q). 
 
 
dissipation of the membrane potential or inhibition of the ATP synthase, is the common 
and crucial stimulus that controls OPA1 processing (Baricault et al., 2007). These results 
suggest that the ATP-dependent OPA1 processing plays a central role in correlating the 
energetic metabolism to mitochondrial dynamics. To verify whether the observed changes 
of organelle morphology were a primary consequence of loss-of fusion activity of OPA1 or 
a secondary effect due to an impaired energy metabolism, functional analysis of the 
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FITR293 cell lines were performed. Respiratory activity (Figure 11 A), ATP levels (Figure 11 
B) and the mitochondrial membrane potential were monitored (Figure 11 C). 
Oxygen consumption in FITR293 cells expressing the Afg3l2 WB revealed normal 
respiratory activity compared to wild type expressing cells (Figure 11 A). The rate of 
oxidative phosphorylation is often assumed to be proportional to the rate of respiration, 
and thus the control of one rate is assumed to be equivalent to the control of the other rate 
(Brown et al., 1990). However, this is not necessarily the case as the protonmotive force 
generated by respiration may be consumed by processes other than oxidative 
phosphorylation, including the passive proton leak or electron slips across the 
mitochondrial inner membrane (Brown et al., 1990). To monitor these effects, respiration 
was measured after inhibition of the ATP synthase with oligomycin. Interestingly, treatment 
with oligomycin revealed a slight but significant higher respiratory rate of Afg3l2 WB 
expressing cells compared to WT or controls. In contrast, dissipation of the membrane 
potential using the ionophore CCCP, mimicking maximal respiratory activity, showed 
lower respiration of the cells (Figure 11 A). The ratio of respiration after CCCP and 
oligomycin treatment is called the respiratory control ratio and indicates the tightness of 
the coupling between respiration and phosphorylation. The respiratory control ratio of the 
Afg3l2 WB cell line was therefore reduced suggesting a proton leak or an electron slip of 
the respiratory chain. Nevertheless, under normal routine or cell culture conditions 
respiration was normal.  
To assess the mitochondrial membrane potential cells were stained with JC-1, a dye 
that can selectively enter into mitochondria and reversibly change color as the membrane 
potential increases (see chapter  2.3.6.2). Fluorescence activated cell sorting revealed no 
significant alteration in the membrane potential compared to CCCP treatment which was 
used as a positive control (Figure 11 B). Moreover, cellular ATP levels were not affected by 
the mutation (Figure 11 C). 
In conclusion, FITR293 cells expressing Afg3l2 WB showed a reduced coupling 
between respiration and phosphorylation. That indicates a putative electron slip or proton 
leak through the inner mitochondrial membrane (Brand et al., 1994; Brand et al., 1994; 
Nicholls, 1974). However, under normal cell culture conditions, interference with the 
ATPase function of m-AAA proteases has no effect on respiration or the formation of the 
membrane potential. Thus, the accelerated processing of OPA1 upon expression of the 
Walker B mutation is apparently not caused by an impaired membrane potential or 
respiratory activity.  
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3.4.1.3. Dominant-negative mutation in Walker B induces destabilization of 
respiratory chain supercomplexes 
The production of ATP requires the coordinated activity of five multi-heteromeric 
enzyme complexes embedded in the mitochondrial inner membrane and of two mobile 
electron carriers, ubiquinone (Q) and cytochrome c (see  
Figure 1). The electron flow through the respiratory chain is coupled to an active 
proton translocation across the inner mitochondrial membrane, generated mostly by 
complexes I, III and IV. The influx of the protons back into the mitochondrial matrix 
through complex V allows the phosphorylation of ADP into ATP (Torraco et al., 2009). 
FITR293 cells expressing Afg3l2 WB showed a decreased respiratory activity thereby 
indicating an effect of m-AAA proteases on the respiratory chain. Thus, the aim of the 
following experiments was to verify the integrity of the respiratory chain through which 
electrons and protons are transported. To monitor the assembly of respiratory chain 
subunits BN-PAGE analysis was performed. Expression of the dominant-negative mutant 
did apparantly not impair the complex formation of the respiratory chain (Figure 12 A). The 
yeast m-AAA protease processes MrpL32 which is important for translation of mtDNA 
(Nolden et al., 2005). Impaired cleavage of MrpL32 results in the disappearance of a subset 
of the respiratory chain complexes which contain mtDNA encoded subunits (Metodiev, 
2005; Nolden et al., 2005). Correlating with BN-PAGE results (Figure 12 A), MRPL32 
processing in FITR293 expressing human AFG3L2 variants was only slightly affected 
(Figure 12 B). Furthermore, in-gel-activity stainings in CN-PAGEs revealed no alteration of 
the activities of complex I (Figure 12 C) and complex IV (Figure 12 D) upon expression of 
AFG3L2 WB. 
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Figure 12: Assembly and activity of the respiratory chain in FITR293 cells expressing dominant-
negative mutant variants is apparently not altered. 
(A) BN-PAGE analysis of mitochondria isolated from murine Afg3l2 expressing cell lines. The 
mitochondrial membrane fraction was solubilized using the indicated amounts of digitonin (dig) per g 
of mitochondrial protein. A 3-11 % [w/v] BN-PAGE was performed and gels were stained with colloidal 
Coomassie. 
(B) Appearance of precursor MrpL32 in immunoblots of total cell lysates from FITR293 cells inducibly 
overexpressing human AFG3L2 WB. Membranes were stained with antibodies specifically recognizing 
OPA1 and MrpL32.  β-actin served as a loading control. p, precursor; m, mature; *, unspecific 
crossreaction. The lower film of the MrpL32 immunostaining was exposed longer to visualize the 
precursor. 
(C) In-gel-activity-staining of NADH:ubiquinone oxidoreductase (complex I) of mitochondrial lysates 
from different FITR293 cell lines. Mitochondria were isolated from cells grown either on glucose or 
galactose. Digitonin (10 g/g protein) solubilized mitochondrial complexes were separated on a 3-
13 % [w/v] CN-PAGE. Bovine heart mitochondria (BHM), solubilized with 8 g dig/g protein, served as 
positive control. NADH dehydrogenase containing complexes were visualized by a complex I staining.  
(D) In-gel-activity-staining of cytochrome c oxidase (complex IV) of solubilized mitochondrial 
membranes from different FITR293 cell lines. Mitochondria were analyzed as in (C) and gels were 
stained by a cytochrome c oxidase staining. 
CI, NADH:ubiquinone oxidoreductase (complex I); CIV, cytochrome c oxidase (complex IV); BMH, 
bovine heart mitochondria; SC, supercomplexes; mon, monomeric; dim, dimeric; -, parental cell line 
control; WT, Afg3l2/AFG3L2 wild type; PS, mutation in the proteolytic site (AFG3L2E575Q); WB, 
mutation in the Walker B motif (Afg3l2E407Q/AFG3L2E408Q); arrows indicate the appearance of 
supercomplexes (>1.5 MDa). 
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Complexes of the respiratory chain have been shown to form large supramolecular 
assemblies, termed respiratory supercomplexes or ‘respirasomes’ (Krause et al., 2004; 
Marques et al., 2007; Schägger and Pfeiffer, 2000; Wittig et al., 2006). This type of 
organization was hypothesized to be of high functional importance for optimizing electron 
transport during respiration (Boekema and Braun, 2007; Schägger, 2001; Schägger, 2002). 
In mammalian mitochondria, almost all complex I is assembled into supercomplexes 
comprising complexes I and III and up to four copies of complex IV (Schägger and Pfeiffer, 
2000). To monitor the supercomplex composition in Afg3l2 expressing FITR293 cell lines 
in more detail, immunoblot analysis of a first dimensional BN-PAGE was performed (Figure 
13 A). Interestingly, immunostaining with antibodies specifically recognizing subunits of 
respiratory chain subunits of complexes I, III and IV revealed a slight accumulation of free 
complexes III and IV and of smaller arrangements which lack complex IV (Figure 13 A). 
This indicates a reduced stability or higher turnover of these supercomplexes. Intriguingly, 
this phenomenon is reminiscent of phenotypes observed in Barth Syndrom patients. 
Isolated mitochondria from these patients harboring mutations in the cardiolipin 
remodelling enzyme tafazzin show a similarly reduced stability of CI/CIII2/CIV1-n containing 
supercomplexes (McKenzie et al., 2006). Earlier, it was hypothesized that the permeability 
changes of the inner membrane towards protons are caused by changes in the lipid 
composition of the membrane phospholipids (Brand et al., 1994). This is confirmed by 
several more recent publications: cardiolipin affects the stability of respiratory chain 
supercomplexes (Claypool et al., 2008; Jiang et al., 2000; McKenzie et al., 2006; 
Schägger, 2002; Schlame et al., 2000; Wittig and Schägger, 2009). Deletions of the yeast 
m-AAA protease show decreased phosphatidylethanolamine and cardiolipin levels (Osman 
et al., 2009). This raised the question whether the mitochondrial phospholipid 
composition was also altered in mammalian cells expressing dominant-negative AFG3L2 
mutants. Therefore, phospholipids of mitochondrial membranes were isolated and 
analyzed by thin layer chromatography (Figure 13 B). However, cardiolipin levels or the 
other phospholipids were not significantly affected after 24 h (or 100 h; Sebastian Müller 
personal communication) induction with tetracycline.  
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Figure 13: Dominant-negative Walker B mutation affects the stability of supercomplexes but not the 
phospholipid composition. 
(A) Western Blot of BN-PAGE performed with mitochondrial preparations from murine Afg3l2 variant 
overexpressing cell lines. Expression was induced for 24 h with tetracycline. Immunostaining was 
performed using antibodies directed against complex I 30 kDa subunit (CI), complex III core 2 subunit 
(CIII) and complex IV subunit II (CIV). Arrows indicate the appearance of supercomplexes (>1.5 MDa). 
(B) Thin layer chromatography (TLC) of isolated phospholipids from FITR293 cells expressing murine 
Afg3l2. TLC was run with chloroform/methanol/water (left, 65:35:5, v/v/v) and 
chloroform/ethanol/water/triethylamin (right, 30:35:7:35, v/v/v/v). CL, cardiolipin; PE, 
phosphatidylethanolamine; PC, phosphatidylcholine; PG, phosphatidylglycerol; PSe, 
phosphatidylserine; PA, phosphatidic acid; PI, phosphatidylinositol. 
-, untransfected control cells; WT, wild type Afg3l2; WB, mutation in the Walker B motif (Afg3l2E407Q). 
 
 
Consistent with these findings, mouse embryonic fibroblasts lacking m-AAA protease 
subunits achieved by siRNA-mediated downregulation showed phospholipid levels 
compared to wild type cells (Sebastian Müller, personal communication). In summary, 
functional m-AAA proteases are needed for the stability of respiratory chain 
supercomplexes although the overall assembly is not affected. The reduced stability of the 
supercomplexes cannot be simply explained by altered phospholipid levels within 
mitochondria.  
 
 
 
 
 
Results 
 
74 
3.4.1.4. Induced OPA1 processing at site S1 and increased turnover of non 
cleavable OPA1 variants  
Accelerated OPA1 processing is not induced by an impaired energy metabolism. 
Membrane potential and ATP levels were not altered (see chapter  3.4.1.2). It has been 
shown that the induced cleavage takes place at site S1 (Song et al., 2007). The subunit 
SPG7 of mammalian m-AAA proteases has been suggested to cleave OPA1 at site S1. To 
address the observed phenotype of induced OPA1 processing in cells expressing ATPase 
mutants of m-AAA proteases in more detail, S1 cleavable and non-cleavable variants of rat 
Opa1 were transfected into Afg3l2 expressing FITR293 cell lines (Figure 14). FLAG-tagged 
rat Opa1 splice variant 1 (rOpa1 v1; L+S-Opa) (Ishihara et al., 2006) (Figure 14 A) gives 
rise to a long and a short isoform, and FLAG-tagged rat Opa1 splice variant 1, lacking the 
cleavage site S1 (rOpa1 v1ΔS1; L-Opa) (Ishihara et al., 2006) (Figure 14 A), yields only the 
long isoform. In line with published findings, transfection of rOpa v1 revealed a long and 
short, whereas v1ΔS1 a long Opa1 isoform only (Ishihara et al., 2006; Song et al., 2007). 
Interestingly, cells inducibly expressing Afg3l2 harboring a mutation in the Walker B motif 
showed an enhanced processing of splice variant 1, illustrated by an accumulation of the 
short compared to the long isoforms. In contrast, cells expressing rat Opa1 variant 1 
lacking cleavage site S1 demonstrated a reduced steady state level of long Opa1 (see 
Figure 14 C). Quantifications of the immunstaining intensities revealed a drastic change of 
the ratio of short and long isoforms (Figure 14 B, left panel) as well as to a reduction of 
long isoforms to 35 % compared to Afg3l2 wild type or control cells (Figure 14 B, right 
panel). 
In summary, these results indicate that a functional ATPase domain of m-AAA proteases 
is necessary to stabilize long-OPA1. In addition, expression of the dominant-negative 
mutant of Afg3l2 facilitated the processing of a yet unknown protease indicating that 
m-AAA proteases control this processing event in a negative regulatory manner. 
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Figure 14: A defective m-AAA protease leads to induced processing of OPA1 at site S1 and an 
increased turnover of long OPA1 isoforms. 
(A) Domain structure of C-terminal FLAG tagged rat Opa1 variant 1 (v1) and non-cleavable rOpa1 
variant 1 (v1ΔS1) lacking the cleavage site S1. DNA constructs were provided by (Ishihara et al., 2006). 
(B) Quantification of the ratio between the short (S1) and the long isoform (L) of rat Opa1 (left panel), 
and the percentage of visible rOpa1 in cells expressing Afg3l2 WT or WB after transfection with the 
indicated construct. Murine Afg3l2 expressing FITR293 cell lines were transiently transfected with rat 
Opa1 splice variant 1-FLAG (v1, left panel) and variant 1-FLAG lacking the processing site S1 (v1ΔS1, 
right panel). After 24 h, cells were split before induction with tetracycline for 24 h. Cells were lysed and 
lysates were separated by SDS-PAGE and analyzed by following immunoblotting using FLAG- , murine 
Afg3l2 and β-actin antibodies. Signals were quantified using ImageQuant TL (GE) software. The 
intensities of non-cleavable rOpa1 v1 were normalized to the respective β-actin signals. 
(C) Western Blot analysis of the experiment described in (B). 
TM, transmembrane domain; CC, coiled coil domain; GED, GTPase effector domain; MPP, 
mitochondrial processing peptidase; tet, tetracycline; r, rat; WT, wild type; WB, mutation in the Walker 
B motif (Afg3l2E407Q); p, precursor of OPA1; L, long Opa1 isoform; S1, short Opa1 generated by 
cleavage at site S1.  
 
3.4.1.5. OPA1 co-immunoprecipitates with overexpressed Afg3l2 
Obviously, m-AAA protease isoenzymes affect the stability of long OPA1 isoforms, but 
so far the mechanism has remained elusive. Previous experiments suggested an interaction 
of exogenously expressed SPG7-HA and FLAG tagged OPA1 v1 in HeLa cells (Ishihara et 
al., 2006). Thus, it is conceivable that also Afg3l2 interacts directly with OPA1. To further 
investigate this, co-immunoprecipitation experiments were performed.  
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Figure 15: OPA1 isoforms and the prohibitins can be co-immunoprecipitated with overexpressed 
m-AAA protease. 
Afg3l2 could be precipitated out of 750 µg lysed mitochondria from FITR293 inducibly overexpressing 
murine Afg3l2 WT or WB using antibodies directed against human AFG3L2. Expression was induced 
for 24 h with tetracycline. Mitochondrial membranes were solubilized using 20 g digitonin/g protein. 
IgG indicates immunoprecipitation (IP) with preimmune serum which was used as a negative control. IP 
samples and 10 % of the total input were loaded and analyzed by SDS-PAGE and Western Blot using 
antisera of human AFG3L2, OPA1, prohibitin 1 and 2 (PHB1 and PHB2). 
WT, wild type; WB, Walker B mutant (Afg3l2E407Q). 
 
 
 
Immunoprecipitation of endogenous AFG3L2 from digitonin lysed FITR293 mitochondria 
using a specific antibody revealed a complex composed of the m-AAA protease and the 
prohibitins as previously described for the yeast and murine m-AAA proteases (Metodiev, 
2005; Steglich et al., 1999). OPA1 could not be detected in the immunoprecipitate (Figure 
17 B). However, performing this experiment with mitochondrial lysates from cells 
inducibly overexpressing murine Afg3l2 WT or WB, both revealed signals of endogenous 
OPA1 in the immunoprecipitate (Figure 15). However, the interaction was weak compared 
to that with the prohibitins.  
In conclusion, m-AAA proteases are in a putative complex with prohibitins and OPA1 
the role of which remains to be elucidated. Interestingly, this complex is not affected by 
the mutation in the Walker B motif. 
 
3.4.1.6. Analysis of the OPA1 complex and apoptotic sensitivity 
Besides its role for mitochondrial fusion OPA1 controls apoptotic cristae remodelling 
(Cipolat et al., 2006; Frezza et al., 2006). Independent of mitofusins it prevents apoptosis 
by preventing cytochrome c release and mitochondrial dysfunction (Frezza et al., 2006). 
As mentioned earlier, OPA1 isoforms are generated by alternative splicing as long OPA1 
isoforms which reside in the inner mitochondrial membrane (Delettre et al., 2001; Olichon 
et al., 2002; Satoh et al., 2003). A minor fraction, however, is subjected to proteolytic 
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processing and gets further released into the intermembrane space which has been 
suggested to be regulated by the inner membrane rhomboid protease PARL (Cipolat et al., 
2006). It is believed that OPA1 oligomers in the intermembrane space are composed of 
both, transmembrane long and soluble short isoforms. Interestingly, Frezza et al. correlated 
the disassembly of OPA1 oligomers with remodelled cristae (Frezza et al., 2006). For 
instance, Parl-/- mouse embryonic fibroblasts exhibit a reduced amount of oligomeric OPA1 
compared to wild type cells (Frezza et al., 2006). Recently, Yamaguchi et al. observed that 
this disassembly is dependent on pro-apoptotic BH3-only proteins or BH3 peptides, and 
requires the presence of either Bak or Bax in the outer mitochondrial membrane 
(Yamaguchi et al., 2008). Considering the role of OPA1 on cristae remodelling during 
apoptosis, the question emerged whether m-AAA proteases not only induce the processing 
and increased turnover of long-OPA1 isoforms but also influence OPA1 complexes and 
therefore the resistance towards apoptotic stress stimuli.  
Therefore, crosslinking of OPA1 as described previously (Frezza et al., 2006; 
Yamaguchi et al., 2008) was carried out using isolated mitochondria from FITR293 
expressing distinct variants of AFG3L2 (Figure 16 A). One distinct band at approximately 
160 kDa and also species with a higher molecular weight appeared after crosslinking. 
Although the dominant-negative mutation in AFG3L2 induced the processing of OPA1, the 
observed oligomers were formed to a similar extent, indicating that m-AAA proteases do 
not influence the formation of OPA1 complexes (Figure 16 A). To test the sensitivity of 
FITR293 cells towards apoptotic stimuli, cells were treated with different concentrations of 
tumor necrosis factor (TNF)-α and cycloheximide. Together they induce the death receptor 
pathway (Aggarwal, 2003) (Figure 16 B). Cell lysates were analyzed using antibodies 
against PARP1, a 116 kDa nuclear poly (ADP-ribose) polymerase which appears to be 
involved in DNA repair in response to environmental stress (Satoh and Lindahl, 1992). This 
protein is cleaved by caspase-3 in vivo and serves as a marker of cells undergoing 
apoptosis (Nicholson et al., 1995; Oliver et al., 1998; Tewari et al., 1995). Visualizing the 
activation of caspase-3 by using antibodies specifically recognizing the cleaved form failed 
since FITR293 cells exhibit low levels of endogenous caspase-3 protein (Eldering et al., 
2004). However, expression of dominant-negative Walker B mutant of AFG3L2 had no 
effect on the sensitivity towards TNF-α and cycloheximide (Figure 16 B). 
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Figure 16: m-AAA protease has no apparent effect on the sensitivity of cells towards apoptosis. 
(A) OPA1-crosslink showing no effect of the expression of AFG3L2 WB on OPA1 complex formation. 
Mitochondria isolated from stable FITR293 cells inducibly overexpressing the indicated AFG3L2 variant 
were incubated with the crosslinker EDC (10 mM/ 1 x PBS) for the indicated time. The reaction was 
quenched with SDS-loading buffer and complexes were separated on 6-12 % [w/v] Tris-glycine SDS-
PAGE and further analyzed by immunoblotting using OPA1 antibodies. (On the right is shown a longer 
exposure time). Staining with complex II subunit 70 kDa served as loading control.  
(B) PARP1 cleavage upon TNF-α induction of apoptosis in cells expressing human AFG3L2 variants. 
Cells were induced for 24 h with tetracycline and further incubated for 24 h in the presence of 0, 5, 10 
and 20 ng/ml TNF-α, 2 µg/ml cycloheximide and tetracycline. Lysates were analyzed by SDS-PAGE and 
immunoblotting using antibodies directed against human AFG3L2, PARP1 and β-actin as a loading 
control. 
-, parental cell line control; WT, AFG3L2 wild type; PS, mutation in the proteolytic site (AFG3L2E575Q); 
WB, mutation in the Walker B motif (AFG3L2E408Q); CII, complex II 70 kDa subunit; PARP1, poly (ADP-
ribose) polymerase 1. 
 
To summarize, expressing the dominant-negative mutant of AFG3L2 did not effect the 
resistance against apoptotic stress induced by TNF-α and cycloheximide. Even though the 
OPA1 pattern was shifted to the short isoforms, the OPA1 complex formation is not 
altered, which is in contrast to PARL knockout cells (Frezza et al., 2006). These findings 
reflect the results of already described co-immunoprecipiation experiments (see chapter 
 3.4.1.5). The m-AAA protease is in a putative complex with OPA1 which is not affected by 
the Walker B mutation. Therefore, m-AAA proteases don’t seem to interfere with apoptosis 
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which is in contradiction to the effects observed in prohibitin 2 knockout cells (Merkwirth 
et al., 2008), indicating that both proteins exert different functions during apoptosis. 
3.4.2. m-AAA proteases play a role in stress induced hyperfusion via 
interaction with Stomatin-like protein 2 
m-AAA proteases regulate mitochondrial fusion by stabilizing long OPA1 isoforms. 
However, the physiological role of mitochondrial fusion and fission in cell function and 
survival is still poorly understood. It has been reported that mitochondria hyperfuse and 
form a highly interconnected network in cells exposed to stresses that inhibit cytosolic 
protein synthesis (Tondera et al., 2009). Stress-induced mitochondrial hyperfusion (SIMH) 
requires metabolically active mitochondria, leads to mitochondrial ATP production and 
represents a novel adaptive pro-survival response against stress (e.g. UV irradiation and 
low concentrations of cycloheximide) (Tondera et al., 2009). It was demonstrated that 
SIMH is dependent on OPA1, mitofusin1, and on SLP2, also known as Stomatin-like 
protein 2 (Santel and Fuller, 2001; Tondera et al., 2009). SLP2, like the prohibitins, 
belongs to the SPFH protein family (Stomatin, Prohibitin, Flotillin and HflK/C) 
(Tavernarakis et al., 1999). Interestingly, various SPFH-domain-containing proteins are 
enriched in detergent-resistant membranes suggesting an association with lipid 
microdomains in several cellular compartments (Browman et al., 2007; Langhorst et al., 
2005). SLP2 forms a complex in the mitochondrial inner membrane and was shown to 
interact specifically with mitofusin 2 which is present in the outer membrane (Hajek et al., 
2007; Santel and Fuller, 2001). Interestingly, SLP2 interacts also with prohibitins and 
contributes to their stability (Da Cruz et al., 2008). To analyze whether SLP2 interacts with 
the m-AAA protease in the inner membrane a 2D-BN/CN-SDS-PAGE was performed to 
monitor the size of the native complex. Gels were either subjected to immunostaining (BN-
SDS-PAGE) or silver staining (CN-SDS-PAGE). Spots from the silver stained gels were 
picked and analyzed by trypsin digest and subsequent mass spectrometry (see appendix 
 6.2). SLP2 is present in an abundant protein complex which could be visualized by silver 
staining (Figure 17 A). Mitofusin 2 proposed to be a binding partner of SLP2 could neither 
be detected in silver stained protein gels nor in the Western Blot. In FITR293 cells, SLP2 
runs at a size of 1-2 MDa, and cofractionates with the prohibitins and the m-AAA protease 
(Figure 17 A). Also prohibitins appeared as very abundant proteins in these experiments 
underlining an important role within mitochondria and the whole cell (Merkwirth et al., 
2008; Merkwirth and Langer, 2009).  
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Figure 17: High molecular weight complex containing the prohibitins, SLP2 and AFG3L2. 
(A) BN/CN-SDS-PAGE analysis of mitochondria isolated from FITR293 cells. Mitochondrial complexes 
were solubilized with digitonin at a detergent/protein mass ratio of 6:1 and separated on a 3-11 % [w/v] 
BN-PAGE and further subjected to a 12 % [w/v] Tris-glycine SDS-PAGE. Gels were analyzed by 
immunoblotting using antibodies directed against human AFG3L2, prohibitin 2 (PHB2) and SLP2 (upper 
panel). A 3-13 % [w/v] CN-PAGE was performed with solubilized mitochondria 
(10 g digitonin/g protein), and the 13 % [w/v] Tris-tricine SDS-PAGE in the second dimension was silver 
stained (lower panel). 
(B) Co-immunoprecipitation (co-IP) of human AFG3L2, SLP2 and prohibitin 2. Human AFG3L2 could 
be precipitated out of 500 µg solubilized mitochondria from FITR293 cells with a digitonin/protein ratio 
of 20:1 using antisera specifically recognizing human AFG3L2. 50 % of the IP samples were loaded. In 
parallel, an IP in the presence of preimmune serum was used as negative control (IgG). 10 % of the total 
input was loaded and analyzed by SDS-PAGE and Western Blot using the antisera specified above.  
(C) Mitochondria isolated from cells stably overexpressing murine Afg3l2 WT or WB were used for the 
co-IP which was performed as described in (B). Samples were analyzed with specific antibodies 
directed against human AFG3L2, PHB1, PHB2, SLP2 and OPA1. 
WT, Afg3l2 wild type; WB, Afg3l2 harboring a mutation in the Walker B motif (Afg3l2E407Q); 
*, crossreactions with immunoglobulins.  
 
 
 
However, SLP2 was shown to be important for mitochondrial hyperfusion, thus, a role of 
prohibitins in hyperfusion, also members of the SPFH domain family, was suggested. 
Surprisingly, downregulation of prohibitins in mouse embryonic fibroblast revealed that 
cells lacking prohibitins are still capable to hyperfuse (Tondera et al., 2009). In contrast, 
cells depleted of m-AAA proteases by downregulation cannot undergo SIMH indicating a 
direct role of m-AAA proteases and SLP2 in stress induced hyperfusion (Ehses et al., 2009; 
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Tondera et al., 2009). Further evidence for a direct interaction of SLP2 and 
m-AAA proteases was revealed by a co-immunoprecipitation (Figure 17 B and C).  
Notably, the presence of a high molecular weight complex consisting of AFG3L2, 
prohibitins and SLP2 could be demonstrated by BN- and CN/SDS-PAGE, and by co-
immunoprecipitation (Figure 17). SLP2 and OPA1 could be co-immunoprecipitated 
together with overexpressed Afg3l2 (Figure 17 C) indicating that m-AAA proteases, OPA1 
and SLP2 probably act together as one complex in the same pathway.  
To conclude, m-AAA proteases and prohibitins are crucial for mitochondrial fusion by 
regulating the stability of long OPA1 isoforms. In addition, m-AAA proteases interact with 
SLP2 which both are required for stress induced mitochondrial hyperfusion suggesting the 
presence of two functional m-AAA protease containing supercomplexes: one fusion-
supercomplex containing prohibitins, and another hyperfusion-supercomplex containing 
SLP2. 
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3.5. m-AAA proteases interact with MICS1 
3.5.1. AFG3L2 harboring a mutation in the Walker B motif as a 
substrate trap 
On the cellular level, it could be shown that defective m-AAA proteases achieved by the 
expression of a dominant-negative mutant variant has severe effects on cell proliferation 
(Figure 8) and mitochondrial morphology (Figure 9) by regulating the stability of long 
OPA1 isoforms (Figure 10 and 9). However, humans harboring missense mutations, or 
completely lacking an m-AAA protease subunit suffer from neurodegeneration (Cagnoli et 
al., 2008; DiBella et al., 2008; Ferreirinha et al., 2004; Maltecca et al., 2008) (Casari et al., 
1998). On the molecular level the neurodegeneration is barely understood. The yeast m-
AAA protease was shown to degrade non-assembled and misfolded polypeptides (Koppen 
and Langer, 2007; Langer, 2000). Besides this quality control function, it also specifically 
processes MrpL32 (Nolden et al., 2005). Processing of MrpL32 is not markedly affected in 
cells expressing AFG3L2 WB and can therefore not or only partially explain the observed 
phenotypes (Figure 12). For mammals, it is hypothesized that an impaired processing of a 
yet unknown protein causes the observed defects (Koppen and Langer, 2007; Rugarli and 
Langer, 2006). Thus, identification of substrate proteins of mammalian m-AAA proteases 
might help to unravel the pathogenesis of neurodegeneration. Data from yeast suggest that 
the dominant negative Walker B mutant can form a substrate trapping complex (Steffen 
Augustin, personal communication). To identify substrates of mammalian m-AAA 
proteases, the human AFG3L2 variants were fused to a carboxy-terminal hexahistidine tag. 
Metal affinity chromatography of digitonin solubilized mitochondrial membranes isolated 
from FITR293 cell lines was performed. Imidazol eluates were size fractionated using a 
gradient Tris-tricine SDS-PAGE (Figure 18 A). Mitochondria isolated from parental cell lines 
were used as a negative control to visualize unspecific protein binding. Additional protein 
bands were cut from the gel and analyzed by mass spectrometry (peptide mass fingerprint) 
(see chapter  6.2). AFG3L2 and the known assembly partners prohibitin 1 and 2 (PHB1, 
PHB2) were identified. Interestingly, one additional band appeared in all affinity 
purifications from AFG3L2 expressing cell lines representing a putative new interacting 
partner of the m-AAA proteases. Mass spectrometry revealed that it is the hypothetical 
protein of the open reading frame C2ORF47. No functional data either for the human or 
mouse protein is available to date. Two additional bands appeared in the samples 
expressing the dominant-negative mutant variant only, indicating that these proteins are 
putative substrate proteins. One band with a molecular mass slightly larger than AFG3L2  
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Figure 18: MICS1 and AFG3L2 itself are putative substrates of mammalian m-AAA proteases. 
(A) Metal affinity chromatography using Ni-NTA to pull down C-terminal hexahistidine tagged human 
AFG3L2 variants. 5 mg of isolated mitochondria were solubilized (6 g digitonin/g protein) and 
incubated with Ni-NTA beads, washed and eluted with indicated imidazole concentrations to purify 
His6-epitope tagged m-AAA protease complexes. Fractions were analyzed by a 8-17.5 % [w/v] Tris-
tricine SDS-PAGE and stained with colloidal coomassie. Protein bands not visible in the control were 
cut from the gel and analyzed by mass spectrometry (MS). 
(B) Specific spot pattern of AFG3L2 in 2D-SDS-PAGE. Mitochondria were treated as in (A) but run on a 
12 % [w/v] Tris-glycine SDS-PAGE containing 6 % [w/v] urea in the first dimension and a 10 % [w/v] 
Tris-tricine SDS-PAGE in the second dimension. Gels were stained with colloidal coomassie. Visible 
spots were cut and analyzed by MS. AFG3L2 is marked. Dashed lines indicate AFG3L2 (precursor). 
-, parental cell line control; WT, AFG3L2 wild type; PS, mutation in the proteolytic site (AFG3L2E575Q); 
WB, mutation in the Walker B motif (AFG3L2E408Q); MAIP1, m-AAA protease interacting protein 1. 
 
 
was identified by the peptide spectrum of the peptide mass fingerprint results (see 
appendix  6.2) as the precursor version of AFG3L2 indicating autocatalytic processing, 
which recently has been observed for paraplegin (Mirko Koppen, manuscript in 
preparation) (Ehses, 2008). The second band with a mass smaller than prohibitins could be 
identified as MICS1, a protein which resides in the inner mitochondrial membrane (see 
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chapter  1.3.3.3) (Oka et al., 2008). Bands in the other lanes (Figure 18 A, -, PS) were cut 
and analyzed by peptide mass fingerprint to exclude any presence of MICS1 in the other 
samples, and indeed, MICS1 was either absent or not detectable by mass spectrometry. 
To further investigate a region of low resolution (50-90 kDa) in the Tris-tricine SDS-
PAGE, a 2D-SDS-PAGE approach was performed (Figure 18 B). A first dimension using a 
12 % [w/v] Tris-glycine SDS-PAGE containing 6 M urea followed by a 10 % Tris-tricine 
SDS-PAGE was used to analyze the samples from the metal affinity purification. Spots 
which were not present in the control gel were marked in Figure 18 B and analyzed by 
mass spectrometry. Spots represent either mature or precursor versions of AFG3L2. 
Proteins running above the diagonal in this approach represent more hydrophilic proteins 
(Rais et al., 2004) indicating that the two species of mature and precursor appear less 
hydrophobic than the main fraction of eluted AFG3L2. Paraplegin could not be detected in 
any purification followed by a colloidal Coomassie staining. Immunoblotting with a 
specific antibody revealed the presence of SLP2 specifically in fractions together with 
AFG3L2 (data not shown). However, it was not visible in protein gels. 
To summarize, affinity purification confirmed the results from co-immunoprecipitation 
experiments. AFG3L2 complexes in the inner mitochondrial membrane interact with 
prohibitins and to a minor extent with SLP2. Second dimensional SDS-PAGE demonstrated 
a specific spot pattern of AFG3L2. C2ORF47 was identified as a putative interacting partner 
of AFG3L2. In addition, MICS1, a highly hydrophobic protein important for cristae 
organization, and AFG3L2 itself appeared as possible substrates of mammalian m-AAA 
proteases. 
3.5.2. MICS1 is not processed by m-AAA proteases 
Concerning the functions of the yeast m-AAA protease (see  1.4.1), MICS1 could be 
either processed like MrpL32, degraded, or its biogenesis could be affected in a non-
proteolytic manner as described for Ccp1 (Leonhard et al., 1996; Nolden et al., 2005; 
Tatsuta et al., 2007). To clarify the effect of m-AAA proteases on MICS1, carboxy-
terminally hemagglutinin (HA)-tagged MICS1 (MICS1-4HA) was expressed in AFG3L2 
expressing cell lines (Figure 19 A). HA tagged MICS1 was shown to localize to 
mitochondria (Oka et al., 2008). Co-expression of MICS1-4HA and AFG3L2 variants 
revealed signals at molecular sizes of 30 kDa in SDS-PAGE visualized by immunoblotting 
with an antiserum specific for the HA-epitope tag. Interestingly, only one band was 
detected independent of the co-expression of AFG3L2 WT or WB mutant indicating that  
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Figure 19: MICS1 binds to but is not processed by m-AAA proteases. 
(A) No processing defect of MICS-4HA in cells expressing dominant-negative forms of AFG3L2. 
MICS1-4HA under a tetracycline-inducible CMV promoter was transiently transfected into FITR293 cells 
expressing AFG3L2 WT or WB variants two days before induction of expression with tetracycline for 
24 h. Cells were harvested and lysed. Samples were size fractionated via SDS-PAGE and analyzed by 
immunoblotting using antisera directed against AFG3L2, the HA-epitope, and prohibitin 2 as a loading 
control. 
(B) MICS1-4HA physically interacts with AFG3L2. FITR293 expressing indicated AFG3L2 variants and 
untransfected (-) FITR293 cells were transiently transfected with MICS1-4HA constructs 2 days before 
induction of expression with tetracycline for 24 h. Cells (~ 1 x 108) were lysed and incubated with HA-
antibody-coupled protein G matrix. Elution samples were size fractionated using SDS-PAGE and either 
analyzed by colloidal coomassie staining (upper panel) or by immunoblotting utilizing antisera 
recognizing the HA-tag and AFG3L2 (lower panels). 20 % of the IP samples were loaded. 
M, protein marker; HA, hemagglutinin epitope; In, 1 % of the input; IP; 20 % of the 
immunoprecipitation elution fraction; WT, wild type; WB, mutation in the Walker B motif 
(AFG3L2E408Q). 
 
 
MICS1-4HA is probably not processed by the m-AAA protease, at least not from the 
N-terminus. Similarly, the band intensity was not significantly changed. However, an effect 
on the turnover of MICS1 might be mimicked by the overexpression of MICS1. Further 
experiments are required to examine an effect of m-AAA proteases on the stability of 
MICS1. However, co-immunoprecipitations using the HA-antiserum revealed that AFG3L2 
is able to bind MICS1-4HA regardless of the mutation in AFG3L2 indicating a direct role of 
the m-AAA proteases (Figure 19 B). 
In conclusion, endogenous MICS1 was co-purified from mitochondria expressing the 
dominant-negative mutant variant of AFG3L2 which is − based on yeast studies − thought 
to work as a substrate trap (Tatsuta et al., 2007) (Steffen Augustin, personal comment). 
Overexpressed HA-tagged MICS1 was not processed by the m-AAA protease. Furthermore, 
exogenously expressed HA-tagged MICS1 can physically bind to the m-AAA protease 
irrespective of a mutation in AFG3L2.  
Discussion 
 
86 
4. Discussion 
4.1. Dominant-negative Walker B mutation – a novel 
approach to study mammalian m-AAA proteases 
m-AAA proteases are nuclear-encoded conserved oligomeric metallopeptidases, key 
components of the mitochondrial protein quality control system with crucial functions in 
mitochondrial biogenesis (Langer, 2000; Leonhard et al., 2000; Nolden et al., 2005). Yeast 
cells lacking a functional m-AAA protease complex exhibit pleiotropic phenotypes (Arlt et 
al., 1998; Arlt et al., 1996). Impaired processing of MrpL32, a subunit of the large 
mitochondrial ribosome, causes the loss of functional complexes of the respiratory chain 
and respiratory deficiency (Nolden et al., 2005). Processing of this protein enables the full 
assembly of the ribosome allowing the translation of the mitochondrial genome leading to 
respiratory activity. To inactivate the proteolytic function of the yeast hetero-oligomeric m-
AAA protease, all subunits have to be mutated in the proteolytic site (Arlt et al., 1998). 
In contrast to the yeast enzyme, which exclusively forms a hetero-oligomeric complex, 
the mammalian proteases also exist as homo-oligomeric arrangements (Koppen et al., 
2007) (Figure 4). Humans harbor homo-oligomeric complexes composed of AFG3L2 and 
hetero-oligomeric complexes containing SPG7 and AFG3L2. In mice, the expression of the 
three subunits paraplegin (Spg7), Afg3l2 and Afg3l1 results in the formation of up to six 
different isoenzymes. Therefore, a complete loss of m-AAA protease activity is only 
achieved by depletion of all subunits. However, siRNA approaches exhibit technical 
difficulties such as low transfection efficiencies of siRNAs, non-specificity and off-target 
effects (Svoboda, 2007). Expression of proteolytic inactive subunits, on the other hand, 
requires mutagenesis of all subunits which is technically difficult to achieve.  
In this study, the inducible FlpIn T-REx system was employed to bypass these issues by 
the overexpression of a dominant negative mutant subunit. Replacement of a glutamate to 
glutamine in the Walker B motif (WB, see Figure 5) of murine Afg3l2 and human AFG3L2 
was identified to cause a dominant negative effect. By the expression of this mutant, crucial 
functions of mammalian m-AAA proteases could be discovered including the control of 
cell proliferation (see  4.3) and mitochondrial dynamics (chapter  4.4). Notably, the FlpIn 
T-REx 293 expression system allowed the inducible, stable and uniform overexpression of 
murine Afg3l2 and human AFG3L2 variants enabling direct comparative analysis of cell 
lines excluding effects of random integrations. However, expression of the dominant 
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negative mutant in FITR293 cells has distinct advantages over the RNA interference 
approach: a high yield of cell material can be produced and used for large scale proteomic 
analysis. Expression of a subunit mutated in the proteolytic site (PS, see Figure 5) behaved 
like the expression of wild type subunits indicating that this mutation is not dominant 
negative and, therefore, not able to inactivate the protease. 
The dominant negative Walker B mutation did not affect the formation of 
m-AAA protease prohibitin supercomplexes confirmed by BN-PAGE analysis and metal 
affinity chromatography (Figure 19). In addition, m-AAA protease complexes containing 
this mutation could be purified together with putative interacting partners and substrates, 
thereby suggesting that this complex is present in the mitochondrial inner membrane, 
proteolytically inactive and works as the proposed substrate trapping complex. In line, data 
from the bacterial homologous ATPase ClpX and the yeast m-AAA protease suggests that, 
during purifications, complexes containing this mutation behave like wild type 
characterized by the formation of hexameric arrangements (Hersch et al., 2005) (Steffen 
Augustin, manuscript in preparation). Yeast cells co-expressing wild type and mutant 
subunits are not able to grow on non-fermentable carbon sources caused by an impaired 
processing of MrpL32. The mutant yeast complex traps MrpL32 as demonstrated by 
pulldown experiments (Steffen Augustin, personal communication). 
The mutation in the Walker B motif has been studied in yeast and bacteria (Steffen 
Augustin, manuscript in preparation) (Hersch et al., 2005). It has been shown that specific 
residues in the pore of the ATPase are in contact with the substrate molecule (Martin et al., 
2008). ATP binding and hydrolysis enable the movement of these pore residues, thereby 
unfolding and pulling the substrate into the proteolytic chamber of the protease (Martin et 
al., 2008). The glutamate side chain in the Walker B motif is thought to activate a water 
molecule for attack on the γ-phosphate of bound ATP, and therefore, is important for ATP 
hydrolysis (Baker and Sauer, 2006; Hersch et al., 2005). However, ATP binding is not 
affected resulting in a trap of ATP (Hersch et al., 2005). Therefore, the findings of this study 
suggest that mutation of the critical glutamate inhibits ATP hydrolysis in the respective 
subunit and additionally in neighboring wild type subunits. Likewise, studies of the yeast 
m-AAA protease showed that this mutation inhibits ATP hydrolysis in the neighboring 
subunit by trapping of ATP (Steffen Augustin, manuscript in preparation). 
In conclusion, this study identified the dominant negative effect of the Walker B 
mutation in m-AAA proteases as a mechanism to inactivate the protease which is 
conserved from yeast to man.   
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4.2. Mammalian m-AAA proteases affect the stability of 
respiratory chain supercomplexes 
The mitochondrial inner membrane is the protein-richest cellular membrane, whose 
functional impairment is associated with aging, myopathies, and neurological disorders in 
humans (Chan, 2006). It harbors the OXPHOS (oxidative phosphorylation system) 
complexes which are crucial to produce the general fuel of the cell – ATP (Saraste, 1999). 
The OXPHOS biogenesis requires a coordinated regulation of two genomes whose 
translation products have to assemble together with the membrane lipids into fully 
functional complexes and supercomplexes, the respirasomes [reviewed in (Wittig and 
Schägger, 2009)]. The yeast m-AAA protease is required for the processing of MrpL32 and 
therefore crucial for mitochondrial translation (Nolden et al., 2005). Expression of AFG3L2 
WB in FITR293 cells only modestly impaired MrpL32 processing (Figure 12 B). This is 
reminiscent of results from Spg7 deficient mice (Nolden et al., 2005) and from siRNA 
mediated downregulation of all m-AAA protease subunits in mouse embryonic fibroblasts 
(MEFs) (Ehses, 2008) indicating that mammalian m-AAA proteases are able to cleave 
MrpL32, in general. However, other redundant proteases seem to be active in processing 
MrpL32.  
The overall assembly of the respiratory chain was not affected in FITR293 cells 
expressing the dominant negative mutant (Figure 12 A). Interestingly, mitochondrial 
translation is reduced to 50 % in mouse liver mitochondria isolated from Spg7-/- mice 
compared to wild type (Nolden et al., 2005), whereas the translation efficiency in Spg7 
deficient brain or spinal cord is not affected (Ehses, 2008). However, expression of the 
dominant negative mutation in Afg3l2 did neither alter the oxygen consumption of 
FITR293 cells (under routine conditions, Figure 11 A) nor the activity of complex I and 
complex IV (Figure 12 C and D). In line, the respiratory activity in brain, spinal cord and 
liver mitochondria of Spg7-/- mice was comparable to wild type (Ehses, 2008). This suggests 
that, in liver, though the translation rate is reduced, cells are able to overcome these 
translation defects resulting in normal respiration. This compensatory mechanism is 
explained by the generation of respiratory complexes in excess which can be mobilized 
and attenuated if cells have increased energy requirements [reviewed in (Bernard and 
Rossignol, 2008)]. However, HSP (see  1.4.3.1) patients which have a deletion in SPG7 
showed OXPHOS defects in muscle biopsy (Casari et al., 1998), indicating that effects on 
OXPHOS might be an important clue but not the primary cause of the disease. Taken 
together, m-AAA proteases are dispensable for respiration in mammals which is in contrast 
to yeast. 
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Nevertheless, inhibition of the ATP synthase by oligomycin in cells expressing Afg3l2 
WB revealed a slight but significant increase in respiratory activity compared to WT or 
control cells (Figure 11 A) indicating an electron slip or proton leak of the respiratory chain 
(Brand et al., 1994; Brand et al., 1994; Brown et al., 1990; Nicholls, 1974). Uncoupling by 
CCCP treatment revealed a reduced maximal respiratory capacity resulting in the reduction 
of the respiratory control ratio of up to 40 % compared to Afg3l2 WT expressing cells. A 
reduced coupling could be explained by a slight decrease in the stability of 
supercomplexes containing complex IV in cells expressing Afg3l2 WB (Figure 13 A). 
Similar, mice lacking Spg7 and one copy of Afg3l2 (see  1.4.3.1) demonstrate a reduced 
stability of OXPHOS supercomplexes although the assembly is not affected (Martinelli et 
al., 2009).  
Recently, cytochrome (cyt) c has been found to associate with both complex IV and 
respiratory supercomplexes, providing a potential mechanism for the requirement for cyt c 
in the assembly and/or stability of complex IV and supercomplexes (Vempati et al., 2009). 
An effect on cyt c has not been examined and should be adressed in future experiments.  
The reduced stability of respiratory chain supercomplexes was reminiscent of findings 
from Barth syndrome patients which harbor mutations in the cardiolipin (CL) transacylase 
tafazzin involved in CL remodeling (McKenzie et al., 2006) (see  1.2.1). Studies have 
demonstrated a loss of energy coupling efficiency in cellular models of Barth syndrome 
(Ma et al., 2004; Xu et al., 2005). In addition, Barth syndrome patients have reduced 
cardiolipin levels (Schlame and Ren, 2006). Interestingly, yeast cells lacking the m-AAA 
protease subunits Yta10 or Yta12 have reduced CL and phosphatidylethanolamine (PE) 
levels (Osman et al., 2009). However, the phospholipid levels of mitochondria from 
Afg3l2 WB expressing FITR293 cells (Figure 13 B) and from m-AAA protease 
downregulated MEFs were comparable to wild type cells (Sebastian Müller, personal 
communication). This suggests that, in contrast to the yeast enzyme, mammalian m-AAA 
proteases do not interfere with CL or PE levels and that the reduced stability of the 
supercomplexes cannot simply be explained by altered phospholipid levels.  
However, the reduced stability may have severe consequences for the organism and in 
particular for distinct tissues. It is conceivable that OXPHOS becomes limited in tissues 
with high energy demands. For instance, Barth syndrome affects heart and skeletal muscle 
and leads to growth retardation (Barth et al., 1983). In line, m-AAA proteases have been 
associated with defects in specific neurons (introduced in chapter  1.4.3.1). Heart, skeletal 
muscle and brain are tissues with high energy demands (DiMauro, 2004; DiMauro and 
Schon, 2003).  
In conlusion, expression of the dominant negative Walker B mutation in FITR293 cells 
reduced the maximal respiratory activity of the cells. MrpL32 processing was only 
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modestly affected and cells comprised an assembled and active respiratory chain. 
However, expression of the Walker B mutation destabilized the respiratory 
supercomplexes which cannot simply be explained by an altered mitochondrial 
phospholipid composition indicating other mechanisms regulated by m-AAA proteases.  
4.3. The m-AAA protease-prohibitin complex is 
indispensable for cell proliferation 
Cells expressing a dominant negative Walker B mutant subunit in yeast poorly grow on 
non-fermentable carbon sources as the processing of MrpL32 is impaired (Steffen Augustin, 
manuscript in preparation). However, the growth is normal on glucose containing plates. 
Expression of Afg3l2/AFG3L2 WB significantly reduced the ability of mammalian cells to 
proliferate (Figure 8). MrpL32 processing was only slightly affected (Figure 12 B). The 
integrity of the respiratory chain was maintained, including the membrane potential and 
ATP levels (Figure 11 andFigure 12), suggesting that mammalian m-AAA proteases control 
cell proliferation independent of a general OXPHOS defect.  
The m-AAA protease in yeast and the AAA protease in bacteria are part of a large 
supercomplex containing the protease and SPFH family members, namely prohibitins 
(Kihara et al., 1996; Steglich et al., 1999) (chapter  1.4.2). The presence of this 
supercomplex containing both proteins, m-AAA protease and prohibitins, could be 
demonstrated by different approaches (Figure 17 andFigure 18) suggesting that both 
prohibitins and m-AAA proteases act together in one pathway controlling cell proliferation. 
In fact, these findings are reminiscent of data from mouse embryonic fibroblasts (MEFs) 
demonstrating an impaired cell proliferation upon Cre-mediated deletion of Phb2 in 
Phb2flox/flox cells leading to the complete loss of prohibitin complexes (Merkwirth et al., 
2008). Similar to expression of the Walker B mutants, knockout of Phb2 results in reduced 
stability of l-OPA1 and subsequent fragmentation of the mitochondrial network. Expression 
of a non-cleavable long OPA1 variant revealed only a partial complementation of 
proliferation, although the tubular shape of mitochondria was restored in up to 60 % of the 
MEFs (Merkwirth et al., 2008). To summarize, both, defective m-AAA proteases or the loss 
of prohibitins, affect cell proliferation. It remains unclear how the supercomplex of 
m-AAA proteases and prohibitins within the mitochondrial inner membrane interferes with 
a reduced cell proliferation. 
Organisms have evolved mechanisms to prevent cell division under conditions of 
nutrient deficiencies by cell cycle regulation (Ryan and Hoogenraad, 2007). For instance, a 
high AMP:ATP ratio of the cell can be sensed by AMP-kinase (AMPK) (Jones et al., 2005; 
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Ryan and Hoogenraad, 2007). One of the AMPK targets is the tumor suppressor p53 which 
upon phosphorylation arrests the cell cycle, whereas cellular differentiation and survival 
are not affected (Jones et al., 2005; Mandal et al., 2005). However, ATP levels in Phb2 
depleted cells (Merkwirth et al., 2008) and cells expressing the WB mutant of Afg3l2 
(Figure 11 B) are not altered indicating that the reduced cell proliferation occurs 
independently of the cellular energy status. 
Mitochondria are the major source of reactive oxygen species (ROS) which alone can 
work as a signaling messenger by blocking cell cycle progression (Finkel, 2003). ROS, 
principally superoxide anion radical and its hydrogen peroxide, are derived from several 
sources in mitochondria, e.g. complex I and III. In addition to the physiological ROS, high 
levels of ROS are especially produced in conditions of mitochondrial dysfunction or 
altered respiration. PKCβ can be activated by these oxidative conditions, and subsequently, 
phosphorylates the cytosolic P66Shc protein which is then able to translocate to the 
mitochondrial intermembrane space where it acts as a oxidoreductase transferring 
electrons directly from cytochrome c to oxygen to generate hydrogen peroxide (Giorgio et 
al., 2005; Pinton et al., 2007; Pinton and Rizzuto, 2008). Changes of the architecture of 
OXPHOS supercomplexes have been implicated in elevated ROS levels and the 
contribution to aging (Dencher et al., 2007). ROS levels in cells expressing the dominant 
negative mutant variant have to be determined in future experiments. 
One of the central regulators of cellular growth are the components of the serine-
threonin kinase mTOR (mammalian target of rapamycin) pathway (DeBerardinis et al., 
2008; Sarbassov et al., 2005). Inhibition of mTOR results in the stop of cell proliferation 
and increased autophagy under starvation conditions. Recently, a mitochondrial outer 
membrane anchored protein, FKBP38, was identified to interact with mTOR and 
contributes to the activation of the signaling cascade (Bai et al., 2007). However, whether 
the m-AAA protease-prohibitin supercomplex interferes with these pathways or, in 
particular, with FKBP38 function in the outer membrane is not studied yet. Mitochondrial 
autophagy, also termed mitophagy, is induced by depolarization of the membrane 
potential of mitochondria (Twig et al., 2008). The membrane potential of Phb2 depleted 
and Afg3l2/AFG3L2 WB mutant expressing cells was comparable to that observed in 
wildtype cells. However, damaged mitochondria could have been depleted from the cell 
population by targeting to autophagosomes resulting in reduced mitochondrial mass.  
Interestingly, overexpression of the inner membrane protein PNC1 (pyrimidine 
nucleotide carrier 1, yeast Rim2) has been shown to enhance cell size and proliferation 
(Floyd et al., 2007). In contrast, lower expression of this six transmembrane spanning-
protein results in reduced mitochondrial UTP levels, an increase of ROS und subsequent 
slower growth, while ATP levels and membrane potential were not affected. Loss of the 
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prohibitin-m-AAA protease complex might interfere with the function or stability of this 
protein in the membrane which has to be elucidated in the future. 
Notably, depletion of prohibitins and m-AAA proteases might compromise a similar 
pathway indicating that a fully active supercomplex containing prohibitins and m-AAA 
proteases is required for cell proliferation. Still, the mechanism linking the loss of 
functional m-AAA protease-prohibitin complexes to cell proliferation is missing. Thus, the 
experimental identification of signaling mediators controlling this path of communication 
dependent on prohibitins or m-AAA proteases is of great importance.  
4.4. m-AAA proteases are essential for mitochondrial 
fusion activity by stabilizing l-OPA1 
Mitochondrial fusion is maintained by an equilibrium of both long and short OPA1 
isoforms (Delettre et al., 2001; Duvezin-Caubet et al., 2007; Ishihara et al., 2006; Olichon 
et al., 2003; Olichon et al., 2007; Song et al., 2007). An imbalance leads to subsequent 
fragmentation of the mitochondrial network (Baricault et al., 2007; Ishihara et al., 2006). 
The processing of OPA1 needs to be tightly controlled in order to maintain fusion activity 
(see chapter  1.3.2). In particular, the constitutive processing is highly regulated to generate 
long and short isoforms, which both are important for mitochondrial fusion (Song et al., 
2007). In contrast, the induced processing, which was identified to occur at site S1 is 
distinct from the constitutive processing (Song et al., 2007). It has been shown that 
dissipation of the membrane potential (ΔΨm), apoptotic stimuli and mitochondrial outer 
membrane permeabilization (MOMP) trigger this processing event (Baricault et al., 2007; 
Griparic et al., 2007; Guillery et al., 2008; Ishihara et al., 2006). In detail, Baricault 
showed that the primary cause of enhanced OPA1 processing is a decrease in ATP levels 
(Baricault et al., 2007). An unknown protease cleaves l-OPA1 to generate short isoforms in 
a deregulated manner (Baricault et al., 2007; Ishihara et al., 2006). Cleavage at site S1 
generates short isoforms. However, although not reflecting the in vivo situation, OPA1 
isoforms which lack the S1 processing site are degraded completely (Griparic et al., 2007; 
Song et al., 2007). The question is raised what stimulus activates this protease and more 
importantly, what protease is doing this highly effective job. PARL and paraplegin (Spg7) 
have been implicated in processing at S1, however MEFs lacking either PARL or paraplegin 
exhibit a normal wild type like OPA1 pattern (Duvezin-Caubet et al., 2007). 
In this study, expression of the dominant-negative Walker B mutant of mammalian 
m-AAA proteases in human FITR293 cells accelerated the processing of OPA1 at site S1 
(Figure 14). This resulted in a major punctate mitochondrial network (Figure 9) most 
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probably due to the imbalance of long and short OPA1 isoforms (Figure 10). Cells respired 
normal, and ATP-levels and ΔΨm were not affected (Figure 11) excluding any secondary 
effect on OPA1 due to an impaired energy metabolism. These findings were consistent 
with data from siRNA-mediated downregulation experiments (Ehses, 2008). Depletion of 
the m-AAA protease in MEFs results in predominantly fragmented mitochondria and an 
accelerated processing of l-OPA1. Expression of different OPA1 splice variants lacking 
either cleavage site S1 or S2 revealed that the induced processing observed in m-AAA 
protease downregulated cells occurs at site S1, not at site S2 (Ehses, 2008).  
The lipid environment has been shown to be a crucial regulator of mitochondrial 
dynamics. Reduced CL levels caused by deletions of Ups1 (Osman et al., 2009; Sesaki et 
al., 2006) and decreased PE levels are linked to an inefficient processing of Mgm1 (Osman 
et al., 2009). Therefore the phospholipid composition, in particular the PE content, might 
be crucial for efficient Mgm1 cleavage by Pcp1 and mitochondrial cristae morphogenesis 
(Herlan et al., 2004; Herlan et al., 2003; McQuibban et al., 2003; Meeusen et al., 2006). 
This study showed, that m-AAA proteases interfere with the processing of OPA1. However, 
neither altered lipid levels nor an accumulation of long OPA1 isofoms were observed in 
Walker B mutants (Figure 10). Instead, expression of Afg3l2/AFG3L2 WB induced the 
processing at site S1 (Figure 14) independent of the phospholipid levels (Figure 13 B).  
Also other circumstances have been identified to interfere with the stability of long 
OPA1 isoforms. Depletion of the assembly partner of the m-AAA protease, prohibitin, from 
the inner mitochondrial membrane results in an accumulation of s-OPA1 caused by an 
enhanced processing of long OPA1 isoforms (Merkwirth et al., 2008). Merkwirth et al. 
concluded that prohibitins are essential for mitochondrial fusion, and importantly, are 
crucial for cristae morphogenesis in an OPA1 dependent manner. It was hypothesized that 
mammalian prohibitins like the bacterial homologues HflKC (Kihara et al., 1996) and yeast 
prohibitins (Steglich et al., 1999) negatively regulate the AAA protease thereby inducing 
the processing upon depletion of prohibitins (Merkwirth et al., 2008; Merkwirth and 
Langer, 2009). 
Taken together, these findings suggest that mammalian m-AAA proteases and 
prohibitins control the induced processing of OPA1 and, therefore, regulate the stability of 
l-OPA1. The molecular mechanism underlying this regulation is unclear.  
The question remains whether mammalian m-AAA proteases are involved in the 
constitutive processing of OPA1. Several evidence point to a proteolytic function of 
mammalian m-AAA protases on OPA1. Firstly, this study demonstrated that mammalian 
m-AAA proteases can interact, when overexpressed, with endogenous OPA1 suggesting 
OPA1 as a putative substrate (Figure 15). This was also shown by crosslinking of 
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exogenously expressed SPG7 and OPA1 (Ishihara et al., 2006). Secondly, Ishihara showed 
that exogenously expressed SPG7 triggers the cleavage of OPA1 (Ishihara et al., 2006), and 
finally, demonstrated by heterologous expression in yeast, m-AAA proteases are able to 
cleave OPA1. Two models are proposed, model A suggests a direct proteolytic function of 
m-AAA proteases on OPA1, model B excludes the m-AAA protease of this function. 
 
Model A: Three proteases are active in the processing of OPA1 (irrespective of MPP 
and the caspase-cleavage site) (model A, Figure 20). The i-AAA protease has been linked to 
the processing at site S2 (Griparic et al., 2007; Song et al., 2007). The constitutive 
processing at site S1 is presumably performed by mammalian m-AAA proteases, which 
together with the i-AAA protease generate the balanced equilibrium required for 
mitochondrial fusion activity. However, upon low ATP conditions or in the absence of 
m-AAA proteases, a yet unknown protease is activated to cleave OPA1.  
 
Model B: A second model excludes m-AAA proteases from a proteolytic function on 
OPA1, resulting in the cleavage by an unknown protease in constitutive and induced 
processing events which are negatively regulated by a functional supercomplex of 
prohibitins and m-AAA proteases (model B, Figure 20). A decrease of the ATP levels 
stimulate the induced processing (Baricault et al., 2007). This envisions a situation that the 
ATP-dependent metallopeptidase upon the reduction of ATP is less active thereby 
producing a certain stress stimulus, which leads to the subsequent activation of the 
unknown protease.  
 
It could be possible that an unknown protein inhibiting the cleavage at S1 is activated 
by m-AAA proteases. By mutating m-AAA proteases this inhibitory protein cannot prevent 
the processing of OPA1. Excluding the protease of a direct function on OPA1 raises the 
question why OPA1 and m-AAA proteases interact with each other. This could be 
explained by the presence of large fusion complexes or organized domains in the 
mitochondrial inner membrane, which promote sterical contacts of fusion components and 
the lipids. It is likely, that these complexes exist. Considering the hypothesis that the  
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Figure 20: Model of OPA1 processing at the mitochondrial inner membrane. 
The mitochondrial targeting sequence of OPA1 is cleaved off by MPP upon import into mitochondria 
(Ishihara et al., 2006).  
(A) m-AAA protease is involved in OPA1 processing. m-AAA protease and/or protease X cleave OPA1 at 
S1, which is negatively regulated by the prohibitins and/or the supercomplex. Loss of functional 
supercomplex leads to induced processing performed by protease X and/or m-AAA protease (if present). 
(B) m-AAA protease-prohibitin-supercomplex negatively regulates OPA1 processing by protease X. Loss 
of m-AAA proteases or prohibitins activates protease X. 
TIM, translocase of the mitochondrial inner membrane; MPP, mitochondrial processing peptidase; IMS, 
intermembrane space; IM, inner membrane; M, matrix. 
 
 
prohibitins work as membrane organizers or scaffold proteins (Merkwirth and Langer, 
2009), it is possible that the m-AAA protease-prohibitin-supercomplex organize these large 
complexes thereby allowing membrane fusion. In fact, m-AAA protease, prohibitins, OPA1 
and SLP2 (discussed in the next chapter  4.5.1) were detected in a putative complex (Figure 
15). 
This interaction does not necessarily have to be direct. In the past, the major part of 
novel protein-protein interactions identified in the mitochondrial morphology field was 
demonstrated by co-IP experiments with the addition of crosslinkers, and thus, might not 
represent physiological conditions. However, by using crosslinkers several fusion and 
fission proteins were demonstrated to physically interact like the mitofusins and OPA1 
(Guillery et al., 2008). In addition, Mfn2 could be crosslinked to SLP2 (Hajek et al., 2007), 
and SLP2 to prohibitins (Da Cruz et al., 2008). If m-AAA proteases interact with prohibitins 
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and SLP2 (Figure 17), and SLP2 interacts with Mfn2 which binds to OPA1, do the m-AAA 
proteases interact with OPA1? Clearly, further experiments are necessary to answer this 
question. It should be emphasized that the observed interaction of OPA1 and AFG3L2 was 
very weak and one binding partner was overexpressed. However, the co-IP was performed 
without the addition of crosslinkers.  
 
In summary, mammalian m-AAA proteases and prohibitins were identified as crucial 
components of mitochondrial fusion by stabilizing l-OPA1. However, the molecular 
mechanism is still not fully understood. The identification of the protease inducibly 
cleaving at site S1 upon expression of Afg3l2/AFG3L2 WB and low ATP levels could 
unravel the understanding of this regulatory mechanism of OPA1 processing. In addition, 
analysis of this protease could further clarify if mammalian m-AAA proteases are involved 
in OPA1-processing or not, or if the m-AAA protease-prohibitin-supercomplex plays a role 
in organizing the large fusion complex by preventing the induced cleavage of OPA1.  
4.5. Identification of novel interacting partners or putative 
substrates of mammalian m-AAA proteases 
This study was initiated to identify substrates and interacting partners of mammalian 
m-AAA proteases in order to unravel molecular functions of the proteases. For this 
purpose, co-immunoprecipitation, 2-dimensional blue- or clear- native PAGEs and metal 
affinity chromatography experiments were performed. Prohibitins, SLP2, and MAIP1 could 
be identified as novel interacting partners. Using the substrate trapping approach discussed 
in chapter  4.1 the precursor of AFG3L2 and MICS1 appeared as potential substrates of 
mammalian m-AAA proteases thereby linking m-AAA proteases to new roles within 
mitochondria. 
4.5.1. m-AAA proteases and SLP2 are crucial for mitochondrial 
hyperfusion 
Co-immunoprecipitation experiments using antibodies directed against AFG3L2 
revealed a complex of m-AAA proteases, PHB1, PHB2 and SLP2 (Figure 17 B). In addition, 
SLP2 was identified in m-AAA protease pulldown experiments although to a lower extend 
as prohibtins (Figure 18 A). BN- and CN-SDS-PAGE analysis of mitochondria isolated from 
human FITR293 cells demonstrated that SLP2, m-AAA proteases, prohibitin complexes co-
migrated at approximately 1-2 MDa. SLP2 was present in complexes which migrated at 
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higher molecular weights when compared to prohibitins (Figure 17 A). Like prohibitins, 
SLP2 was very abundant and visible in silver stained CN-SDS-PAGE.  
SLP2 or Stomatin like protein 2 is a member of the SPFH family, a large group of 
proteins including prohibitins and HflKC (chapter  1.4.2) (Browman et al., 2007; 
Tavernarakis et al., 1999). SLP2 was recently identified as a mitochondrial protein (Hajek 
et al., 2007). Within mitochondria SLP2 is suggested to be anchored to the inner 
membrane facing the intermembrane space (Da Cruz et al., 2008; Hajek et al., 2007). 
SLP2 binds to prohibitins and contributes to their stability (Da Cruz et al., 2008). 
Downregulation of SLP2 induces a metalloprotease dependent turnover of prohibitin 1, 
subunits of respiratory complex IV and complex I. Additionally, SLP2 together with 
prohibitin 1 is upregulated upon inhibition of mitochondrial protein synthesis by 
chloramphenicol (Da Cruz et al., 2008). However, the physiological functions of SLP2 are 
barely understood.  
Recently, Tondera et al. discovered the phenomenon of mitochondrial hyperfusion 
which is believed to be a cellular stress response and therefore termed SIMH (stress 
induced mitochondrial hyperfusion) (Tondera et al., 2009). Treatment of mammalian cells 
with UV irradation or low concentrations of cycloheximide (CHX) results in the 
hyperfusion of mitochondria generating a highly elongated interconnected network in 
combination with elevated ATP levels in the cell. Tondera discovered that SIMH is 
dependent on its key players, namely Mfn1, OPA1 and, interestingly, SLP2. It is claimed 
that long OPA1 isoforms are necessary for mitochondrial hyperfusion. However, Phb2 
depleted MEFs, which accumulate only short OPA1 isoforms, are competent for 
hyperfusion (Tondera et al., 2009). Upon shRNA mediated downregulation of SLP2, OPA1 
processing at site S1 is modestly elevated, whereas processing at S2 was slightly inhibited. 
However, treatment with CHX leads to an enhanced processing of l-OPA1, in particular at 
S1. It should be emphasized that expression of a non-cleavable OPA1 variant lacking the 
S1 cleavage site was stable, which was also observed in Phb2 depleted MEFs (Merkwirth et 
al., 2008). These results are distinct from findings obtained in this study. While non-
functional m-AAA protease induced the processing at S1, non-cleavable OPA1 isoforms 
lacking the processing site S1 were degraded indicating that defective m-AAA proteases 
induce the turnover of l-OPA1 (Figure 14). It is suggested that the protease which mediates 
this turnover requires the presence of prohibitins and/or SLP2, possibly for organizing 
protein and lipid domains which allow efficient degradation in close proximity. In 
addition, SLP2 negatively affects the processing at S1 upon SIMH, indicating that SLP2 
stabilizes l-OPA1 during stress induced hyperfusion. These findings lead to the hypothesis  
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Figure 21: Dependence of mitochondrial fusion events on ATP levels. 
To simplify the model, m-AAA proteases were excluded of any proteolytic function on OPA1. 
(A) Constitutive processing of OPA1 at normal ATP levels. The supercomplex containing 
m-AAA proteases and prohibitins negatively regulates the cleavage by the protease X. 
(B) Induced processing caused by lower ATP levels. The processing is deregulated leading to enhanced 
cleavage at site S1 and increased turnover of l-OPA1. 
(C) SLP2 and m-AAA proteases containing supercomplexes inhibit the cleavage of l-OPA1 upon 
elevated ATP levels. Loss of SLP2 under hyperfusion conditions leads to induced processing of l-OPA1 
at S1 by protease X.  
 
 
that m-AAA proteases are required under both conditions: for prohibitin dependent 
mitochondrial fusion and for SLP2 dependent hyperfusion (Ehses, 2008; Tondera et al., 
2009). 
It is concluded that during hyperfusion, ATP levels increase, and that this subsequently 
inhibits the processing of OPA1 in an ATP and SLP2 dependent manner thereby allowing 
hyperfusion. The ATP-dependent inhibition presumably is performed by the m-AAA 
protease which negatively regulates the cleavage at S1 (discussed in chapter  4.4) (Figure 
21). These findings point to an interesting dichotomy: both SLP2 and m-AAA proteases are 
required for SIMH, whereas for fusion, m-AAA proteases and PHBs are necessary. 
Considering the co-migration of the m-AAA protease with both SLP2 and PHB2 containing 
complexes in BN-SDS-PAGE (Figure 17 A), and the fact that the interaction of endogenous 
prohibitins and SLP2 could be crosslinked to each other (Da Cruz et al., 2008), it is 
conceivable that the interaction of prohibitins and SLP2 is not direct but rather mediated 
by m-AAA proteases. This possibility has to be proven in future experiments e.g. by 
downregulation of m-AAA proteases and subsequent co-immunoprecipitation of SLP2 and 
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prohibitins. Furthermore, another more striking model predicts two distinct 
m-AAA protease containing supercomplexes, one active in hyperfusion including SLP2, 
and another more abundant fusion supercomplex containing prohibitins (Figure 21).  
In conclusion, SLP2 and mammalian m-AAA proteases form a high molecular weight 
complex in the inner mitochondrial membrane which is crucial for mitochondrial 
hyperfusion. It is hypothesized that elevated ATP levels prevent the enhanced processing 
of l-OPA1 which is negatively regulated by m-AAA proteases and SLP2. The degradation of 
non-cleavable l-OPA1 is controlled in an ATP-dependent process, presumably by 
mammalian m-AAA proteases. However, the exact molecular mechanism of hyperfusion 
and the protein machineries involved remain elusive. 
4.5.2. m-AAA proteases interact with MAIP1 (m-AAA protease 
interacting protein 1) 
In metal affinity chromatography experiments C2ORF47 co-eluted with AFG3L2 
indicating that C2ORF47 (chromosome 2 open reading frame 47) is an interaction partner 
of mammalian m-AAA proteases (Figure 19 A). Therefore, it was named MAIP1 (m-AAA 
protease interacting protein 1). The open reading frame of MAIP1 encodes for a protein 
that was predicted to target to mitochondria. The apparent molecular weight of mature 
MAIP1 is 22 kDa, which fits to the calculated molecular mass of the identified protein 
(Figure 18 A). MAIP1 carries a 100 amino acid long aminoterminal mitochondrial targeting 
sequence (MitoProt). The program HMMTOP (Tusnady and Simon, 2001) predicts one 
transmembrane domain in the N-terminal region, and a topology that the C-terminal part of 
the protein exposes the intermembrane space (sequence analysis in the appendix  6.3.2). 
Evolutionary conserved homologues of MAIP1 could not be identified in bacteria or yeast, 
but in other vertebrates and a more distantly related protein in insects. To date, there are 
no functional data on the vertebrate protein, but the insect homologue of MAIP1 is known 
as juvenile hormone esterase (JHE) binding protein 29 (Liu et al., 2007). Juvenile hormone 
(JH) disperses throughout the hemolymph and act on responsive tissues. JHE is critical for 
the appropriate regulation and degradation of JH during insect development. MAIP1 
identified as a binding protein of JHE has been shown to localize to mitochondria but its 
function is not understood (Liu et al., 2007; Liu et al., 2008). Based on the localization and 
detection of the esterase within mitochondria, it was hypothesized that the homologue of 
MAIP1 chaperones the esterase into and/or out of the mitochondria. Whether JHE 
functions in the mitochondria, or is stored there is unknown (Liu et al., 2007; Liu et al., 
2008; Liu et al., 2007). JHE is homologous to esterases and lipases, e.g. carboxyl esterase 
lipases or cholesterol esterases, proteins which mediate the hydrolysis and mobilization of 
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lipids in cells. However, a role of the interaction of MAIP1 with the m-AAA protease and a 
link to cholesterol esterases remains speculative. 
4.5.3. AFG3L2 is autocatalytically processed 
Ectopically expressed AFG3L2 was affinity purifed via a C-terminal hexa-histidine tag. 
In 2D-gelelectrophoresis a set of spots were detected and evaluated by mass spectrometric 
analysis, all were identified as human AFG3L2 (Figure 18 B). In the 2D-SDS-PAGE 
approach used in this study, hydrophobic proteins run below the diagonal (Rais et al., 
2004). The minor fraction of AFG3L2 spots migrated above the diagonal indicating less 
hydrophobicity of the corresponding protein possibly reflecting distinct charge variants of 
AFG3L2. This could be a result of conformational protein variants, existing in an 
equilibrium during sample preparation and Tris-tricine gel-electrophoresis and therefore 
not caused from heterogeneity in the primary structure of the protein. This has been 
previously demonstrated in a Lectin protein rViscumin (Lutter et al., 2001). No molecular 
differences like common chemical or post-translational modifications or nonenzymatic 
deamidation were found to cause the different charge values of the separated spots. The 
spot pattern was observed even under high urea concentration (Lutter et al., 2001), such as 
those which were used in this study. However, a post-translational modification of AFG3L2 
cannot be excluded and will be examined in future experiments. 
Interestingly, the precursor of AFG3L2 was detected upon purification of AFG3L2 WB 
(Figure 19 A). Considering that the WB variant functions as a substrate trap, the precursor 
itself might be a substrate of the protease leading to autocatalytic cleavage. Similar results 
were obtained from murine fibroblasts (Mirko Koppen, manuscript in preparation) 
indicating a conserved mechanism in mouse and human. Briefly, cells downregulated of 
Afg3l1 and Afg3l2 accumulate precursors of paraplegin. Import of radioactively labeled 
lysate into isolated mitochondria lacking various subunit combinations revealed that 
Afg3l2 and paraplegin are processed by Afg3l1 and/or Afg3l2 during import. This two-step 
processing of paraplegin and Afg3l2 reminds of other mitochondrial inner membrane and 
intermembrane space proteins, like Mgm1 or Ccp1 whose intramitochondrial sorting is 
ensured by bipartite presequences (Neupert and Herrmann, 2007). Also Lon, a AAA+ 
protease soluble in the matrix and FtsH can cleave itself (Akiyama, 1999; Wagner et al., 
1997). It remains unclear which factors determine the specificity of the protease resulting 
in either degradation or proteolytic processing of its substrate. Studies with other ATP-
dependent proteases indicate that stable proteolytic fragments are generated if the protein 
contains tightly folded structures that prevent the complete degradation of the protein 
(Piwko and Jentsch, 2006). A tightly folded domain may interrupt processive degradation 
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by m-AAA proteases initiated from the N-terminus resulting in the release of the matured 
protein like MrpL32, AFG3L2 or OPA1. This hypothesis is likely since AAA proteases like 
FtsH are poor unfoldases compared to other AAA+ proteases such as ClpXP (Herman et al., 
2003; Ito and Akiyama, 2005). 
4.5.4. MICS1 is a putative substrate of mammalian m-AAA 
proteases 
MICS1 co-eluted with hexa-histidin tagged AFG3L2 which harbors the mutation in the 
Walker B motif indicating that MICS1 is a putative substrate of mammalian 
m-AAA proteases. MICS1 was recently identified as a 23-26 kDa mitochondrial membrane 
protein (Oka et al., 2008). MICS1 has seven transmembrane domains and resides in the 
mitochondrial inner membrane facing its carboxy-terminal region into the intermembrane 
space. Due to the induction of mitochondrial fragmentation in up to 55 % of the cells and 
the disorganization of mitochondrial cristae upon siRNA mediated downregulation, the so 
far unknown protein was named MICS1 (for mitochondrial morphology and cristae 
structure) (see chapter  1.3.3.3) (Oka et al., 2008). The interaction with AFG3L2 WB can be 
explained by several hypotheses: MICS1 might be processed by mammalian m-AAA 
proteases resulting in an accumulation of a precursor version, like it was observed for 
MrpL32 or AFG3L2 itself (Figure 12 andFigure 18) (Nolden et al., 2005). Secondly, MICS1, 
like other yeast inner membrane proteins, could be degraded by m-AAA proteases (Arlt et 
al., 1998; Arlt et al., 1996; Langer et al., 1997; Pajic et al., 1994). Finally, m-AAA 
proteases may affect the import of MICS1, rather than its turnover, as it was shown for 
cytochrome c peroxidase (Esser et al., 2002; Tatsuta et al., 2007). 
Downregulation of MICS1 rendered the cells more susceptible towards apoptotic 
stimuli (Oka et al., 2008). Instead, overexpression of MICS1 inhibits apoptosis and 
crosslinking experiments showed a physical interaction with cytochrome c pointing to a 
protective role of MICS1 to help cells to survive under unhealthy conditions. Expression of 
Afg3L2/AFG3L2 WB had apparently no effect on the sensitivity of cells to apoptosis (Figure 
16), which is in contrast to Phb2 knockout MEFs (discussed in chapter  4.6). Thus, a 
negative effect of the inactivation of AFG3L2 on MICS1 is unlikely, pointing to either a 
degradation or dislocation function of mammalian m-AAA proteases. To investigate these 
issues, FITR293 cells were transfected with HA-tagged MICS1. In SDS-PAGE, MICS1 ran at 
the estimated size which corresponds to a mature version of MICS1 with cleaved 
mitochondrial presequence (Figure 18 A). A precursor band of MICS1-4HA did not 
accumulate in cells expressing AFG3L2 WB (Figure 19 A) excluding MICS1 as a 
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proteolytically processed substrate of mammalian m-AAA proteases. MICS1 did not 
accumulate in cells expressing AFG3L2 WB when compared to WT.  
Interestingly, sequence analysis revealed distant homology to a bacterial membrane 
protein YccA which is degraded by FtsH. YccA spans the membrane seven times and, 
when overexpressed, is FtsH-dependently degraded with a half-life of 15 min. (Kihara et 
al., 1998). YccA in wild-type cells can be crosslinked with FtsH, and its level increases by 
shortening of the N-terminally located cytosolic tail which is believed to be the 
degradation initiation region (see chapter  1.4.4). The physiological function of YccA is 
unclear. These findings even more propose that m-AAA proteases are linked to MICS1. 
Furthermore, due to its homology to YccA, it can be speculated that MICS1 is degraded 
dependent on m-AAA proteases. MICS1 accumulates and binds to the substrate trapping 
WB complex. To confirm the interaction of MICS1, co-IPs using the HA-antibody were 
performed, and surprisingly, overexpressed MICS1 could also bind to the AFG3L2 wild 
type version (Figure 19 B). This might be caused by the overexpression of MICS1 resulting 
in the accumulation on m-AAA proteases indicating that MICS1 could be a quality control 
substrate of mammalian m-AAA proteases. However, endogenous MICS1 co-eluted only 
with WB in pulldown experiments.  
To summarize, endogenous MICS1 co-eluted with the putative substrate trapping 
m-AAA protease complex, however the processing of overexpressed MICS1 was not 
affected and an accumulation of MICS1 in FITR293 cells expressing AFG3L2 WB was not 
observed. It should be mentioned that Ccp1, a yeast protein which is dislocalized by the 
m-AAA protease was never trapped in pulldown experiments (Takashi Tatsuta, personal 
communication). However, in IP samples of HA-tagged MICS1, also AFG3L2 was present 
further underlining that m-AAA proteases are linked to MICS1. 
Interestingly, MEFs depleted of the m-AAA protease by siRNA-mediated 
downregulation show an aberrant cristae morphology (Sarah Ehses, manuscript in 
preparation). MICS1 is a likely candidate to link m-AAA proteases and cristae organization, 
however, Walker B expressing cells exhibit also destabilized respiratory supercomplexes. 
There are good indications that the bends in membranes induced by ATP synthase dimers 
are responsible for shaping the inner membranes and forming the cristae (see chapter  1.3.3 
and  1.3.3.1) [reviewed in (Zick et al., 2009)]. Thus, the organisation of complex V appears 
to play a structural role. However, an effect on the ATP synthase was not observed in cells 
expressing the Walker B variant. Mitochondrial morphology may also have an effect on or 
be affected by cristae morphology (Vonck and Schäfer, 2009). Up to now it is unclear if, 
once a supercomplex is formed, it persists until degradation, or if there is a permanent 
transition between individual complexes floating in the membrane and supercomplexes 
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(Vonck and Schäfer, 2009). The question remains “what comes first”: unstable 
supercomplexes or disorganized cristae? 
Considering the suggested role of MICS1 in cristae organization and apoptosis, 
mammalian m-AAA proteases might contribute to these functions of MICS1 by regulating 
the steady state levels of MICS1. To investigate this, the stability of MICS1 in cells 
expressing the Walker B mutant compared to wild type has to be determined, e.g. with 
chase experiments. 
4.6. m-AAA proteases and prohibitins – highly conserved 
complexes with overlapping functions? 
Prohibitins and m-AAA proteases are crucial for cell proliferation (discussed in chapter 
 4.3). Deletions or mutations in prohibitins and m-AAA proteases results in an impaired cell 
proliferation indicating that the supercomplex is required to maintain cell growth. In 
addition, both have been demonstrated to be important for the stabilization of l-OPA1 (see 
 4.4). It was concluded that the supercomplex containing prohibitins and m-AAA proteases 
regulates the induced processing of OPA1 at the processing site S1 in a negative regulatory 
manner. Finally, deletions of prohibitins or m-AAA proteases have been shown to alter the 
cristae morphogenesis ( 4.5.4).  
Yet, phenotypes are not completely similar. Firstly, inactivation of m-AAA proteases 
induces the turnover of non-cleavable OPA1 isoforms which were stable upon depletion of 
Phb2 in MEFs (see  4.4). Secondly, prohibitins are dispensable for mitochondrial 
hyperfusion, whereas m-AAA proteases are necessary to allow fusion under hyperfusion 
conditions (discussed in chapter  4.5.1). Interestingly, Phb-/- MEFs are more susceptible to 
apoptosis (Merkwirth et al., 2008). Although major analysis of apoptosis in cells expressing 
the Walker B mutant is missing, there is evidence that WB cells behave different from Phb2 
knockout cells. Treatment with TNF-α and cycloheximide, an inducer of the extrinsic 
pathway, had no significant effect on the sensitivity towards apoptosis (Figure 16). In 
addition, siRNA-mediated downregulation of m-AAA proteases in MEFs revealed that MEFs 
were not more sensitive, instead they seemed modestly protected against etoposide, an 
inducer of the intrinsic apoptotic pathway (Sarah Ehses, personal communication).  
Besides fusion, OPA1 has an important role for inner membrane dynamics, cristae 
organization and apoptosis (Cipolat et al., 2006; Frezza et al., 2006) (introduced in 
chapters  1.3.3.2 and  1.3.3.3). The question is raised why the resistance towards apoptosis 
upon deletion of prohibitins or m-AAA proteases is distinct though depletion of both leads 
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to an accumulation of s-OPA1. The disassembly of OPA1 complexes has been shown to be 
an important step during mitochondrial dependent apoptosis (Yamaguchi et al., 2008).  
For instance, PARL deficient MEFs show reduced amounts of crosslinked OPA1 
oligomers (Frezza et al., 2006). In line, PARL knockout cells are more susceptible to 
apoptotic stimuli (Cipolat et al., 2006). However, in FITR293 cells expressing AFG3L2 WB, 
OPA1 complex accumulated comparable to wild type. This indicates, though less long 
isoforms present, the expression of the dominant negative mutant did apparently not affect 
complex formation of OPA1. Prohibitins were linked to apoptosis. Whether the loss of 
prohibitins affects the OPA1 complex is unclear and has to be determined. Since apoptosis 
is linked to the disassembly of OPA1 complexes, it can be assumed that this might be the 
cause of the increased sensitivity towards apoptosis of prohibitin depleted cells.  
However, the formation of OPA1 complexes might not be the only phenotypical 
difference in apoptosis resistance between m-AAA protease and Phb2 deficient cells. The 
identification of MICS1 may be the key to understand this phenomenon. MICS1 has been 
demonstrated to bind cyt c and upon overexpression to increase the resistance to apoptosis 
due to a delay in cyt c release (Oka et al., 2008). Thus, an impaired degradation would 
necessarily result in the accumulation of MICS1 protecting m-AAA protease mutant cells to 
release cyt c. In contrast, Phb2-/- MEFs lack the inhibitory function of prohibitins on the 
protease (Merkwirth and Langer, 2009). This results in an increased activity of 
m-AAA proteases which subsequently decreases MICS1 levels in the inner membrane 
resulting in disorganized cristae and increased sensitivity towards apoptotic stress. 
Although this model appears attractive, it should be considered that observed cristae 
phenotypes of the Phb2 depletion, siRNA of m-AAA proteases and MICS1 are not 
completely similar. Instead, Phb2-/- cells show more vesicular cristae which are comparable 
to those which was termed the stage 2 after inducing apoptosis (Sun et al., 2007). Stage 2 
is characterized by a release of cyt c but membrane potential is maintained.  
It will be of interest to compare the cristae morphology in MICS1 and m-AAA protease 
depleted cells in different physiological conditions. 
4.7. Translating cellular phenotypes to neurodegenerative 
diseases  
Human AFG3L2 and SPG7 are associated with distinct neurodegenerative diseases, 
spinocerebellar ataxia (SCA) (Cagnoli et al., 2006; Cagnoli et al., 2008; DiBella et al., 
2008) and hereditary spastic paraplegia (HSP) (Casari et al., 1998), respectively. The 
question remains whether the observed phenotypes in the cell culture system reflect the 
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physiological situation in humans. This is difficult to judge, since the dominant negative 
Walker B mutation is deleterious to the activity of the protease. It appears likely that 
humans or mice expressing this mutation in one subunit die or exhibit more severe defects 
than observed in SCA and HSP patients. Considering that expression of SPG7 WB in T-REx-
HeLa cells resulted in fragmentation of the mitochondrial network (Figure 9 C) it is 
assumed that the mutation in SPG7 is also dominant negative over the activity of the 
protease. In line, an SPG7 Walker B disease mutation in HSP patients could not be 
identified so far (Elleuch et al., 2006). The diseases do not resemble the deletion 
phenotype rather representing nuances of a functional state of the proteases considering 
tissue-specific expression of m-AAA protease subunits (Martinelli et al., 2009). 
Interestingly, Spg7-deficient mice show a rather mild phenotype with neuronal 
degeneration restricted to regions in the longest motorneurons (Ferreirinha et al., 2004). 
Spg7-/- mice additionally lacking one copy of Afg3l2 demonstrate severe degeneration of 
the cerebellum and the hippocampus (Martinelli et al., 2009) indicating that these tissues 
particularly require Afg3l2 function. This observation is reminiscent of the CMT2A 
pathogenesis linked to mitofusin 2 (Züchner et al., 2006). A low expression of Mfn1 
explains the susceptibility of Purkinje cells in CMT2A pathogenesis. A conditional 
knockout of mitofusins in the cerebellum of mice revealed a requirement of Mfn2 but not 
of Mfn1 for Purkinje cells (Chen et al., 2007). In fact, Afg3l2 is strongly expressed in 
Purkinje cells. While Spg7 expression appeared confined to Purkinje cells and specific 
neurons, Afg3l1 transcript was instead poorly detected in the brain. These findings suggest 
that reduced expression levels of the subunits result in a lower abundance of active 
subunits. This subsequently triggers the degeneration Purkinje cells and the cerebellum. 
However, it cannot be excluded that differences in the enzymatic properties or substrate 
specificities of m-AAA protease isoenzymes or even different substrate proteins exist which 
explain the tissue specific defects observed in HSP or SCA patients. 
Notably, mitochondrial dysfunction is an early event in virtually all common 
neurodegenerative diseases, including Huntingtin’s disease (HD), Parkinson’s disease (PD) 
and Alzheimer’s disease (AD) (Lin and Beal, 2006). Interestingly, respiratory deficiency 
occurs late in mice lacking Spg7 and one allele of Afg3l2 (Martinelli et al., 2009) 
indicating that this is not the primary cause of neurodegeneration. This study revealed 
crucial functions of m-AAA proteases for the regulation of mitochondrial morphology 
suggesting dysfunctions of mitochondrial dynamics as the primary cause of the diseases. In 
fact, research suggests that many of the mitochondrial defects associated with HD, PD and 
AD could result, at least in part, from disruption of the fusion/fission mechanism indicating 
mitochondrial fragmentation as a hallmark of neurodegenerative diseases (Knott and Bossy-
Wetzel, 2008).  
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But why are in particular neurons prone for mitochondrial dysfunctions? Neurons are 
highly specialized cells. They have a huge energy demand and extremely long processes 
with axons extending up to one meter in motor neurons, indicating that energy has to be 
transmitted across long distances. Finally, their major function is communication which 
suggests a tightly regulated signalling system that relies on balances of ions in synapses and 
efficient functioning of ion channels, receptors and pumps (Chan, 2006; Chen and Chan, 
2006; Detmer and Chan, 2007; Knott and Bossy-Wetzel, 2008; Knott et al., 2008). For 
instance, due to the extremely long axons, or to their remarkable dendritic tree Purkinje 
cells can be a preferential target when mitochondrial dynamics, transport, and function are 
even slightly perturbed. Interestingly, Purkinje cell mitochondria from mice lacking Spg7 
and one allele of Afg3l2 were giant and contained swollen cristae (Martinelli et al., 2009). 
This might be explained by a lack of mitochondrial fusion, and implies that dysfunctional 
giant mitochondria cannot restore their function by fusing and exchanging their contents 
with fully functional mitochondria (Navratil et al., 2008). Martinelli et al. observed that 
mitochondria in these mice tend to lose mitochoncrial DNA (Martinelli et al., 2009) which 
is attributed as a secondary effect of the loss of fusion activity (Hoppins et al., 2007).  
Therefore, the observed phenotypes in HSP, SCA or CMT2A are presumably caused by 
a decreased fusion activity resulting in the loss of mtDNA and later to reduced OXPHOS 
activities. In addition, the compensatory mechanisms of OXPHOS might reduce with age 
thereby explaining the progressive disease pathogenesis (Bernard and Rossignol, 2008). 
 
In conclusion, this study identified key functions of mammalian m-AAA protease in cell 
proliferation and mitochondrial morphogenesis. In addition, MICS1 was discovered to 
interact with mammalian m-AAA proteases suggesting that MICS1 might be a potential 
substrate or regulatory binding partner of the proteases. Moreover, the identification of 
MICS1 could contribute to the understanding of the observed phenotypes associated with 
mutations of m-AAA protease subunits in human and mice. The presence of swollen cristae 
in synaptic terminals of Spg7-/- mice might be caused by an impaired function of MICS1. 
Although those cells might exhibit an increased resistance towards apoptosis, OXPHOS 
supercomplexes could be destabilized resulting in a reduced maximal respiratory capacity. 
This effect may also contribute to mitochondrial dysfunction especially in neuronal cells. 
However, the role of this interaction is yet unclear, therefore further experiments will aim 
to analyze the stability of MICS1 in cells expressing dominant negative mutant AFG3L2. 
Future experiments will also focus on putative signaling events which are involved in the 
maintenance of cell proliferation by mitochondrially localized proteases. Finally, the 
identification of the protease which cleaves OPA1 in an inducible manner might help to 
elucidate molecular details of the fusion process. This protease could be a therapeutic 
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target against diseases associated with dysfunctions in mitochondrial dynamics due to an 
impaired energy metabolism. 
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6. Appendix 
6.1. List of abbreviations 
AAA   ATPases associated with a variety of cellular activities  
ADOA  autosomal dominant optic atrophy  
ADP   adenosine diphosphate  
Afg3l1  ATPase family gene 3-like 1  
Afg3l2  murine ATPase family gene 3-like 2 
AFG3L2 human ATPase family gene 3-like 2 
AMP  adenosine monophosphate 
APS   ammoniumperoxo disulfate  
ATP   adenosine triphosphate  
Bcl-2  B-cell lymphoma 2 
BN   blue native  
bp   base pairs  
CCCP   carbonyl cyanide m-chlorophenyl hyradzone 
cDNA   complementary DNA  
CMT2A/4A Charcot-Marie-Tooth type 2A/4A 
CMV  cytomegalo-virus 
CN  colorless/clear native 
Co-IP  co-immunoprecipitation 
C-terminal  carboxy-terminal  
C-terminus  carboxy-terminus  
DMSO  dimethyl sulfoxide  
DNA   deoxyribonucleic acid  
E. coli  Escherichia coli 
EDTA   ethylene diamine tetraacetic acid  
FITR293 FlpIn T-REx-293 cell line 
g   gram  
g  gravity 
GTP   guanosine triphosphate  
h   hour(s)  
HA   hemagglutinin  
HCl   hydrochloric acid  
HEPES   N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic-acid  
His/6His/8His histidine/hexa-histidine/octa-histidine  
HSP   hereditary spastic paraplegia  
IP  immunoprecipitation 
JHEbp29 juvenile hormone esterase binding protein 29 
K   potassium  
kb   kilobase pairs  
KCl   potassium chloride  
kDa   kilodalton  
KOH   potassium hydroxide  
m   meter  
M   molar (mole per liter)  
MDa   megadalton  
Mg   magnesium  
µg  microgram  
µl   microliter  
mg   milligram  
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min   minute(s)  
ml   milliliter  
mM   millimolar  
MOMP mitochondrial outer membrane permeabilization 
MPP   mitochondrial processing peptidase  
mRNA  messenger RNA  
mtDNA  mitochondrial DNA 
MTS   mitochondrial targeting sequence  
NaCl   sodium chloride  
NAD+  nicotinamide adenine dinucleotide (oxidized form) 
NADH  nicotinamide adenine dinucleotide (reduced form)  
nDNA  nuclear DNA 
N-terminal  aminoterminal  
N-terminus  amino terminus  
Oligo  oligonucleotide 
ORF  open reading frame 
PA  phosphatic acid 
PAGE   polyacrylamide gel electrophoresis  
PBS   phosphate buffered saline  
PC  phosphatidylcholine 
PCR   polymerase chain reaction  
PE  phosphatidylethanolamine 
PG  phosphatidylglycerol 
PI  phosphatidylinositol 
PMSF   phenylmethylsulphonyl fluoride  
PS  m-AAA protease subunit variant harboring mutation in the proteolytic site 
PSe  phosphatidylserine 
PVDF   polyvinylidene fluoride  
RNA   ribonucleic acid  
ROS   reactive oxygen species  
rpm  rounds per minute 
RT   room temperature  
s   second(s)  
SDS   sodium dodecyl sulfate  
SPG   spastic paraplegia gene  
SPG7  Spastic Paraplegia 7, human paraplegin 
Spg7  Spastic Paraplegia 7, murine paraplegin 
SRH  second region of homology  
TBS   Tris buffered saline  
TIM   translocase of the inner membrane  
TM   transmembrane domain  
Tris   2-amino-2-(hydroxymethyl)-1,3-propandiole  
U   unit(s)  
V  volt(s) 
v/v   volume per volume  
w/v   weight per volume  
WB  m-AAA protease subunit variant harboring mutation in the Walker B motif 
within the ATPase domain 
WT  wild type 
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6.2. Mass spectrometric analysis 
Bands from 1D and 2D gels were subjected to a gel digestion according to 
(Shevchenko et al., 2006) with slight modifications. MS analyses were performed using a 
MALDI-TOFTOF instrument (4800 Plus, Applied Biosystems) and α-cyano-4-
hydroxycinnamic acid as matrix. Proteins were identified comparing the NCBI.nr-protein 
sequence database of Homo sapiens (human) with the MALDI-MS spectra of tryptic 
peptides by using the MOWSE algorithm as implemented in the MS search engine 
MASCOT (Matrix Science, London, UK) (Perkins et al., 1999). The analyses were 
performed at the Proteomics Mass Spectrometry Facility of the CECAD (Cologne – 
Excellent in Aging Research) by Dr. rer. nat. Tobias Lamkemeyer.  
Results are depicted in the following tables. Abbreviations in the tables: Acc No, 
accession number; MWpred, predicted mass; MWexp, experimental mass; MWtheor, theoretical 
mass corresponding to the mass of mature proteins (containing the mitochondrial targeting 
sequences); MWtheor+tags, theoretical mass including epitope tags [predicted with the 
ProtParam tool (Gasteiger et al., 2005)]; Seq-cov, sequence coverage; No PMF, number of 
matched masses. 
 
  
Table 5: MASCOT results of AFG3L2 precursor (Figure 18 B). 
Acc No MWpred  
[kDa] 
MWexp 
[kDa] 
MWtheor 
[kDa] 
MWtheo+tags 
[kDa] 
Score* Seq-cov 
[%] 
No PMF 
Q9Y4W6 88.528 ~85 88.584 89.407 136 32 30 
 
Matched peptides of AFG3L2 precursor shown in Bold Red. 
     1 MAHRCLRLWG RGGCWPRGLQ QLLVPGGVGP GEQPCLRTLY RFVTTQARAS  
    51 RNSLLTDIIA AYQRFCSRPP KGFEKYFPNG KNGKKASEPK EVMGEKKESK  
   101 PAATTRSSGG GGGGGGKRGG KKDDSHWWSR FQKGDIPWDD KDFRMFFLWT  
   151 ALFWGGVMFY LLLKRSGREI TWKDFVNNYL SKGVVDRLEV VNKRFVRVTF  
   201 TPGKTPVDGQ YVWFNIGSVD TFERNLETLQ QELGIEGENR VPVVYIAESD  
   251 GSFLLSMLPT VLIIAFLLYT IRRGPAGIGR TGRGMGGLFS VGETTAKVLK  
   301 DEIDVKFKDV AGCEEAKLEI MEFVNFLKNP KQYQDLGAKI PKGAILTGPP  
   351 GTGKTLLAKA TAGEANVPFI TVSGSEFLEM FVGVGPARVR DLFALARKNA  
   401 PCILFIDEID AVGRKRGRGN FGGQSEQENT LNQLLVEMDG FNTTTNVVIL  
   451 AGTNRPDILD PALLRPGRFD RQIFIGPPDI KGRASIFKVH LRPLKLDSTL  
   501 EKDKLARKLA SLTPGFSGAD VANVCNEAAL IAARHLSDSI NQKHFEQAIE  
   551 RVIGGLEKKT QVLQPEEKKT VAYHEAGHAV AGWYLEHADP LLKVSIIPRG  
   601 KGLGYAQYLP KEQYLYTKEQ LLDRMCMTLG GRVSEEIFFG RITTGAQDDL  
   651 RKVTQSAYAQ IVQFGMNEKV GQISFDLPRQ GDMVLEKPYS EATARLIDDE  
   701 VRILINDAYK RTVALLTEKK ADVEKVALLL LEKEVLDKND MVELLGPRPF  
   751 AEKSTYEEFV EGTGSLDEDT SLPEGLKDWN KEREKEKEEP PGEKVAN 
 
 
 
 
 
 
Appendix 
 
132 
Table 6: MASCOT results of AFG3L2 (Figure 18 B). 
Acc No MWpred  
[kDa] 
MWexp 
[kDa] 
MWtheor 
[kDa] 
MWtheo+tags 
[kDa] 
Score* Seq-cov 
[%] 
No PMF 
EAX01551 84.392 ~75 88.584 89.407 126 26 24 
 
Matched peptides of AFG3L2 shown in Bold Red. 
     1 LYRFVTTQAR ASRNSLLTDI IAAYQRFCSR PPKGFEKYFP NGKNGKKASE  
    51 PKEVMGEKKE SKPAATTRSS GGGGGGGGKR GGKKDDSHWW SRFQKGDIPW  
   101 DDKDFRMFFL WTALFWGGVM FYLLLKRSGR EITWKDFVNN YLSKGVVDRL  
   151 EVVNKRFVRV TFTPGKTPVD GQYVWFNIGS VDTFERNLET LQQELGIEGE  
   201 NRVPVVYIAE SDGSFLLSML PTVLIIAFLL YTIRRGPAGI GRTGRGMGGL  
   251 FSVGETTAKV LKDEIDVKFK DVAGCEEAKL EIMEFVNFLK NPKQYQDLGA  
   301 KIPKGAILTG PPGTGKTLLA KATAGEANVP FITVSGSEFL EMFVGVGPAR  
   351 VRDLFALARK NAPCILFIDE IDAVGRKRGR GNFGGQSEQE NTLNQLLVEM  
   401 DGFNTTTNVV ILAGTNRPDI LDPALLRPGR FDRQIFIGPP DIKGRASIFK  
   451 VHLRPLKLDS TLEKDKLARK LASLTPGFSG ADVANVCNEA ALIAARHLSD  
   501 SINQKHFEQA IERVIGGLEK KTQVLQPEEK KTVAYHEAGH AVAGWYLEHA  
   551 DPLLKVSIIP RGKGLGYAQY LPKEQYLYTK EQLLDRMCMT LGGRVSEEIF  
   601 FGRITTGAQD DLRKVTQSAY AQIVQFGMNE KVGQISFDLP RQGDMVLEKP  
   651 YSEATARLID DEVRILINDA YKRTVALLTE KKADVEKVAL LLLEKEVLDK  
   701 NDMVELLGPR PFAEKSTYEE FVEGTGSLDE DTSLPEGLKD WNKEREKEKE  
   751 EPPGEKVAN 
 
 
 
Table 7: MASCOT results of MICS1 (Figure 18 A). 
Acc No MWpred  
[kDa] 
MWexp 
[kDa] 
MWtheor 
[kDa] 
MWtheo+tags 
[kDa] 
Score* Seq-cov 
[%] 
No PMF 
CAH72661 35.259 ~28 35.282 - 101 51 16 
 
Matched peptides of MICS1 shown in Bold Red. 
     1 MLAARLVCLR TLPSRVFHPA FTKASPVVKN SITKNQWLLT PSREYATKTR  
    51 IGIRRGRTGQ ELKEAALEPS MEKIFKIDQM GRWFVAGGAI EKAVIWPQYV  
   101 KDRIHSTYMY LAGSIGLTAL SAIAISRTPV LMNFMMRGSW VTIGVTFAAM  
   151 VGAGMLVRSI PYDQSPGPKH LAWLLHSGVM GAVVAPLTIL GGPLLIRAAW  
   201 YTAGIVGGLS TVAMCAPSEK FLNMGAPLGV GLGLVFVSSL GSMFLPPTTV  
   251 AGATLYSVAM YGGLVLFSMF LLYDTQKVIK RAEVSPMYGV QKYDPINSML  
   301 SIYMDTLNIF MRVATMLATG GNRKK 
 
 
 
Table 8: MASCOT results of MAIP1 (Figure 18 A). 
Acc No MWpred  
[kDa] 
MWexp 
[kDa] 
MWtheor 
[kDa] 
MWtheo+tags 
[kDa] 
Score* Seq-cov 
[%] 
No PMF 
Q8WWC4 32.524 ~25 32.545 - 91 50 12 
 
Matched peptides of MAIP1 shown in Bold Red. 
     1 MALAARLLPQ FLHSRSLPCG AVRLRTPAVA EVRLPSATLC YFCRCRLGLG  
    51 AALFPRSARA LAASALPAQG SRWPVLSSPG LPAAFASFPA CPQRSYSTEE  
   101 KPQQHQKTKM IVLGFSNPIN WVRTRIKAFL IWAYFDKEFS ITEFSEGAKQ  
   151 AFAHVSKLLS QCKFDLLEEL VAKEVLHALK EKVTSLPDNH KNALAANIDE  
   201 IVFTSTGDIS IYYDEKGRKF VNILMCFWYL TSANIPSETL RGASVFQVKL  
   251 GNQNVETKQL LSASYEFQRE FTQGVKPDWT IARIEHSKLL E 
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Table 9: MASCOT results of PHB1 (Figure 18 A). 
Acc No MWpred  
[kDa] 
MWexp 
[kDa] 
MWtheor 
[kDa] 
MWtheo+tags 
[kDa] 
Score* Seq-cov 
[%] 
No PMF 
NP_002625 29.787 ~30 32.972 - 239 86 22 
 
Matched peptides of prohibitin 1 shown in Bold Red 
 
     1 MAAKVFESIG KFGLALAVAG GVVNSALYNV DAGHRAVIFD RFRGVQDIVV  
    51 GEGTHFLIPW VQKPIIFDCR SRPRNVPVIT GSKDLQNVNI TLRILFRPVA  
   101 SQLPRIFTSI GEDYDERVLP SITTEILKSV VARFDAGELI TQRELVSRQV  
   151 SDDLTERAAT FGLILDDVSL THLTFGKEFT EAVEAKQVAQ QEAERARFVV  
   201 EKAEQQKKAA IISAEGDSKA AELIANSLAT AGDGLIELRK LEAAEDIAYQ  
   251 LSRSRNITYL PAGQSVLLQL PQ 
 
 
 
Table 10: MASCOT results of PHB2 (Figure 18 A). 
Acc No MWpred  
[kDa] 
MWexp 
[kDa] 
MWtheor 
[kDa] 
MWtheo+tags 
[kDa] 
Score* Seq-cov 
[%] 
No PMF 
NP_009204 33.276 ~32 33296.3 - 234 82 28 
 
Matched peptides of prohibitin 2 shown in Bold Red 
 
     1 MAQNLKDLAG RLPAGPRGMG TALKLLLGAG AVAYGVRESV FTVEGGHRAI  
    51 FFNRIGGVQQ DTILAEGLHF RIPWFQYPII YDIRARPRKI SSPTGSKDLQ  
   101 MVNISLRVLS RPNAQELPSM YQRLGLDYEE RVLPSIVNEV LKSVVAKFNA  
   151 SQLITQRAQV SLLIRRELTE RAKDFSLILD DVAITELSFS REYTAAVEAK  
   201 QVAQQEAQRA QFLVEKAKQE QRQKIVQAEG EAEAAKMLGE ALSKNPGYIK  
   251 LRKIRAAQNI SKTIATSQNR IYLTADNLVL NLQDESFTRG SDSLIKGKK 
 
 
Search Parameters 
Type of search:    Peptide Mass Fingerprint 
Enzyme:    trypsin 
Variable modifications:  oxidation (M) 
Mass values:   monoisotopic 
Protein mass:   unrestricted 
Peptide mass Tolerance:   ± 50 ppm 
Peptide charge state:   1+ 
Max missed cleavages:   1 
(*)    Protein score is -10*Log (P), where P is the 
probability that the observed match is a random 
event. Protein scores greater than 66 are significant 
(p<0.05). 
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6.3. Protein sequence analysis 
All sequence alignments were generated by the ClustalW program. Accession numbers 
used were the following: 
 
FtsH (Thermus thermophilus)  BAA96090 
Yta12 (Saccharomyces cerevisiae) CAA56953 
Yta10 (Saccharomyces cerevisiae) NP_013807 
Spg7 (Mus musculus)   AAN03852 
Afg3l2 (Mus musculus)  Q8JZQ2 
Afg3l1 (Mus musculus)  NP_473411 
SPG7 (Homo sapiens)   Q9UQ90 
AFG3L2 (Homo sapiens)  NP_006787 
MICS1 (Homo sapiens)  NP_055209 
YccA (Escherichia coli)  P0AAC6 
C2ORF47/MAIP1 (Homo sapiens) Q8WWC4 
JHEbp29 (Drosophila melanogaster) AAF47306 
 
6.3.1. m-AAA proteases 
 
Table 11: Sequence identities/similarities of human compared to other m-AAA protease subunits. 
- Yta10 Yta12 Afg3l2 Afg3l1 Spg7 
AFG3L2 46% / 57% 44% / 55% 92% / 94% 69% / 78% 39% / 51% 
SPG7 39% / 52% 37% / 50% 39% / 51 % 38% / 51% 87% / 91% 
 
 
 
 
                      1                                               50 
FtsH (Th. th.)    (1) -------------------------------------------------- 
 Yta12 (S. c.)    (1) ---MLLLSWSRIATKVVRRPVRFRSYY-GLTHIKSLHTQYRLLNRLQENK 
 Yta10 (S. c.)    (1) -----MMMWQRYARGAPRS-----------------------LTSLSFGK 
  Spg7 (M. m.)    (1) --MAAALLLLRGLRPGPEPRPRRLWGLLSGRGPGLSSGAGARRPYAARGT 
Afg3l2 (M. m.)    (1) MAHRCLLLWSRGGCR-RGLPPLLVPR--GCLGPDRRPCLRTLYQYATVQT 
Afg3l1 (M. m.)    (1) ---MLLRLVGAAGSRALAWPFSKLWRCGGCAGSGGTVWSSVRACGIALQG 
  SPG7 (H. s.)    (1) --MAVLLLLLRALRRGPGPGPRPLWGPGPAWSPGFPARPGRGRPYMASRP 
AFG3L2 (H. s.)    (1) MAHRCLRLWGRGGCWPRGLQQLLVP---GGVGPGEQPCLRTLYRFVTTQA 
 
                      51                                             100 
FtsH (Th. th.)    (1) -------------------------------------------------- 
 Yta12 (S. c.)   (47) SGNKNEDNNEDAKLNKEIPTDEEVEAIRKQVEKYIEQTKNNTIPANWKEQ 
 Yta10 (S. c.)   (23) AS----------RISTVKPVLRSRMPVHQRLQTLSGLATRNTIHRSTQIR 
  Spg7 (M. m.)   (49) PV------------GPAAAGGHAPQSLLLRILTPSFEGISGLLLKQHIVP 
Afg3l2 (M. m.)   (48) ASSRR-------------SLLRDVIAAYQRFCSRPPKGFEKYFPNGKNGK 
Afg3l1 (M. m.)   (48) HLGRCS---------QQLALQGKLTSFSPRLYSKPPRGFEKFFKNKKNRK 
  SPG7 (H. s.)   (49) PG------------DLAEAGGRALQSLQLRLLTPTFEGINGLLLKQHLVQ 
AFG3L2 (H. s.)   (48) RASRN-------------SLLTDIIAAYQRFCSRPPKGFGKYFPNGKNGK 
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                      101                                            150 
FtsH (Th. th.)    (1) -------------------------------------------------- 
 Yta12 (S. c.)   (97) KRKIDESIRRLEDAVLKQESNRIQEERKEK-------EEENGPSKAKSNR 
 Yta10 (S. c.)   (63) S--------------FHISWTRLNENRPNK-------EGEGKNNGNKDNN 
  Spg7 (M. m.)   (87) NAVR-----LWPLSGSTLYFNTSRMKQKNK-------DNDK--PKGKTPE 
Afg3l2 (M. m.)   (85) KASE--------------PKEAVGEKKEPQPSGPQ-PSGGAGGGGGKRRG 
Afg3l1 (M. m.)   (89) SAS---------------PGNSVPPKKEPK-------NAGPGGDGGNRGG 
  SPG7 (H. s.)   (87) NPVR-----LWQLLGGTFYFNTSRLKQKNK-------EKDK--SKGKAPE 
AFG3L2 (H. s.)   (85) KASE--------------PKEVMGEKKESKPAATTRSSGGGGGGGGKRGG 
 
                      151                                            200 
FtsH (Th. th.)    (1) ----------------------------------MPRAPFSLLALVLGLA 
 Yta12 (S. c.)  (140) TKEQGYFEGNNSRNIPPPPPPPPPKPPLNDPS-NPVSKNVNLFQIGLTFF 
 Yta10 (S. c.)   (92) SNKE---DGKDKRNE---------FGSLSEYFRSKEFANTMFLTIGFTII 
  Spg7 (M. m.)  (123) DDEE---E-KRRKER------------EDQMY-RERLRTLFIIALVMSLL 
Afg3l2 (M. m.)  (120) KKEDSHWWSRFQKGD----------FPWDDKDFRMYFLWTALFWGGVMIY 
Afg3l1 (M. m.)  (117) KGDDFPWWKRMQKGE----------FPWDDKDFRSLAVLGAGVAAGFLYF 
  SPG7 (H. s.)  (123) EDEE---E-RRRRER------------DDQMY-RERLRTLLVIAVVMSLL 
AFG3L2 (H. s.)  (121) KKDDSHWWSRFQKGD----------IPWDDKDFRMFFLWTALFWGGVMFY 
 
                      201                                            250 
FtsH (Th. th.)   (17) FLAWPSASRGTVGAPSGTVNYTTFLEDLKAGRVKEVVVRAGDTRIQGVLE 
 Yta12 (S. c.)  (189) LLSFLLDLLNSLEEQS-EITWQDFREKLLAKGYVAKLIVVNKSMVKVMLN 
 Yta10 (S. c.)  (130) FTLLTPSSNNSGDDSNRVLTFQDFKTKYLEKGLVSKIYVVNKFLVEAELV 
  Spg7 (M. m.)  (156) NSLSTS---------GGSISWADFVNEMLAKGEVQRVQVVPESDVVEVYL 
Afg3l2 (M. m.)  (160) FVFKSS---------GREITWKDFVNNYLSKGVVDRLEVVNKRFVRVTFT 
Afg3l1 (M. m.)  (157) YFRDP----------GKEITWKHFVQYYLARGLVDRLEVVNKQFVRVIPV 
  SPG7 (H. s.)  (156) NALSTS---------GGSISWNDFVHEMLAKGEVQRVQVVPESDVVEVYL 
AFG3L2 (H. s.)  (161) LLLKRS---------GREITWKDFVNNYLSKGVVDRLEVVNKRFVRVTFT 
 
                      251                                            300 
FtsH (Th. th.)   (67) DG-----------------SAFTTYAASPPDNATLEGWMARGVSVRVEPP 
 Yta12 (S. c.)  (238) DNGKNQADN-YGRNFYYFTIGSIDSFEHKLQKAQDELDIDKDFRIPVLYV 
 Yta10 (S. c.)  (180) N----------TKQVVSFTIGSVDIFEEQMDQIQDLLNIPPRDRIPIKYI 
  Spg7 (M. m.)  (197) HPGAVVFGRPRLALMYRMQVANIDKFEEKLRAAEDELNIESKDRIPVSYK 
Afg3l2 (M. m.)  (201) PGKTP-----VDGQYVWFNIGSVDTFERNLETLQQELGIEGENRVPVVYI 
Afg3l1 (M. m.)  (197) PGTT-------SERFVWFNIGSVDTFERNLESAQWELGIEPTNQAAVVYT 
  SPG7 (H. s.)  (197) HPGAVVFGRPRLALMYRMQVANIDKFEEKLRAAEDELNIEAKDRIPVSYK 
AFG3L2 (H. s.)  (202) PGKTP-----VDGQYVWFNIGSVDTFERNLETLQQELGIEGENRVPVVYI 
 
                      301                                            350 
FtsH (Th. th.)  (100) QGQNALGFLWPLLLVGLLIGALYYFSRNG----------RAGPSDSAFSF 
 Yta12 (S. c.)  (287) QEGNWAKAMFQILPTVLMIAGIIWLTRRS------AQAAGGS-RGGIFGL 
 Yta10 (S. c.)  (220) ERSSPFTFLFPFLPTIILLGGLYFITRKINSSPPNANGGGGGGLGGMFNV 
  Spg7 (M. m.)  (247) RTGFFGNALYALGMTAVGLAILWYVFRLAG-----MTGREGG-FSAFNQL 
Afg3l2 (M. m.)  (246) AESD-GSFLLSMLPTVLIIAFLLYTIRRG----PAGIGRTGRGMGGLFSV 
Afg3l1 (M. m.)  (240) TESD-GSFLRSLVPTLVLVSILLYAMRRG----PMGTGRGGRG-GGLFSV 
  SPG7 (H. s.)  (247) RTGFFGNALYSVGMTAVGLAILWYVFRLAG-----MTGREGG-FSAFNQL 
AFG3L2 (H. s.)  (247) AESD-GSFLLSMLPTVLIIAFLLYTIRRG----PAGIGRTGRGMGGLFSV 
 
                      351                                            400 
FtsH (Th. th.)  (140) TKSRARVLTEAPKVT--FKDVAGAEEAKEELKEIVEFLKNPSRFHEMGAR 
 Yta12 (S. c.)  (330) SRSKAKKFNTETDVKIKFKDVAGCDEAKEEIMEFVSFLKEPSRYEKMGAK 
 Yta10 (S. c.)  (270) GKSRAKLFNKETDIKISFKNVAGCDEAKQEIMEFVHFLKNPGKYTKLGAK 
  Spg7 (M. m.)  (291) KMARFTIVDGKTGKGVSFQDVAGMHEAKLEVREFVDYLKSPERFLQLGAK 
Afg3l2 (M. m.)  (291) GETTAKVLKDEIDVK--FKDVAGCEEAKLEIMEFVNFLKNPKQYQDLGAK 
Afg3l1 (M. m.)  (284) GETTAKILKNNIDVR--FADVAGCEEAKLEIMEFVNFLKNPKQYQDLGAK 
  SPG7 (H. s.)  (291) KMARFTIVDGKMGKGVSFKDVAGMHEAKLEVREFVDYLKSPERFLQLGAK 
AFG3L2 (H. s.)  (292) GETTAKVLKDEIDVK--FKDVAGCEEAKLEIMEFVNFLKNPKQYQDLGAK 
 
                      401                                            450 
FtsH (Th. th.)  (188) IPKGVLLVGPPGVGKTHLARAVAGEARVPFITASGSDFVEMFVGVGAARV 
 Yta12 (S. c.)  (380) IPRGAILSGPPGTGKTLLAKATAGEAGVPFYFVSGSEFVEMFVGVGAARV 
 Yta10 (S. c.)  (320) IPRGAILSGPPGTGKTLLAKATAGEANVPFLSVSGSEFVEMFVGVGASRV 
  Spg7 (M. m.)  (341) VPKGALLLGPPGCGKTLLAKAVATEAQVPFLAMAGPEFVEVIGGLGAARV 
Afg3l2 (M. m.)  (339) IPKGAILTGPPGTGKTLLAKATAGEANVPFITVSGSEFLEMFVGVGPARV 
Afg3l1 (M. m.)  (332) IPKGAMLTGPPGTGKTLLAKATAGEANVPFITVNGSEFLEMFVGVGPARV 
  SPG7 (H. s.)  (341) VPKGALLLGPPGCGKTLLAKAVATEAQVPFLAMAGPEFVEVIGGLGAARV 
AFG3L2 (H. s.)  (340) IPKGAILTGPPGTGKTLLAKATAGEANVPFITVSGSEFLEMFVGVGPARV 
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         Walker B 
                      451                                            500 
FtsH (Th. th.)  (238) RDLFETAKRHAPCIVFIDEIDAVGRKRGSG--VGGGNDEREQTLNQLLVE 
 Yta12 (S. c.)  (430) RDLFKTARENAPSIVFIDEIDAIGKARQKG-NFSGANDERENTLNQMLVE 
 Yta10 (S. c.)  (370) RDLFTQARSMAPSIIFIDEIDAIGKERGKGGALGGANDEREATLNQLLVE 
  Spg7 (M. m.)  (391) RSLFKEARARAPCIVYIDEIDAVGKKRSTSMSGFSNTEE-EQTLNQLLVE 
Afg3l2 (M. m.)  (389) RDLFALARKNAPCILFIDEIDAVGRKRGRG-NFGGQSEQ-ENTLNQLLVE 
Afg3l1 (M. m.)  (382) RDMFAMARKHAPCILFIDEIDAIGRKRGRG-HLGGQSEQ-ENTLNQMLVE 
  SPG7 (H. s.)  (391) RSLFKEARARAPCIVYIDEIDAVGKKRSTTMSGFSNTEE-EQTLNQLLVE 
AFG3L2 (H. s.)  (390) RDLFALARKNAPCILFIDEIDAVGRKRGRG-NFGGQSEQ-ENTLNQLLVE 
 
                      501                                            550 
FtsH (Th. th.)  (286) MDGFEKDTAIVVMAATNRPDILDPALLRPGRFDRQIAIDAPDVKGREQIL 
 Yta12 (S. c.)  (479) MDGFTPADHVVVLAGTNRPDILDKALLRPGRFDRHINIDKPELEGRKAIF 
 Yta10 (S. c.)  (420) MDGFTTSDQVVVLAGTNRPDVLDNALMRPGRFDRHIQIDSPDVNGRQQIY 
  Spg7 (M. m.)  (440) MDGMGTTDHVIVLASTNRADVLDNALMRPGRFDRHVFIDLPTLQERREIF 
Afg3l2 (M. m.)  (437) MDGFNTTTNVVILAGTNRPDILDPALLRPGRFDRQIFIGPPDIKGRASIF 
Afg3l1 (M. m.)  (430) MDGFNSSTNVVVLAGTNRPDILDPALTRPGRFDRQIYIGPPDIKGRSSIF 
  SPG7 (H. s.)  (440) MDGMGTTDHVIVLASTNRADILDGALMRPGRLDRHVFIDLPTLQERREIF 
AFG3L2 (H. s.)  (438) MDGFNTTTNVVILAGTNRPDILDPALLRPGRFDRQIFIGPPDIKGRASIF 
 
                      551                                            600 
FtsH (Th. th.)  (336) RIHARGKPLAEDVDLALL-----AKRT-PGFVGADLENLLNEAALLAARE 
 Yta12 (S. c.)  (529) AVHLHHLKLAGEIFDLKN----RLAALTPGFSGADIANVCNEAALIAARS 
 Yta10 (S. c.)  (470) LVHLKRLNLDPLLTDDMNNLSGKLATLTPGFTGADIANACNEAALIAARH 
  Spg7 (M. m.)  (490) EQHLKGLKLTQPSSFYSQ----RLAELTPGFSGADIANICNEAALHAARE 
Afg3l2 (M. m.)  (487) KVHLRPLKLDSALEKDKLAR--KLASLTPGFSGADVANVCNEAALIAARH 
Afg3l1 (M. m.)  (480) KVHLRPLKLDGSLSKDALSR--KLAALTPGFTGADISNVCNEAALIAARH 
  SPG7 (H. s.)  (490) EQHLKSLKLTQSSTFYSQ----RLAELTPGFSGADIANICNEAALHAARE 
AFG3L2 (H. s.)  (488) KVHLRPLKLDSTLEKDKLAR--KLASLTPGFSGADVANVCNEAALIAARH 
 
            proteolytic site 
                      601                                            650 
FtsH (Th. th.)  (380) GRRKITMKDLEEAADRVMMGPAKKSLVLSPRDRRITAYHEAGHALAAHFL 
 Yta12 (S. c.)  (575) DEDAVKLNHFEQAIERVIGGVERKSKLLSPEEKKVVAYHEAGHAVCGWYL 
 Yta10 (S. c.)  (520) NDPYITIHHFEQAIERVIAGLEKKTRVLSKEEKRSVAYHEAGHAVCGWFL 
  Spg7 (M. m.)  (536) GHTSVHTFNFEYAVERVIAGTAKKSKILSKEEQRVVAFHESGHALVGWLL 
Afg3l2 (M. m.)  (535) LSDAINEKHFEQAIERVIGGLEKKTQVLQPEEKKTVAYHEAGHAVAGWYL 
Afg3l1 (M. m.)  (528) LSPSVQERHFEQAIERVIGGLEKKTQVLQPSEKTTVAYHEAGHAVVGWFL 
  SPG7 (H. s.)  (536) GHTSVHTLNFEYAVERVLAGTAKKSKILSKEEQKVVAFHESGHALVGWML 
AFG3L2 (H. s.)  (536) LSDSINQKHFEQAIERVIGGLEKKTQVLQPEEKKTVAYHEAGHAVAGWYL 
 
                      651                                            700 
FtsH (Th. th.)  (430) EHADGVHKVTIVPRGR-ALGFMMPRREDMLHWSRKRLLDQIAVALAGRAA 
 Yta12 (S. c.)  (625) KYADPLLKVSIIPRGQGALGYAQYLPGDIFLLTEQQLKDRMTMSLGGRVS 
 Yta10 (S. c.)  (570) KYADPLLKVSIIPRGQGALGYAQYLPPDQYLISEEQFRHRMIMALGGRVS 
  Spg7 (M. m.)  (586) EHTEAVMKVSIAPRTNAALGFSQMLPRDQYLFTKEQLFERMCMALGGRAA 
Afg3l2 (M. m.)  (585) EHADPLLKVSIIPRGK-GLGYAQYLPKEQYLYTKEQLLDRMCMTLGGRVS 
Afg3l1 (M. m.)  (578) EHADPLLKVSIIPRGK-GLGYAQYLPREQFLYTREQLFDRMCMMLGGRVA 
  SPG7 (H. s.)  (586) EHTEAVMKVSITPRTNAALGFAQMLPRDQHLFTKEQLFERMCMALGGRAS 
AFG3L2 (H. s.)  (586) EHADPLLKVSIIPRGK-GLGYAQYLPKEQYLYTKEQLLDRMCMTLGGRAS 
 
                      701                                            750 
FtsH (Th. th.)  (479) EEIVFDDVTTGAENDFRQATELARRMITEWGMHPEFGPVAYAVREDTYLG 
 Yta12 (S. c.)  (675) EELHFPSVTSGASDDFKKVTSMATAMVTELGMSDKIGWVNYQKRD----D 
 Yta10 (S. c.)  (620) EELHFPSVTSGAHDDFKKVTQMANAMVTSLGMSPKIGYLSFDQNDG---N 
  Spg7 (M. m.)  (636) EAISFSRVTSGAQDDLRKVTRIAYSMVKQFGMAPSIGPVSFPEAQEG-LM 
Afg3l2 (M. m.)  (634) EEIFFGRITTGAQDDLRKVTQSAYAQIVQFGMNEKVGQISFDLPRQ--GD 
Afg3l1 (M. m.)  (627) EQLFFGQITTGAQDDLRKVTQSAYAQIVQFGMSEKLGQVSFDFPRQ--GE 
  SPG7 (H. s.)  (636) EALSFNEVTSGAQDDLRKVTRIAYSMVKQFGMAPGIGPISFPEAQEG-LM 
AFG3L2 (H. s.)  (635) EEIFFGRITTGAQDDLRKVTQSAYAQIVQFGMNEKVGQISFDLPRQ--GD 
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                      751                                            800 
FtsH (Th. th.)  (529) GYDVRQYSEETAKRIDEAVRRLIEEQYQRVKALLLEKREVLERVAETLLE 
 Yta12 (S. c.)  (721) SDLTKPFSDETGDIIDSEVYRIVQECHDRCTKLLKEKAEDVEKIAQVLLK 
 Yta10 (S. c.)  (667) FKVNKPFSNKTARTIDLEVKSIVDDAHRACTELLTKNLDKVDLVAKELLR 
  Spg7 (M. m.)  (685) GIGRRPFSQGLQQMMDHEAKLLVAKAYRHTEKVLLDNLDKLQALANALLE 
Afg3l2 (M. m.)  (682) MVLEKPYSEATARMIDDEVRILISDAYRRTVALLTEKKADVEKVALLLLE 
Afg3l1 (M. m.)  (675) TMVEKPYSEATAQLIDEEVRCLVRSAYNRTLELLTQCREQVEKVGRRLLE 
  SPG7 (H. s.)  (685) GIGRRPFSQGLQQMMDHEARLLVAKAYRHTEKVLQDNLDKLQALANALLE 
AFG3L2 (H. s.)  (683) MVLEKPYSEATARLIDDEVRILINDAYKRTVALLTEKKADVEKVALLLLE 
 
                      801                                            850 
FtsH (Th. th.)  (579) RETLTAEEFQRVVEGLPLEAPEEAREEREPPR---------VVPKVKPGG 
 Yta12 (S. c.)  (771) KEVLTREDMIDLLGKRPFP-ERNDAFDKYLNDY--ETE---KIRKEEEKN 
 Yta10 (S. c.)  (717) KEAITREDMIRLLGPRPFK-ERNEAFEKYLDP---------------KSN 
  Spg7 (M. m.)  (735) KEVINYEDIEALIGPPPHGPKKMIAPQKWIDAE---------KERQASGE 
Afg3l2 (M. m.)  (732) KEVLDKNDMVQLLGPRPFT-EKS-TYEEFVEGTGSLDEDTSLPEGLQDWN 
Afg3l1 (M. m.)  (725) KEVLEKADMIELLGPRPFA-EKS-TYEEFVEGTGSLEEDTSLPEGLKDWN 
  SPG7 (H. s.)  (735) KEVINYEDIEALIGPPPHGPKKMIAPQRWIDAQ---------REKQDLGE 
AFG3L2 (H. s.)  (733) KEVLDKNDMVELLGPRPFA-EKS-TYEEFVEGTGSLDEDTSLPEGLKDWN 
 
                      851                 873 
FtsH (Th. th.)  (620) ALGGA------------------ 
 Yta12 (S. c.)  (815) EKRNEP---------KPSTN--- 
 Yta10 (S. c.)  (751) TEPPEA---------PAATN--- 
  Spg7 (M. m.)  (776) EEAPAP----------------- 
Afg3l2 (M. m.)  (780) KEREKEEKKEKEKEEPLNEKVVS 
Afg3l1 (M. m.)  (773) KGREEGG-----TERGLQESPV- 
  SPG7 (H. s.)  (776) EETEETQQPPLGGEEPTWPK--- 
AFG3L2 (H. s.)  (781) KEREKE------KEEPPGEKVAN 
 
 
 
 
 
 
FtsH (Th. th.) (0.3138)
SPG7 (H. s.) (0.0593)
Spg7 (M. m.) (0.0598)
AFG3L2 (H. s.) (0.0346)
Afg3l2 (M. m.) (0.0333)
Afg3l1 (M. m.) (0.1536)
Yta10 (S. c.) (0.2206)
Yta12 (S. c.) (0.2325)  
 
Figure 22: Phylogenetic dendrogram showing the relationship of m-AAA protease subunits. 
The phylogenetic tree is based on the ClustalW alignment shown above and generated with the AlignX 
program of Vector NTI (Invitrogen).  
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6.3.2. MAIP1 and JHEbdp29 
MAIP1 and juvenile hormone binding protein 29 share18 % sequence identity and 32 % 
similarity. 
                       1                                               50 
JHEbp29 (D. m.)    (1) --------------------------------------MQHTLIRCLGMA 
C2ORF47 (H. s.)    (1) MALAARLLPQFLHSRSLPCGAVRLRTPAVAEVRLPSATLCYFCRCRLGLG 
 
                       51                                             100 
JHEbp29 (D. m.)   (13) RISLMRLQPRPTVAASGGQEAGSISKPTQPVSRSFASLPQEQDKKEQNAR 
C2ORF47 (H. s.)   (51) AALFPRSARALAASALPAQGSRWPVLSSPGLPAAFASFPACPQRS--YST 
 
                       101                                            150 
JHEbp29 (D. m.)   (63) ESLNRLPRLMDFPEIVWPSALNSLKNWITIQFIIRPYFDSEFQLKDFIYG 
C2ORF47 (H. s.)   (99) EEKPQQHQKTKMIVLGFSNPINWVR-TRIKAFLIWAYFDKEFSITEFSEG 
 
                       151                                            200 
JHEbp29 (D. m.)  (113) AKQALQVVSSKLMGGDLDSLDNLVSPEAIAELRPVIQKLSMTQRRQLEIK 
C2ORF47 (H. s.)  (148) AKQAFAHVSKLLSQCKFDLLEELVAKEVLHALKEKVTSLPDNHKNALAAN 
 
                       201                                            250 
JHEbp29 (D. m.)  (163) ESDIYLSFPYQVGIMFDDANDKLQKRFVEITMVFHVMRGLSEMRERGE-- 
C2ORF47 (H. s.)  (198) IDEIVFTSTGDISIYYDEK----GRKFVNILMCFWYLTSANIPSETLRGA 
 
                       251                                            300 
JHEbp29 (D. m.)  (211) -EIPWNMGTLPEYQDKVFICNYRFVKEFTAGHQSDWTVNVANQFRAIDLI 
C2ORF47 (H. s.)  (244) SVFQVKLGNQNVETKQLLSASYEFQREFTQGVKPDWTIARIEHSKLLE-- 
 
                       301 
JHEbp29 (D. m.)  (260) NETI 
C2ORF47 (H. s.)  (292) ---- 
6.3.3. MICS1 and YccA 
MICS1 and YccA have 11% sequence identity and 25% similarity. 
                     1                                               50 
 YccA (E. c.)    (1) -------------------------------------------------- 
MICS1 (H. s.)    (1) MLAARLVCLRTLPSRVFHPAFTKASPVVKNSITKNQWLLTPSREYATKTR 
 
                     51                                             100 
 YccA (E. c.)    (1) -------------------------------------------------- 
MICS1 (H. s.)   (51) IGIRRGRTGQELKEAALEPSMEKIFKIDQMGRWFVAGGAAVGLGALCYYG 
 
                     101                                            150 
 YccA (E. c.)    (1) ---MDRIVSSSHDRTSLLSTHKVLRNTYFLLSLTLAFSAITATASTVLML 
MICS1 (H. s.)  (101) LGLSNEIGAIEKAVIWPQYVKDRIHSTYMYLAGSIGLTALSAIAISRTPV 
 
                     151                                            200 
 YccA (E. c.)   (48) PSPGLILTLVGMYGLMFLTYKTANKPTGIISAFAFTG-------FLGYIL 
MICS1 (H. s.)  (151) LMNFMMRGSWVTIGVTFAAMVGAGMLVRSIPYDQSPGPKHLAWLLHSGVM 
 
                     201                                            250 
 YccA (E. c.)   (91) GPILNTYLSAGMGDVIAMALGGTALVFFCCSAYVLTTRKDMSFLGGMLMA 
MICS1 (H. s.)  (201) GAVVAPLTILGGPLLIRAAWYTAGIVGGLSTVAMCAPSEKFLNMGAPLGV 
 
                     251                                            300 
 YccA (E. c.)  (141) GIVVVLIGMVANIFLQLP-----ALHLAISAVFILISSGAILFETSNIIH 
MICS1 (H. s.)  (251) GLGLVFVSSLGSMFLPPTTVAGATLYSVAMYGGLVLFSMFLLYDTQKVIK 
 
                     301                                       345 
 YccA (E. c.)  (186) GGETN---------YIRATVSLYVSLYNIFVSLLSILGFASRD-- 
MICS1 (H. s.)  (301) RAEVSPMYGVQKYDPINSMLSIYMDTLNIFMRVATMLATGGNRKK
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7. Zusammenfassung 
Mitochondrien besitzen ein Qualitätskontrollsystem für Proteine, das aus 
verschiedenen Proteasen unterschiedlicher Lokalisation besteht, um falsch gefaltete und 
nicht assemblierte Proteine abzubauen. Ein wichtiger Bestandteil dieses Systems in der 
inneren Mitochondrienmembran ist die m-AAA Protease, die als ATP-abhängige oligomere 
Metalloprotease ihr aktives Zentrum zur Matrix exponiert. Die m-AAA Proteasen im 
Menschen bilden sowohl hetero- als auch homo-oligomere Komplexe aus den 
Untereinheiten AFG3L2 und SPG7 aus. Eine dritte Untereinheit in Mäusen (Afg3l1) 
resultiert in einer Vielzahl möglicher Isoenzyme in der inneren Mitochondrienmembran. 
Mutationen oder Deletionen verschiedener Untereinheiten der humanen m-AAA Proteasen 
führen zu Neurodegenerationen in unterschiedlichen Regionen des zentralen aber auch 
peripheren Nervensystems. Somit scheint eine bestimmte Zusammensetzung von aktiven 
Isoenzymen in unterschiedlichen Gewebe vor allem aber in Neuronen erforderlich ist. 
Eine weitere Funktion der m-AAA Protease – zumindest in Hefe – ist die spezifische 
Prozessierung von Proteinen. Welche Aktivität zur Pathogeneses der assoziierten 
Krankheiten beiträgt ist unklar, weil die Funktion der menschlichen m-AAA Proteasen auf 
zellulärer und molekularer Ebene und damit auch der Hintergrund der verschiedenen 
Krankheitszustände nicht bekannt sind. Die Säuger m-AAA Proteasen wurden mit der 
Prozessierung der Dynamin-ähnlichen GTPase OPA1 in Verbinding gebracht. Dies 
impliziert eine Rolle der m-AAA Proteasen bei der mitochondrialen Fusion. Um die 
Funktion der m-AAA Proteasen innerhalb der Mitochondrien vollständig zu entschlüsseln 
ist es nötig weitere Substrate der Proteasen zu identifizieren. 
In dieser Arbeit konnte eine dominant negative Mutation im Walker B Motiv der 
ATPase Domäne in der m-AAA Protease Untereinheit AFG3L2/Afg3l2 identifizert werden. 
Die Expression dieser dominant negativen Mutation in humanen Zelllinien  ermöglichte 
die Generierung eines m-AAA Protease Komplexes, der als Substratfalle fungierte. Mit Hilfe 
dieses Ansatzes konnten mögliche neue Bindingspartner und Substrate der Protease 
identifizert und damit auch die molekulare Funktion der Protease geklärt werden. So 
befinden sich die m-AAA Proteasen mit den Prohibitinen in der inneren 
Mitochondrienmembran in einem Superkomplex, der Zellwachstum und durch die 
Stabilisierung von langen OPA1 Isoformen die mitochondriale Fusion kontrolliert. 
Gleichzeitig interagieren die Proteasen mit SLP2 und regulieren möglicherweise in einem 
weiteren Superkomplex stress-induzierte Hyperfusion. Unreifes AFG3L2 (mit 
mitochondrialer Präsequenz) und MICS1 ein Protein in der inneren 
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Mitochondrienmembran, konnten als mögliche Substrate identifiziert werden. MICS1 ist 
essentiell für die Cristae Morphogenese und soll bei Apoptose eine Rolle spielen. 
Mit Hife dieser Arbeit konnten m-AAA Proteasen mit zellulären Funktionen wie 
mitochondriale Morphologie, Cristae Organisation und Apoptose in Zusammenhang 
gebracht werden. Diese Arbeit könnte daher dazu beitragen, die molekularen Ursachen 
von Neurodegenerationen, die mit Mutationen von humanen m-AAA Protease Unterheiten 
assoziiert sind, aufzudecken. 
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